Hemispherx könnte morgen abgehen,Congress approved $3b on bird flu - 500 Beiträge pro Seite

[jyraflyer]

und HEB besitzt ,Tamiflu ein Medikament gegen die Vogelgrippe
Da wird sich Hemispherx ein Stückchen vom grossen Kuchen abschneiden können.

Good luck

[Aptamilla]

ganz recht!Steht kurz vor der Zulassung(Phase 3)und wird zum Blockbusterpräperat.So viel ich weiss,forscht Hemispherx als (Globalplayer) das (Nischenprodukt) gegen Vogelgrippe aus.Es gibt keinen Konkurrenzdruck.Umsätze an der AMEX mit hohem Volumen.Es zeichnet sich anscheinend etwas grosses an.MfG

[cyberhai]

Bin schon investiert, hier die Pipeline:

http://www.hemispherx.net/content/rnd/product_candidates.htm

Gruß Cyberhai

[Trappertoni]

Ich denke, das warten auf signifikant bessere Kurse hat ein Ende.
Allen investierten weiterhin viel Glück.

So long
Trappertoni

[Trappertoni]

@all

Wenn ich mir den Kursverlauf von Biota (WKN: 887853)ansehe, welcher wohl allein auf die Phantasie bzgl. der Vogelgrippe basiert, könnte ich mir bei Hemispherx einen ebenso stürmischen Anstieg durchaus vorstellen. Es sollte jedoch nicht vergessen werden, daß Hemispherx noch weitere sehr interessante Produkte in der Pipline hat und damit wohl auch breiter aufgestellt sein sollte.

So long allen investierten

Trappertoni

[Aptamilla]

[posting]18.116.184 von Trappertoni am 03.10.05 12:02:34[/posting]letzten Monat hatte der Vorstand fleissig gekauft!Davor in Abständen sukzessive.Heisst im Klartexta steht eine Meldung an.Übrigens,Im Onvista(Snapshot)zu lesen:2006 KGV unter 20,Gewinn pro Aktie=schaut selbst(Überraschung)!!!Da sind wohl Meilensteinzahlungen mit eingebunden.Schönen Feiertag an alle Hemi-Fans.

[cyberhai]

Press Release Source: Hemispherx Biopharma

Hemispherx Biopharma Signs Research Agreement with Japanese National Institute of Infectious Disease
Monday October 3, 8:56 am ET
Ampligen(R) Sought as Adjuvant for Nasal Flu Vaccine

PHILADELPHIA--(BUSINESS WIRE)--Oct. 3, 2005--Hemispherx Biopharma, Inc (AMEX: HEB - News) has signed a research agreement with the National Institute of Infectious Diseases, in Tokyo, Japan. The collaboration, by Hideki Hasegawa, M.D., Ph.D., Chief of the Laboratory of Infectious Disease Pathology, will assess Hemispherx` experimental therapeutic Ampligen® as an adjuvant to the Institution`s nasal flu vaccine.

ADVERTISEMENT
click here
In a recent published study in the Journal of Virology (March 2005, p. 2910-2919), Dr. Hasegawa and colleagues found that double-stranded RNA (dsRNA), such as Ampligen®, increases the effectiveness of the influenza vaccine by more than 300% and Ampligen® may also convey cross-protection ability against variant viruses (mutated strains of influenza virus).

New data from preclinical studies on dsRNA, including Ampligen® supports the role of dsRNA therapeutics in improving the efficacy of the present standards of care in both influenza prevention and treatment of acute disease.

A recent preclinical report, conducted by research affiliates of the National Institutes of Health at Utah State University, compared the relative protection conveyed by Tamiflu (oseltamivir, Roche) and the Company`s experimental therapeutic Ampligen®, alone and in combination against the avian flu virus (H5N1). Ampligen was among more than 10 different drug combinations examined in the studies aimed to seek therapeutic synergy with the vaccines.

In antimicrobial (antibacterial) therapy, which is the best studied clinical model, synergistic drug combinations may result in curative conditions/outcomes, often not observed when the single drugs are given alone. In the case of avian influenza where global drug supplies are presumptively in very limited supply relative to potential needs, therapeutic synergistic combinations could not only affect the disease outcome, but also the number of individuals able to access therapies.

By providing a new mechanism of inhibition of avian flu, (i.e. immunologic/host defensive immune cascades), Ampligen®, an experimental therapeutic, may also afford a new time interval to help combat the influenza virus. At present, a narrow window of opportunity (approximately 48 hours) exists for effective utilization of Tamilflu after exposure to influenza.

Hemispherx recently completed Phase III testing of Ampligen® for Chronic Fatigue Syndrome (CFS).


Gruß Cyberhai

[Aptamilla]

1,5 Millionen Handelsvolumen an der AMEX!!!Also Hemis,da kommt was!!!

[x50y]

konnte gestern zu 1.71 USD fettest rein und nun lernt das Teil fliegen

Das werden easy 100%

[erbla]

Vogelgrippe-Aktien haben zu laufen angefangen. Bin heute auch in HEB und SVA rein. Mal sehen, wohin uns der Weg führt.

Kurz vor dem Grippe-Exitus im Krankenhaus ein letzte Blick auf`s Depot: "Ja, ja, endlich Millionär! *Röchel*"

[cyberhai]

HEB und NVAX retten heute zum Glück mein Depot vor einem dicken Verlust.

Bei SVA würde ich nicht investierten, da gibt es eigentlich nur Insiderverkäufe, hier die von diesem Jahr:

19-Sep-05 WANG, XIANPING
24,000 Direct Planned Sale $466,0001
19-Sep-05 WANG, XIANPING
130,000 Direct Planned Sale $466,0001
15-Aug-05 WANG, HEPING
Director 370,000 Direct Planned Sale $995,3001
10-Aug-05 WILLIAM, BUTLER
5,049 Direct Planned Sale $14,8901
22-Jun-05 NASDAK GROUP S.A.
100,000 Direct Planned Sale $229,0001
17-Jun-05 WANG, XIANPING
Director 370,000 Direct Planned Sale $740,0001
16-Jun-05 WU, MAC
5,500 Direct Planned Sale $10,5601
16-Jun-05 WANG, HEPING
Director 130,000 Direct Planned Sale $249,6001
20-May-05 BLANK, MARC S.
40,000 Direct Planned Sale $96,0001
20-Apr-05 HEPING, WANG
Director 350,000 Direct Planned Sale $896,0001
1-Apr-05 MARX, LOUIS
20,000 Direct Planned Sale $60,2001
16-Mar-05 GLOBAL CAPITAL GROUP, INC
10,000 Direct Planned Sale $30,0001
14-Mar-05 ALPHA CAPITAL AG
100,000 Direct Planned Sale $310,0001
8-Mar-05 KENNY, JAMES M.
12,000 Direct Planned Sale $37,2001
24-Feb-05 VOLTRON VENTURES LP
40,000 Direct Planned Sale $122,8741
24-Feb-05 MITTLEMAN, PHILLIP
20,000 Direct Planned Sale $61,437

Gruß Cyberhai

[Aptamilla]

das Mauerblümchen mit Blockbusterambitionen.4.2 Mio Volumen-Umsatz an der AMEX.Waaaaahnsinn!!!

[cyberhai]

Da haben wir glaube ich eine Perle entdeckt

[Aptamilla]

[posting]18.154.041 von cyberhai am 05.10.05 21:01:50[/posting]Perle???Ein Goldschatz ist das Cyberhai,momentan mit sage und schreibe 4.55 Mio.Volumen bei der AMEX(wohlgemerkt)(OTC=Zockerbude).Weg ist frei noch Norden.Volumen=noch nie so hoch(Rekord).Wünsche uns viel Freude

[cyberhai]

Kennt von Euch jemand die Bedingungen an der AMEX, an der OTC kann ja wohl gelogen werden ohne dass irgendwer dafür belangt werden kann; an der Nasdaq würde man dafür in den Knast wandern. Ist die AMEX vergleichbar mit der Nasdaq?

Gruß Cyberhai

[Aptamilla]

[posting]18.154.587 von cyberhai am 05.10.05 21:46:16[/posting]Ist sie Cyber(AMEX=American Stock Enchange=seriös).Nun die Hammermeldung !ARD-Tagesthemen(ca.22 Uhr) berichteten über Tamiflu(Hemispherx).George W.Bush hielt eine Ansprache über Vogelgippe und deren Folgen.US-Militär stellt 4 Milliarden Dollar für Bekämpfung in Aussicht.Hammermeldung!!!Cyber-kauf was das Zeug hält.Leichter geht`s nimmer.

[Trappertoni]

@ Dr.Zeissler

Hi Doc.

Eine Konsolidierung auf Deinem Niveau wird definitiv nicht stattfinden.
Deine Postings sind absolut provokativ und so was von überflüssig. Schade um so eine destruktive mitarbeit deinerseits.
Ich erinnere nur an das Sparbuch.

Allen investierten weiterhin viel Erfolg

Trappertoni

[Aptamilla]

[posting]18.155.616 von Trappertoni am 05.10.05 22:29:47[/posting]Hey Trainer,Du bist im falschen Film!!!

[erbla]

Nachbörslich HEB 2,40 $, SVA 6,00 $

[Aptamilla]

[posting]18.156.130 von erbla am 05.10.05 23:37:55[/posting]Booooooooom!!!!!!!!!!

[Trappertoni]

@Aptamilla

Sorry, stimmt.

Nichtsdestotrotz freue ich mich irrsinnig über den lang erwarteten Kursanstieg sowie die weiteren Aussichten.

So long
Trappertoni

[Aptamilla]

An alle Hemi-Aktionäre,wir haben hier im negativen Börsenumfeld die 2 Euro Marke erreicht.Die AMEX hatte gestern sage und schreibe 5,77 Mio. Volumina.Das ist verdammt viel.Nachbörslich ist die Nachfrage(AMEX) stattlich hoch und mit grosser Wahrscheinlichkeit sehen wir weitere Kursanstiege.Wie gepostet:George W.Bush hat sich gestern(ARD)persönlich besorgt über die Vogelgrippe geäussert.Vier Milliarden Dollar Subventionsgelder sind freigegeben worden(ernste Vorsorge).Hemispherx ist kurz vor der Zulassung ihres vielversprechenden Produktes gegen Vogelgrippe.Worauf wartet ihr denn noch.2 Euro sind immer noch hervorragende Einstiegskurse.Bei Viropharma fing alles ziemlich ähnlich an.(2 E gestern-20 E heute).MfG Aptamilla

[erbla]

HEB vorbörslich 2,5 $!

[erbla]

Auch SVA läuft weiter: 6,01 $ in der Vorbörse!

[Aptamilla]

[posting]18.163.284 von erbla am 06.10.05 14:13:42[/posting]US Gewinnmitnahmen,eigentlich zum Beginn normal.5.77 Mio.Volumina gestern,jetzt ein Bruchteil dessen.

[erbla]

Vielleicht beiß ich mich heut noch in den Arsch, aber neben meinem Teilverkauf zu 2 € heute hat`s beim Rest den Stop ausgelöst, welcher viel zu tief gesetzt war. Ich bin raus. SVA das selbe, allerdings mit deutlich günstigerem Stop *g*.

[erbla]

*Schnapp!* *Beiß!*

[MartenK]

[posting]18.167.690 von erbla am 06.10.05 19:05:57[/posting]wie heisst es so schön "entgangenen Gewinnen nicht nachtrauern"

[Aptamilla]

[posting]18.167.690 von erbla am 06.10.05 19:05:57[/posting]Mensch Erbla,bleib cool.Meine letzten Postings haben Logik und Glaube.Hemispherx ist und bleibt sehr interessant.War nun mal ein generell schlaffer Börsentag heute und Du erkennst,das sich Verkauforder momentan in Kauforder gewandelt haben(Volumina von gestern sind komprimiert).Das heisst:wir haben nun festen Boden unter den Füssen.2 Euro sind wirklich gute Einstiegschancen(bei der Story plus 2006 KGV und Gewinn pro Aktie).ERBLA,nicht verzagen und ein bisserl Geduld aneignen.Du wirst schnell erkennen,es funktioniert.Also,nicht ärgern sondern aktuell vernünftig handeln.MfG Aptamilla

[Aptamilla]

[posting]18.168.980 von Aptamilla am 06.10.05 20:46:30[/posting]Und übrigens!Ich bin kein Pusher.Habe heute für 2 Euro einiges geordert.Nebenbei bemerkt:AMEX wiederum mit hohen positiven Volumina.Lässt weiter hoffen auf den Weg gen Norden.

[erbla]

Ja, ja, ich kann mich auch absolutigst nicht über den Tag beschweren, aber HEB wurmt mich doch. Gestern zu 1,98 $ rein, heute zu 2,05 $ die Reißleine gezogen (dazwischen ein Nachkauf zu 1,8 € und ein Verkauf zu 2 €, damit die Position nicht ins Minus läuft. Wenn man dann sieht, dass man quasi auf Tagestief verkauft hat und die danach noch 30 % macht, dann ist die Laune dahin.

Der Teilverkauf war richtig, aber zu wenig Stücke. Die Reißleine war richtig, aber ich hätte sie nach knapp 2,3 $ gestern und fetten Umsätzen bei 2,4 $ in der Vorbörse höher ansetzen sollen, damit mehr bleibt.

Insgesamt aber ein sehr erfolgreicher Tag.

[MartenK]

[posting]18.169.045 von Aptamilla am 06.10.05 20:52:29[/posting]Hallo Aptamilla,

ich habe heute auch noch mal nachgelegt weil mir das Thema ganz gut gefällt. Bis jetzt bin ich auch froh drüber.

Was mich wundert ist das in US Boards (und hier) kaum über HEB geschrieben wird(zumindest nicht in den Boards wo ich geschaut habe) Hast du da vielleicht noch andere Infos?

Was wäre denn deiner Meinung nach ein realistisches Kursziel?

Gruß

Marten

[erbla]

Der Smilie soll eigentlich eine ) und ein , sein.

[Aptamilla]

[posting]18.169.181 von erbla am 06.10.05 21:04:16[/posting]dumm gelaufen bei Dir wie ich lesen kann.Trost;wir sind immer noch Menschen und keine Propheten!Versuchs nochmal.Bist schon ein schlauer Fuchs und hast klug gehandelt.Aber Börsen sind nunmal zeitweise unkalkulierbar bis arg zynisch.

[erbla]

[posting]18.169.190 von MartenK am 06.10.05 21:04:58[/posting]Vergiss bei aller Euphorie nicht, dass HEB vermutlich im Wesentlichen ein Vogelgrippe-Hype ist. Wenn die Vogelgrippe abgeblasen wird (was ich allen hier wünsche!), dann sieht HEB ganz schnell auch wieder anders aus.

Ich bin fundamental nicht sehr informiert über HEB und co., rate aber jedem, das Schicksal anderer Hype-Aktien in Betracht zu ziehen bei der Betrachtung der Kurschancen von HEB und co.

Aktuell schadet ein Blick auf WEGI nicht. Der Hurrikan ist vorbei, der Hype damit auch: http://finance.yahoo.com/q/bc?s=WEGI.OB&t=3m

[MartenK]

[posting]18.169.325 von erbla am 06.10.05 21:17:06[/posting]Ist schon klar das es kurzfristige Hypes gibt die mit temporären Ereignissen zusammenhängen. Meist werden solche Aktien dann aber in jedem Board heiss diskutiert, ganz zu schweigen von Börsenbriefen.
Hier find ich aber nix dergleichen, kaum News, keine wilden Boarddiskussionen, keine Pusherei. Und trotzdem hohe Umsätze.
Für mich klingt das positiv.
Übrigens gabs grad nen Kursprung auf 2,5...
sehr interessant

Gruß

Marten

[Aptamilla]

[posting]18.169.325 von erbla am 06.10.05 21:17:06[/posting]Bist anscheinend völlig frustriert.HEB forscht im Sektor HIV,Hepatitis C und Vogelgrippe im letzten Stadium.Alferon und Ampligen sind die Hoffnungsträger.Mit Hype lass es mal.Die Vogelgrippe ist ernst zu nehmen,denn diese Erreger können mutieren bzw. resistent ausarten.Ganze Völker können draufgehen.Für mich allein schon moralisch ein Investment,weils der Menschheit hilft.Denn merke:Vögel fliegen weit-Hurricans drehen in gewissen Breitengraden ihre Wirbel!

[Aptamilla]

Ist ja interessant.Nur kumulierte Kurse.Keine Verkäufe an deutsche Börsenplätze.AMEX hat gestern mustergültig konsolidiert.7 Millionen Volumina in zwei Handelstagen.Kurs kann sich sehen lassen mit Tendenz nach oben.

[erbla]

[posting]18.169.844 von Aptamilla am 06.10.05 22:01:19[/posting]Dann hätte ich den Beitrag nicht so neutral vormuliert.

HEB bleibt auf jeden Fall auf meiner Beobachtungsliste, das Thema ist ja noch heiß.

[Aptamilla]

Immer noch hohes Volumina an der AMEX.Momentan bei 1.5 Millionen.Zeugt von weiterhin reges Interesse an der kleinen Biotech-HEB.

[Aptamilla]

ZDF-Nachtjournal:Zugvögel,ausgehend von Indonesien über Russland nach Rumänien gelangt.Verdacht durch Innenminister bestätigt.USA arbeitet mit Hochdruck an Abwehrstrategien.Sehr ernste Angelegenheit weltweit mit einheitlichem Tenor der Bekämpfung.Roche und Hemispherx sind die einzigen Hoffnungsträger!

[tilt]

@all

lest euch diesen beitrag von vor 6-7 jahren mal durch und sagt mir dann mal ob HEB jetzt endlich mal soweit ist und ihre produkte wirklich zur zulassung bringt oder die anleger jahr für jahr weiter vertröstet werden


Dieser Beitrag ist von LarryL vom09.04.99!!!!!
Habe diesen Dino der Biotechs ausgegraben weil die Produktpipeline
aus 99 sich jetzt schon in weiteren Phasen befindet so das in nächster Zeit einige Produkte marktreife erlangen werden.

mfg fatbull



Hemispherx Biopharma Inc.

Hintergrund
HEB wurde ergründet und wird geleitet von Dr. Wiliam Carter einem der Pioniere der INTERFERON Therapie (Natürliches, vom Körper erzeugtes Mittel gegen Virus-Infektionen, kann auch künstlich hergestellt werden). Er eignete sich über 3 Jahrzente theoretisches und praktisches Wissen in der Erforschung von „nucleid acid (NA) compounds“ (genetisch erzeugbare Mittel zur Bekämpfung von chronischen Virus-Infektionen. HEB ist das einzige Unternehmen, deren Wissenstand so fortgeschritten ist, um NA-technology wirksam einzusetzen. Das Unternehmen hat sich weltweit über 300 Patente gesichert, und ist damit führend unter allen Pharmakonzernen.

Das Kernprodukt von HEB ist Ampligen, welches wirksam in der Bekämpfung von Krankheiten, welche das Immun-System schädigen und schwächen wie z.B. CFS (Chronic Fatigue Syndrom), HIV und Hepatitis B.

Es ist bewiesen, dass Ampligen das einzige Mittel zur Bekämpfung von CFS ist. CFS ist eine komplexe Krankheit welche tiefe Müdigkeit, Schlafstörungen und Muskelschmerzen hervorruft. In 30 % aller Fälle führt sie bis zur Bettlägerigkeit und Pflegefall. Alleine in den USA gibt es 600.000 Betroffene und in Europa noch einmal 600.000. Anhand einer Studie der Harvard Universität liegt die Anzahl der Betroffenen Amerikaner bei 2.500.000.

CFS wurde vor kurzen in die Liste der „Priorität 1“ Krankheiten eingetragen, dort handelt es sich um Krankheiten, welche noch nicht mit Medikamenten heilbar sind, wie z.B. AIDS.

Die Behandlung von CFS ist derzeit in PHASE III fortgeschritten und in das Programm Treatment IND aufgenommen (Treatment investigational new drug). Dieses Programm unterstützt HEB um umfangreiche Testreihen in der Behandlung von CFS mit Ampligen durchzuführen und die FDA übernimmt dabei einen Grossteil der Kosten. HEB hat sich auch als einziges Unternehmen weltweit die Lizenz gesichert um Ampligen zu verkaufen.

Im Falle eines steigenden Interesses von Investoren, wäre HEB derzeit mit 14 $ fair bewertet, da andere vergleichbare Pharmaunternehmen mit gleich- oder weniger-vielversprechenden Aussichten um mehr als das vierfache höher gehandelt werden.

Wir glauben, dass auf der Basis einer kompletten FDA-Zulassung von Ampligen, die Aktie ein Potential von 50 $ hat.

HEB hat vor kurzem zwei „Senior executives“ eingestellt um die Expandierung nach Europa zu beschleunigen, des weiteren wird es in naher Zukunft ein paralleles Listing am NEUEN MARKT und an der EASDAQ geben.

NUCLEIC ACID Pharmaceuticals-Ampligen

Ribonucleic acid (RNA) ist eine natürliche Gruppe von Informations-Molekülen welche das Verhalten von Zellen steuern, eingeschlossen deren Zellen die das menschliche Immunsystem steuern.

Hemispherx erforschte eine Substanz basierend auf künstlichem RNA. Die Substanz heisst AMPLIGEN.

Ampligen ruft eine eine Anti-Virus-Reaktion im menschlichen Immunsystem auf zwei Arten hervor:

1.) Es aktiviert das zellulare Abwehrsystem
2.) Es aktiviert die Produktion von natürlichem Interferon, und andere Substanzen, welche das menschliche Immunsystem stärken und Viren abwehren.

CFS (Chronic fatigue System)

CFS ist eine Krankeit welche diese Folgen nach sich zieht:

Tiefe Müdigkeit, Schlafstörungen, starke Halsschmerzen, und mentale Müdigkeit und Unkonzentriertheit.

Es gibt dabei viele Symptome, welche aber von Patient zu Patient verschieden sind.

Extreme Müdigkeit nach Stess, Halsschmerzen, Kopfweh, Schwindelanfälle, erhöhte Temperatur.....

Das amerikanische Institut für Krankheiten (CDC) hat in einer Studie von 600.000 CFS-Kranken in den USA gesprochen. Die Harvard-Universität veröffentlichte eine Studie in der es um ca. 2.500.000 CFS-Kranke in den USA geht. In dieser Studie wurde auch festgehalten, dass von allen CFS-Erkrankten auf die Dauer nur bei 4 % eine Besserung ohne Behandlung eintritt. Es gibt aber bisher ausser Ampligen noch kein wirksames Mittel gegen CFS.
Zwischen 10 % bis 30 % aller Erkrankten werden zum Pflegefall.

Klinische Tests von Ampligen

HEB machte einen 24-Wochen placebo-kontrollierten Test mit 92 CFS-Erkrankten.

Die Behandlung brachte minimale bis gar keine Nebenwirkungen zum Vorschein, und war sehr postiv angenommen unter den Patienten.

Das Testergebnis:

10 % aller Patienten zeigten keine Wirkung auf die Behandlung.
60 % aller Patienten konnten zum Teil völig geheilt, aber mindestens soweit geheilt werden, dass sie ein neues Leben, weg von Pflegebedürftigkeit führen konnten.
30 % aller Patienten wurden geheilt, mussten aber nach einem Rückfall, die Behandlung wiederholen. (Dauer 9 Monate, insgesamt 24 Monate)

Die FDA hat nun bis zur vollständigen Zulassung eine weitere Testreihe unter dem IND
Status genehmigt, in dem 200 Personen behandelt werden dürfen. Bis jetzt sind alle
Medikamente, welche den IND-Status genehmigt bekamen, vollständig zugelassen
worden, und das zwischen 3 und 18 Monaten.



CFS Diagnostik-Geräte

HEB steht in Zusammenarbeit mit dem belgischen Unternehmen R.E.D Laboratories, welches
Apparate zur Diagnostizierung von CFS-Erkrankten produziert und verwendet. Bei Tests dieser Apparate wurden 92 % aller Testpersonen welche an CFS erkrankt sind entdeckt. Diese Geräte arbeiten schnell und wirkungsvoll, da sie nur die Gen-Struktur des Patienten analysieren.

Ampligen Vertrieb und Vermarktung

In den USA wird das Produkt nach der Zulassung über Olsten Corporation, die grösste amerikanische Vertriebsstelle für Medikamente mit weit über 600 Vertriebsstellen.

In Europa wird das Produkt über die zwei neu eingestellten Senior executives vertrieben, welche Zweigniederlassungen in Europa eröffnen werden.

Ampligen Produktion

Bei einer Zahlung von 3 Millionen Dollar und einer 8 % igen Beteiligung an SAB/Bioclones RNA drug sales, bekommt HEB eine exklusiv-Lizenz für eingeschränkte geographische Gebiete. Bioclones willigte ein eine Produktion zu eröffnen, in welcher HEB zu 25 % beteiligt ist, und in dieser ist es möglich bis Ende 98 Ampligen-Vorräte herzustellen, welche für über 50.000 Personen verwendbar sind.

PRODUKTE – PIPELINE von Hemispherx

Krankheit Produkt Klinischer Status

CFS Ampligen Phase II/III Komplett

Hepatitis B Polyadenur Phase III

HIV monotherapy Ampligen Phase II

HIV kombinierte Therapie Ampligen Phase II

Metastasic kidney cancer Ampligen Phase II

Malignant Melanoma Ampligen Phase II

Brust Krebs Polyadenur Phase II

Hepatitis B Oragen Preklinisch

HIV Oragen Preklinisch

Hepatitis C alle 3 Preklinisch

Polyadenur ist ein fast identisches Mittel zu Ampligen

Ampligen und Hepatitis B/C Behandlung

Marktpotential: ca. 55 Millionen Erkrankte weltweit !!!!

Das einzige Konkurrenz-Mittel ist Introgen, welches weltweit 600 Millionen Dollar alleine im Jahr 1997 an Einnahmen erbracht hat. Das Mittel wird vertrieben von Schering-Plough.

Introgen beeinhaltet viele Nebenwirkungen: Nur 25 – 40% sprechen auf eine Behandlung an davon zeigen noch einmal 25 – 40 % Nebenwirkungen und müssen die Therapie abbrechen!!!

Bei Test von Ampligen im den frühen Testphasen (jetzt) lag die Ansprechung auf die Behandlung wesentlich höher und nur 5 % mussten die Therapie mit Ampligen wegen Nebenwirkungen abbrechen.


















Die Kosten einer Ampligen-Behandlung bei CFS-Erkrankung

Eine 6-monatige Therapie kostet 7.200 $

Bei einer 4 % igen Behandlung vom gesamten Potential in den USA (mind. 500.000)
Ergibt sich folgendes:

50 % - einmalige Behandlung (6 M) 144.000.000 $
20.000 Patienten
50 % - nochmalige Behandlung (12 M) 216.000.000 $


Die Finanzzahlen entnehmen sie bitte aus der Englischen Studie www.going-public.de

[Aptamilla]

[posting]18.202.989 von tilt am 09.10.05 13:00:08[/posting]Ist bemerkenswert,aber eigentlich schon uralt.Klar,dieser Text erweckt nachdenken,ist aber mit Logik kaum nachzuvollziehen.Klinische Studien verweilen nicht so lange in sich selbst.Wenn,dann hätte man als Anleger längst gehandelt und Ergebnisse gefordert.Falls die Studienphase nicht den gewünschten Erfolg erzielt hätte,wäre sie nunmehr eingestellt.Dies ist bis heute nicht passiert.Gerade im Gegenteil!HEB berichtet über Alferon bzw.Ampligen recht transparent.Die an der AMEX gelistete HEB hat strenge Auflagen im Bezug auf Forschung und Investorenbeziehungen.Die Volumina in den letzten Tagen war besonders hoch.Die Amerikaner sehen dort mehr Aufwärtspotenzial als wir.Viele Brokerhäuser und Researcher prüfen regelmässiger und strenger als gedacht wird.Deshalb ist eine Recherche zu 1999 kaum anzustellen.Fakt ist:HEB steht kurz vor der Zulassung von Ampligen!Ich bin fest davon überzeugt,weil der Phase 3 hervorragende Verträglich- und Wirksamkeit bescheinigt wurden.

[MartenK]

So lang scheint die Einführung von Ampligen doch nicht mehr zu dauern. Heute in den News.
Partnerschaft mit HollisterStier für Produktion von 10000 Ampullen die Woche. Danach sollen weitere Kapazitäten aufgebaut werden.



Hemispherx Biopharma Signs Letter of Intent with HollisterStier..
2005/10/10 08:31:10
Laboratories LLC for the Production of Ampligen(R)
PHILADELPHIA, Oct 10, 2005 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (AMEX: HEB) has signed a Letter of Intent (LOI) with HollisterStier Laboratories of Spokane, Washington, for the contract manufacturing of Hemispherx`s experimental drug, Ampligen(R). The achievement of the initial objectives described in the LOI, in combination with the Polymer production facility under construction in New Brunswick, N.J., will enable Hemispherx to manufacture the Active Pharmaceutical Ingredient (API) for approximately 10,000 doses of Ampligen(R) per week. Based on the LOI, HollisterStier Contract Manufacturing has agreed to fill the Ampligen(R) API from Hemispherx. Production for significantly larger quantities of product are planned thereafter. Hemispherx has already commenced the process of transferring manufacturing technology to HollisterStier.
Doug Hulse, Chief Operating Officer and President commented, "We are pleased to be working with HollisterStier, a highly professional group who can support the full commercialization of Ampligen(R) upon FDA approval. We selected this group from a qualified pool of manufacturers and look forward to executing our manufacturing strategy with them."
Anthony Bonanzino, President and CEO of HollisterStier noted, "The new relationship with Hemispherx Biopharma represents an exciting addition to our well established client portfolio. We are pleased with the Hemispherx decision, and strongly believe the Hemispherx manufacturing strategy is an excellent match to HollisterStier`s core competencies."
Hemispherx recently completed Phase III testing of Ampligen(R) for Chronic Fatigue Syndrome (CFS).

[Aptamilla]

[posting]18.215.025 von MartenK am 10.10.05 17:40:58[/posting]Kompliment Marten!Danke für die Info.MfG Aptamilla

[erbla]

So, war heut mal wieder drin in ner ganzen Reihe von Vogelgrippe-Aktien, darunter HEB. Zwar mit Plus geschlossen, aber die HEB hat nix dazu beigetragen. Die Aktie mag mich nicht.

[Aptamilla]

[posting]18.220.243 von erbla am 10.10.05 23:59:52[/posting]Kommt Zeit,Kommt Rat!!!MfG

[Aptamilla]

[posting]18.226.984 von Aptamilla am 11.10.05 14:34:31[/posting]Null Umsätze in Deutschland.USA aber in Folge mit Millionen.Neue Nachricht(10.10.)findet kein Interesse.Dabei ist sie doch sehr gut.10.000 Ampullen "Ampligen" pro Woche herstellen.(520.000 Ampullen im Jahr).Das sind Umsätze mit bemerkenswertem Aspekt und niemand merkt es!!!Wohl dem,der es zu schätzen weiss.

[Aptamilla]

Hallo an alle Aktionäre von HEB oder die es noch werden wollen.Im Handelsblatt erschien heute ein sehr interessanter Bericht über die Vogelgrippe."Grippefurcht heizt Arzneinachfrage an".Präsident Bush empfing kürzlich Vertreter der Pharmaindustrie im Weissen Haus und forderte sie auf,"Entwicklung und Produktion von Impfstoffen und Medikamenten zu verstärken.Dafür werden Milliarden Dollar Beträge zu Verfügung gestellt.Tamiflu(Roche) und Ampligen(HEB) haben in Kooperation die Wirkstoffe erfolgreich miteinander getestet.Da die FDA eng mit Hemispherx in Verbindung steht und letzlich auch den Orphan-Drug Status erteilte,können wir in nächster Zeit mit guten News rechnen.Erinnere:Ampligen-Phase 3(kurz vor Zulassung und finanzielle Unterstützung vom Weissen Haus).Wohl dem,der darüber nachdenkt und handelt MfG Aptamilla

[Aptamilla]

Volumina wieder hoch in den USA.Nach der Kurskorrektur geht es wieder aufwärts.Charttechnisch klassischer Turnaround mit Tendenz stabiler Kursentwicklung.Bei erfreulichen News 7 Dollar Marke kurzfristig durchaus erreichbar.

[Aptamilla]

Hallo allerseits,schreibe eigentlich alleine die letzen Postings,aber sicherlich sind viele Leser unter Euch.Die Vogelgrippe hat nunmehr Europa erreicht.Wer zwischen den Zeilen liest,weiss, das dieses Thema bewusst von den Regierungen in Europa heruntergespielt wird.Das Gegenteil würde schon eine schleichende Hysterie auslösen.Die Wirtschaft käme unter Druck und die Touristikbranche würde lahmen.Wenn`s heikel wird ist Tamiflu und Ampligen die einzigen Hoffnungsträger.Sie dienen zum Schutz unsereins und verdienen hervorgehoben zu werden.Allein schon aus diesem Grund poste ich für die Allgemeinheit.Pushen liegt mir fern,weil Hemispherx eigentlich krass unterbewertet ist.Onvista-Snapshot zeigt es in Zahlen an.Schaut mal herein.Wohl dem,der darüber nachdenkt und handelt MfG

[biotech_nett]

@ all:

Hemispherx wurde damals, 1999 bereits vom Biotech-Investor empfohlen. Seitdem habe ich die Aktie, mal super verkauft, dann langsam wieder eine größere Position aufgebaut. Wie bei allen Biotech-Aktien dauert einfach die Entwicklung, einschliesslich der diversen Testphasen unglaublich lange, kommt ein Hype, dann sind die Spekus, wie Ihr, zufrieden.



Meiner Meinung nach macht sich die lange Geduld, sowie Beobachtung jetzt langsam wirklich bezahlt, Trapattoni hat schon immer einen guten Spürsinn für solche Aktien,

@ erbla:

mit diesen Daytrades wirst Du hier wahrscheinlich immer loosen, manches ist gut, manches ist schlecht,

Du weisst, zuviel hin und her macht einfach nur den Geldbeutel leer,

doch wenn es dann doch mehr wird hast Du immer den netten Fiskus dabei, zumindest falls Du ein ordentlicher Steuerzahler bist, was natürlich niemand bezweifelt

... doch mancher sollte bedenken, bei einer Haltefrist von über einem Jahr können diese Gewinne steuerfrei in das eigene Portemonnai fliessen

Ergo:

Es sollte versucht werden kurzfristige Verluste zu melden und dafür langfristíge Gewinne steuerfrei zu kassieren, doch jeder versucht halt was er kann - bzw. wie er kann, die biologischen Grundkenntnisse usw. sind.

Auf jedenfall finde ich die momentane Situation für diesen Wert extrem positiv und die Analystenschätzungen in den USA gehen bereits längst von einem Kursziel von etwa 9 $ aus, was bei einer an der AMEX gelisteten Gesellschaft die noch dtl. Unterbewertung klar aufzeigt,

d.h. für mich jedenfalls, es gibt für Euch nur eine Devise, und die heisst kaufen

@ all: keep cool and look forward at your largest wave this year

[erbla]

@biotech_nett

@ erbla:

mit diesen Daytrades wirst Du hier wahrscheinlich immer loosen, manches ist gut, manches ist schlecht,

Sei versichert, ich mache meinen Schnitt mit meinen Geschäften, insbesondere diesen Sommer/Herbst, auch wenn immer mal wieder eines daneben geht.

Du weisst, zuviel hin und her macht einfach nur den Geldbeutel leer,

doch wenn es dann doch mehr wird hast Du immer den netten Fiskus dabei, zumindest falls Du ein ordentlicher Steuerzahler bist, was natürlich niemand bezweifelt

... doch mancher sollte bedenken, bei einer Haltefrist von über einem Jahr können diese Gewinne steuerfrei in das eigene Portemonnai fliessen

Ich hab lieber steuerpflichtige Gewinne als steuerfreie Verluste. Ich beteilige den Eichel bzw. nun seinen designierten Nachfolger Steinbrück gerne, denn für jeden Euro, denn ich denen geb, landen etwa drei in meinem Sack.

Ergo:

Es sollte versucht werden kurzfristige Verluste zu melden und dafür langfristíge Gewinne steuerfrei zu kassieren, doch jeder versucht halt was er kann - bzw. wie er kann, die biologischen Grundkenntnisse usw. sind.

Ja, jeder nach seinem Gusto. Für langfristige Geschäfte hab ich weder das Händchen noch die Geduld, von den kurzfristigen Geschäften versteh ich was und es macht Spass.

[erbla]

Hier übrigens noch etwas Bedenkliches zum Thema Tamiflu:

Vogelgrippe-Virus mit Resistenz gegen Tamiflu entdeckt

http://www.spiegel.de/wissenschaft/mensch/0,1518,379817,00.h…

[Aptamilla]

[posting]18.283.677 von erbla am 14.10.05 21:21:49[/posting]Hallo Erbla!Du bist ein Trader mit High Risk Syndrom und hast Deinen berühmten Nervenkitzel dabei.Ist okay und absolut Deine Sache.Doch im Endeffekt sind Spieler gefährdet,denn sie agieren in der Grauzone zwischen"Gut und Böse."Meine Meinung(kein Vorwurf).Tamiflu wird im Moment angepriesen und massenhaft geordert.Keine Frage!Doch Roche ist im Grunde genommen nur Lizenzteilnehmer.Forschen veranstalten(Bio-Firmen) z.B.Antisoma im Krebssektor oder Hemispherx im HIV,Hepatitis C und in der Vogelgrippesparte.HEB ist nah dran mutierende H5N1 Erreger mit Ampligen zu korregieren und auszuschalten.Tamiflu und Ampligen zeigten in Kooperation beste Resultate.Dies bestätigt eine Dualkombi als fortgeschrittene Alternative zum Normalprodukt.Da wir als Anlger mit Logik und Verstand arbeiten,sagt mir diese klinische Studie ein konkretes Geschäft voraus.Da Erreger mutieren,könnte diese spezielle Kombi durchaus greifen,fortgesetzt zu werden.Für Roche ist HEB ein gefundenes Fressen(Peanuts) diese Kooperation auszubauen und zu lizenzieren.Es liegt nahe diese Annahme ernstzunehmen.Für Infos klicke auf Hemispherx.net/invest und betrachte den Newsflow vom 06.09.2005.MfG

[Aptamilla]

[posting]18.284.045 von Aptamilla am 14.10.05 22:01:21[/posting]Die AMEX hat im positiven Terrain am späten Freitag geschlossen.Die erwartete Konsolidierung ist nunmehr abgeschlossen.

[Aptamilla]

Also liebe passive Lesergemeinschaft.Nicht mehr zögern sondern handeln.Das Virus schreitet unaufhaltsam nach Europa.Roche ist als Pharmahändler mit Tamiflu beauftragt worden grosse Mengen zu produzieren,aber selbst kein Entwickler von Antikörpern.Das machen die"kleinen"Biotechfirmen,unter anderem Hemispherx.Da sehr bald endgültige Resultate vorliegen werden,kann sich Roche durchaus einem lukrativen Deal mit HEB leisten.Die Begründung liegt darin,das H5N1 als mutierendes Virus durchaus ausarten könnte.Eine Kombistudie von Roche und Hemispherx waren im September besonders positiv verlaufen.Ein Grund auf HEB zu setzen und nicht weiter zu zögern.Gestern gab es an der AMEX verdammt hohe Umsätze.Das sagt grosses Interesse der amerikanischen Anlegerschaft aus.Wer Infos über KGV und EPS von HEB einsehen möchte,kann Onvista(Snapshot)anklicken und staunen.MfG Aptamilla

[Aptamilla]

In den ARD-Tagesthemen wurde konkret über die Virusgrippe berichtet.Demnach wird in Amerika die Forschung gegen H5N1 ernsthaft gebündelt.Meine Vermutung bzgl.Roche nach Forschungspartnern bestätigt sich nunmehr punktgenau .Das hat für HEB einen immens grossen spekulativen Charakter.Weil Kombistudien mit Ampligen und Tamiflu hervorragend ausfielen,ist eine Kooperation mehr als wahrscheinlich.Wohl dem der handelt und sich einige Stücke ins Depot legt!P.Sie AMEX hat mit leichten Abschlägen mustergültig konsolidiert.Somit ist der Weg für weitere Kursaufschläge frei.

[Aptamilla]

Gestern 5,5 Millionen Volumina,heute gerade mal ein Zehntel bei diesem Börsenumfeld an der AMEX.Das heisst,leichte Gewinnmitnahmen und keine zittrigen Hände.Wohl dem der an HEB dranbleibt!

[biotech_nett]

Guten Morgen @ all,

es soll Leute geben, die ärgern sich darüber gewisse Aktien zu früh verkauft zu haben,

ich halte, wie weit sagtet ihr nochmal???

[Aptamilla]

Was mich wundert ist,das in Deutschland fast null Aktien gehandelt werden.Die letzten zwei Wochen waren es in Amerika zig Millionen.HEB wird anscheinend nicht beachtet.Sehe mich fast schon als"only alone"an.Doch wenn es funktioniert mit der Zulassung,werde ich einer der wenigen sein die jubeln.Wohl dem der einsteigt.

[cyberhai]

Ich werde mitjubeln

Gruß Cyberhai

[Trappertoni]

Ich auch

Könnte `ne nette Anzahlung auf ein Häuschen werden

Vielleicht sollte man den Fokus nicht immer nur auf die Vogelgrippe beziehen. Da wird im Pharmabereich derzeit nur von Tamflu bzw. Relenza gesprochen. Ampligen ist hier völlig außen vor.

So long
Trappertoni

[biotech_nett]

Hallo Trapprtoni,

schön Dich zu sehen, sagte doch, Du hast die richtige Nase

Was sagst Du ist real??? - KZ anvisieren, langfristig??? - Die ersten sind schon steuerfrei

[Aptamilla]

Was mich verblüfft ist die Tatsache,das hier bei uns das Handelsvolumen lächerlich dünn ist.Da sind doch immer noch Basher dabei ,die zum Discountpreis HEB drücken und haben wollen.Anstatt vernünftig zu ordern,liebäugeln sie mit der 1 Euro-Marke.Wohl dem,der dabei im Rohr krepiert!!!

[Aptamilla]

Der Vogelgrippevirus hat nun Schweden erreicht.Das Einzugsgebiet nach Deutschland ist nur eine Frage der Zeit.H5N1 bleibt die Gefahrenquelle Nummer eins für die Menschheit.Das haben wohl alle Regierungen verstanden.Hemispherx ist das einzige Biotechunternehmen,welches mit Ampligen nah vor der Zulassung gegen Vogelgrippe steht.Dieses Medikament wird grosse Wirksamkeit erzielen,weil es intravenös verabreicht wird und nicht oral.Tamiflu ist dagegen ein Basisprodukt,welches auf mutierende Viren an Effektivität einbüsst.Akzo Nobel z.B.forscht neuerdings nach Vg.,das aber viel zu spät.HEB steht mit Phase 3 auf Zulassungskurs.Wer bald handelt wird gewinnen.Apta!

[cyberhai]

Hallo Aptamilla,

ich habe mir die Sache nochmals genauer angeschaut, der Wirkstoff gegen die Vogelgrippe befindet sich meiner Meinung nach erst in der vorklinischen Studie, hier die letzte Meldung:

Ampligen (R) Enhances the Effectiveness of Tamiflu Against Avian Influenza
Tuesday September 6, 8:30 am ET
Second Independent Preclinical Study Confirms dsRNA Increases Flu Vaccine Effectiveness

PHILADELPHIA--(BUSINESS WIRE)--Sept. 6, 2005--Hemispherx Biopharma, Inc. (AMEX: HEB - News) today reported two new preclinical studies on double-stranded RNA (dsRNA), including Ampligen®, one of its flagship experimental immunomodulators. Both preclinical studies suggest a new, and potentially pivotal, role of dsRNA therapeutics in improving the efficacy of the present standards of care in both influenza prevention and treatment of acute disease.

ADVERTISEMENT
The first preclinical report, conducted by research affiliates of the National Institutes of Health at Utah State University, compared the relative protection conveyed by Tamiflu (oseltamivir, Roche) and Ampligen® (dsRNA, Hemispherx), alone and in combination against the avian flu virus (H5N1). Cell destruction was measured in vitro using different drug combinations. Both drugs, given alone, were effective in inhibiting cell destruction by avian influenza, but viral "suppression with the combination was greater than either drug alone". The researchers reported, in summary; "The overall assessment is that there was improvement in cell protection when Ampligen® was combined with oseltamivir carboxylate" (Tamiflu). Further immediate experimental tests are planned.

At present, a narrow window of opportunity (approximately 48 hours) exists for effective utilization of Tamiflu after exposure to influenza. By providing a new mechanism of inhibition of avian flu, (i.e. immunologic/host defensive immune cascades), Ampligen®, an experimental immunotherapeutic, may afford a new approach to help combat influenza virus.

Double-stranded RNA (dsRNA), such as Ampligen®, are also specific inducers of broad-spectrum antiviral/immune response. Recently, Japanese researchers (Journal of Virology page 2910, 2005) have also found that dsRNA`s increase the effectiveness of influenza vaccine by more than 300% and may also convey "cross-protection ability against variant viruses" (mutated strains of influenza virus). Ampligen® recently completed Phase III testing in the chronic disease, Chronic Fatigue Syndrome (CFS).

Hemispherx Biopharma recently disclosed in a letter to shareholders (September 1, 2005) that it has increased the capacity of its facility in New Brunswick, NJ to manufacture Ampligen® , as well as advancements in the application of Alferon LDO for potential treatment of avian flu.

Lt. Pipeline wird Alferon auch gegen die Vogelgrippe vorklinisch getestet:

http://www.hemispherx.net/content/rnd/product_candidates.htm

Oder sehe ich da was falsch?

Gruß Cyberhai

[Aptamilla]

[posting]18.404.333 von cyberhai am 23.10.05 22:01:03[/posting]Hallo Cyberhai,Schau mal unter(HEB-Homepage)"Investor Relations"-Recent News vom 06.09.2005.Habe mir die Seite übersetzen lassen.Dort wurde eindeutig die von mir beschriebene Ampligen-Tamiflu-Kooperationsstudie beschrieben.Wenn Du HEB zurück verfolgst,sind übrigens bemerkenswerte Textreihen über weitere Präperate beschrieben.Ein Grund mehr,HEB zu favoritisieren.Gruss Apta

[cyberhai]

Aptamilla, ja diese Studie ist aber vorklinisch und Du schreibst von Phase III...

[Aptamilla]

[posting]18.417.226 von cyberhai am 24.10.05 18:07:28[/posting]Stimmt Cyberhai,doch hineininterpretiert stellt sich dennoch eine vergleichbare Zulassung dar.Die Testergebnisse in Kooperation mit Tamiflu sind nahezu vorzüglich.Kommt es zum "Showdown",ist mit Roche und HEB ein gewolltes und zwingendes Medikament vorhanden.Die FDA wird nicht nach Testreihen verlangen,da Ampligen ein anerkanntes und vielseitiges Produkt darstellt.Nicht umsonst wird fieberhaft geforscht und Milliarden von Dollars zur Verfügung gestellt.Ich korrigiere mich aber mit Phase 3.Im Endeffekt interessiert aber der Markt und die Kurse.Eine Mogelpackung ist Hemispherx auf keinen Fall!Gruss Apta

[cyberhai]

O.K. Aptamilla, jetzt haben wir die Sache geklärt und wir können uns zusammen auf weiterhin steigende Kurse freuen, hier der letzte:

HEMISPHERX BIOPHARMA (RT-ECN)
Symbol: HEB
Last Trade: 2.42 1:44PM ET
After Hours Change: N/A
Today`s Change: Up 0.19 (8.52%)
Bid: N/A
Ask: 2.89

Ich sehe hier gleiches Potential wie bei Novavax, wo ich ebenfalls investiert bin.

Gruß Cyberhai

[Aptamilla]

[posting]18.423.041 von cyberhai am 24.10.05 22:14:39[/posting]Hi Cyber,der Weg zeigt nach oben.Gruss Apta

[cyberhai]

Ja, sieht super aus, hier der Langfristchart:



Gruß Cyberhai

[Aptamilla]

Cyberhai,Deine Art und Weise gefällt mir.Drücken wir die Daumen,das es weiter aufwärts geht.Gruss Aptamilla

[cyberhai]

Beruht auf Gegenseitigkeit, schau Dir mal Novavax an

Gruß Cyberhai

[Aptamilla]

[posting]18.439.032 von cyberhai am 25.10.05 20:05:42[/posting]Woooh,da geht ja die Post ab!Gibt es irgendwelche Neuigkeiten bei beiden Unternehmen?Weiss wohl,das Nico Voss"Novavax" empfiehlt.Bei HEB kann ich nichts finden,aber mich verblüfft das aussergewöhnlich hohe Umsatzvolumen seit ca. 2 Wochen.Schau ich mir Deinen Chart an,wurde HEB noch nie so intensiv gehandelt.Hast Du schon das 2006 KGV und EPS gescheckt?Bei Onvista(Snapshot)kannst Du es erkennen.Schaut gut aus. Gruss Aptamilla

[cyberhai]

Aptamilla, Du hast recht, das Volumen ist riesig (hast ja auch bereits bei Novavax geschrieben). Ich kann mir durchaus vorstellen, dass sowohl Hemispherx als auch Novavax aufgrund der hervorragenden Pipeline und der noch relativ niedrigen MK übernommen werden.

Ansonsten wie immer, Umsatz und Kurs niedrig - keinen interessierts. Phantasie + mehr Umsatzvolumen und alle rennen hinterher und wollen kaufen

Gruß Cyberhai

[cyberhai]

Das habe ich noch gefunden:

Hemispherx Biopharma Signs Letter of Intent with HollisterStier Laboratories LLC for the Production of Ampligen(R)
Monday October 10, 8:30 am ET

PHILADELPHIA--(BUSINESS WIRE)--Oct. 10, 2005--Hemispherx Biopharma, Inc. (AMEX: HEB - News) has signed a Letter of Intent (LOI) with HollisterStier Laboratories of Spokane, Washington, for the contract manufacturing of Hemispherx`s experimental drug, Ampligen®. The achievement of the initial objectives described in the LOI, in combination with the Polymer production facility under construction in New Brunswick, N.J., will enable Hemispherx to manufacture the Active Pharmaceutical Ingredient (API) for approximately 10,000 doses of Ampligen® per week. Based on the LOI, HollisterStier Contract Manufacturing has agreed to fill the Ampligen® API from Hemispherx. Production for significantly larger quantities of product are planned thereafter. Hemispherx has already commenced the process of transferring manufacturing technology to HollisterStier.

ADVERTISEMENT
Doug Hulse, Chief Operating Officer and President commented, "We are pleased to be working with HollisterStier, a highly professional group who can support the full commercialization of Ampligen® upon FDA approval. We selected this group from a qualified pool of manufacturers and look forward to executing our manufacturing strategy with them."

Anthony Bonanzino, President and CEO of HollisterStier noted, "The new relationship with Hemispherx Biopharma represents an exciting addition to our well established client portfolio. We are pleased with the Hemispherx decision, and strongly believe the Hemispherx manufacturing strategy is an excellent match to HollisterStier`s core competencies."

Hemispherx recently completed Phase III testing of Ampligen® for Chronic Fatigue Syndrome (CFS).

About Hemispherx Biopharma

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Hemispherx`s flagship products include Alferon and the experimental immunotherapeutics/antivirals Ampligen® and Oragens(TM). Alferon is approved for a category of STD infection, and Ampligen® and Oragens(TM) represent experimental nucleic acids being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Hemispherx`s platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has in excess of 140 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

About HollisterStier

HollisterStier Contract Manufacturing provides a complete range of services to support the pharmaceutical and biopharmaceutical industries. The company has specialized competencies essential for compounding and filling sterile products. Outsourcing services include vial and syringe filling, as well as commercial and clinical scale capabilities for lyophilization. HollisterStier Laboratories LLC is privately held and located in Spokane, Washington. For more information go to fill.hollisterstier.com.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen® and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon® do not imply that the product will ever be specifically approved commercially for these other treatment indications.

_________________________________________________________


20-Oct-2005

Entry into Material Agreement

Item 1.01 Entry into a Material Definitive Agreement.

On October 17, 2005, we engaged the Sage Group, Inc., a health care, technology oriented, strategy and transaction advisory firm, to assist us in obtaining a strategic alliance in Japan for the use of Ampligen(R) in treating Chronic Fatigue Syndrome or CFS.

The initial term of the engagement will be one year unless terminated by either party in six months. The engagement may terminate prior to the end of the term upon the completion of a licensing or other conveyance of Ampligen(R) rights for use in CFS for Japan or a sale of all, or substantially all, of our common stock or assets (a "Transaction") to an entity identified by Sage or us prior to or during the term of the engagement that may have an interest in Ampligen(R) for use in CFS in Japan (a "Target"). The engagement may be extended by mutual agreement of the parties.

For its services, Sage will receive a monthly fee during the term of the arrangement of $2,000. It also will receive up to an aggregate of 340,000 10 year common stock purchase options upon completion of certain stated goals. If we enter into one or more Transactions with a Target during the term of the engagement or during the year thereafter, Sage will be entitled to a success fee equal to 3% of our receipts from the Transaction up to a maximum fee of $3,000,000.

R. Douglas Hulse, our President and Chief Operating Officer, is a principal and an executive director of The Sage Group, Inc.

_____________________________________________________


AWBV, HEB and URBN Update The Investment Community in All-New Interviews With WallSt.net
Tuesday October 25, 7:00 am ET

NEW YORK, Oct. 25 /PRNewswire/ -- On September 22, Donald Platten, CEO of American-Way Business Development Corp. (OTC: AWBV - News) updated the investment community in an all-new, exclusive interview with Wall Street Network (www.wallst.net). Interview highlights include detailed discussions on the following topics:

* closing five acquisitions since the onset of 2005
* paying shareholders seven dividend checks from seven spin-off companies
in 12-18 months
* current capitalization
* overview of the Company`s subsidiaries
* acquisition strategy
* upcoming strategic and financial milestones

To hear the interview in its entirety, and to read an in-depth report on the Company, visit http://wallst.net/superstock/AWBV/awbv.html

On October 21, Doug Hulse, President and Chief Operating Officer for Hemispherx Biopharma, Inc. (Amex: HEB - News) updated the investment community in an all-new, exclusive interview with Wall Street Network. Interview highlights include detailed discussions on the following topics:

- target markets for Alferon N
- overview of the Company`s drug candidates
- relationship with the National Institute of Infectious Diseases of
Tokyo
- role of the Company`s double-stranded RNA-based Ampligen in an
influenza vaccine
- current capitalization
- upcoming development and financial milestones

On October 17, John Kyees, Chief Financial Officer for Urban Outfitters, Inc. (Nasdaq: URBN - News) updated the investment community in an all-new, exclusive interview with Wall Street Network. Interview highlights include detailed discussions on the following topics:

- organic growth vs. M&A
- acquisition strategy
- key drivers behind consistent growth
- expanding on current target demographics
- why the Company is a safe investment in retail
- upcoming strategic and financial milestones

To hear the interviews in their entirety, visit www.wallst.net. The interviews can be accessed by locating the respective company`s ticker symbol under the appropriate exchange on the left-hand column of the homepage, or by entering the respective company`s ticker symbol in the Audio Search window.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO )

About Wall Street Network

Wall Street Network is owned and licensed by Wall Street Direct, Inc. All material herein was prepared by Digital Wall Street, Inc., a multimedia provider of original, insightful commentary and news from North America`s leading publicly traded companies giving a direct link to the management of today`s fastest-growing companies through encompassing executive interviews and sector seminars. Digital Wall Street, Inc. has received four million five hundred thousand restricted shares of AWBV from the company for media and advertising services. For a complete list of our business relationships, visit www.wallst.net/disclaimer.asp.

Contact:
Nick Iyer
Digital Wall Street, Inc.
800-4-WALL-ST


Gruß Cyberhai

[Aptamilla]

[posting]18.440.657 von cyberhai am 25.10.05 21:53:19[/posting]Dito!!!

[Aptamilla]

Hallo Cyberhai,Du musst ja in Glückseeligkeit baden.Deine beiden Werte sind heute rein zufällig zusammen im Anlegermagazin"Der Aktionaer"beschrieben worden.Habe einen kleinen Beitrag dazugegeben,indem ich schon vor 2 Wochen der Redaktion einige Mails gesendet hatte;bezüglich HEB-Pipline.Wünsche uns noch steile Anstiege!Gruss Aptamilla

[cyberhai]

Hallo Aptamilla,

ja, läuft ganz gut. Jetzt kommt wieder die quälende Frage, wann man die Gewinne realisiert bzw. wieviel, wollte ursprünglich mal einen Tenbagger ohne Gewinnmitnahmen durchhalten - Novavax müsste sich jetzt noch ca. verdoppeln, dann wäre es soweit Bei Hemispherx sind es jetzt ca. 100%.

Weiterhin viel Erfolg

Gruß Cyberhai

[Aptamilla]

[posting]18.455.895 von cyberhai am 26.10.05 16:41:46[/posting]Widerstandsmarke bei 3 Dollar wie Butter durchbrochen.Für HEB hohes Volumina weiterhin.Geht nun Richtung 5 Dollar.Gruss Apta

[Aptamilla]

Fettes Volumen auch heute.Bin der Meinung,das die Konsortiumbanken von Hemispherx kräftig ordern.Ausserdem vermute ich Treuhänderkäufe für den Roche-Konzern.Ergebnis:....$$$$$ Gruss Apta

[Aptamilla]

Wenn man sich den Newsflow von Hemispherx anschaut,merkt man schnell,wie Ampligen als potenzieller Hoffnungsträger fungiert.Habe mich eben über die gegenwärtigen Preise von Tamiflu bzw.Relenza informiert.Das Päckchen Tamiflu kostet 50$.Relenza ist mit einer 5 Tagesration 57$ teuer.Eine Familie müsste mit durchschnittlich 200$ rechnen.Jetzt rechnet man hoch und kommt zum Ergebnis eines gigantischen Milliardenmarktes.Hemispherx ist in Eigenschaft eines Globalplayers im Sektor Grippe stark unterbewertet.

[cyberhai]

Habe heute ein Interview mit dem Vorstand von Roche gelesen, planen ca. 1,5 Milliarden Umsatz mit Tamiflu für dieses Jahr.

Heute hat es mich extrem gebäutelt - war einer der größten Tagesverluste in meinem Gesamtdepot

Gruß + gute Nacht

Cyberhai

[Aptamilla]

Prognose von GlobalValue punktgenau getroffen!HEB hat gut konsolidiert.Trend nach oben unverkennbar.Newsflow von HEB hochinteressant.Weil:1.japanisches Institut stellt 300% Wiksamkeit fest.Hintergrund:Japan liegt am "Brandherd" des Auslösers.Wenn es zum Ernstfall käme,könnte kein Schiff mehr anlegen,kein Flugzeug in Japan landen.Isoliert käme es wirtschaftlich einer Katastrophe nahe.Die amerikanische Regierung stellte Chiron heute 62,5 Millionen Dollar für eine rechtzeitige Einführung eines Grippeimpfstoffes zur Verfügung.Leider hat Chiron Probleme einen Grippewirkstoff schnellstens anzudienen.Die Tamiflu/Ampligen Kombination ist die einzigste Alternative im mutierenden Grippevirusbereich.Da es sich um einen aggressiven Grippevirus handelt,der in seiner H5 Form 16 Typen beinhaltet und N1 mit 8 Typen aufwartet,erkennen wir eine enorme Gefährdung vom prinzipiellen Aufbau.Weder Novavax noch Akzo Nobel oder Chiron können dieser Aufgabe kurzfritig gerecht werden.Roche weiss um die Bedeutung eines neuen Präparats in Verbindung des "Katalysators"Ampligen.Schon bald merken wir,das sich einiges in der Hinsicht bewegen wird.Roche macht Milliarden Umsätze durch Biotechfirmen aus zweiter Reihe.Auch Antisoma hat 2006 grosse Chancen,Roche ein weiteres Highlight zu präsentieren.Überlegt und handelt im Sinne von Hemispherx Gruss Aptamilla

[cyberhai]

O.K. Aptamilla, hast mich überredet, werde nächste Woche nachkaufen, falls es runter geht, kriegst Du die Rechnung

Gruß Cyberhai

[Aptamilla]

[posting]18.500.321 von cyberhai am 29.10.05 08:57:39[/posting]Good morning Cyberhai,ist im Grunde Deine Entscheidung.Ich versuche immer zwei Schritte mit Logik vorauszudenken.Novavax ist bestimmt nicht schlecht,aber HEB mit Roche ist super spannend.Roche wird mit grosser Sicherheit nicht der anstehenden Konkurrenz das Feld überlassen.Wie schonmal gesagt,so oder so kommt ein neuer Impfstoff auf den Markt.Tamiflu und Ampligen sind derzeit konkurrenzlos erfolgreich.Ist vielleicht noch eine Frage der Zeit.Gruss Aptamilla

[Masse]

Hallo,

das Short Interest von HEB ist im Okober wieder stark angestiegen:

Date / Short / Avg Daily / Days to Cover
Oct. 14, 2005 890,572 810,028 1.10
Sep. 15, 2005 387,758 127,228 3.05
Aug. 15, 2005 419,539 61,971 6.77
Jul. 15, 2005 368,446 79,900 4.61
Jun. 15, 2005 367,675 72,809 5.05
May 13, 2005 372,618 52,268 7.13
Apr. 15, 2005 383,791 86,742 4.42
Mar. 15, 2005 382,651 167,815 2.28
Feb. 15, 2005 380,781 87,119 4.37
Jan. 14, 2005 478,749 100,614 4.76
Dec. 15, 2004 631,332 154,109 4.10
Nov. 15, 2004 1,551,516 90,790 17.09

Auf Grund des hohen Volumens, ist aber "Days to Cover" stark zurückgegangen.

Gruss Masse

[Aptamilla]

Tamiflu braucht Ampligen.Aber Ampligen nicht unbedingt Tamiflu.Somit würde kein neues dringend notwendiges Grippemedikament enstehen.Das weiss der Roche Konzern.Seit September wird fieberhaft und gezielt mit Ampligen getestet.In Japan und Amerika.Schon sehr bald werden wir Ergebnisse sehen,die bestimmt herausragen werden.In diesem Sinne;der Erfolg steht eigentlich vor der Tür.

[Aptamilla]

Hallöchen miteinander,wenn ich mir den Chart so anschaue,dann bin ich für die zukünftigen Monate wohlgestimmt.Warum?Nur postive News zeigen den Weg nach oben!

[VNDong]

[posting]18.824.308 von Aptamilla am 15.11.05 14:41:15[/posting]hi Apta, ich bin leider nicht richtig zeitpunkt eingestiegen, bei 3.3 usd, (beobachtet biotech wert gerade seit paar wochen) seitdem leider ich nur in der misser, habe keine ahnung ob HEB nochmal 3.3 sehen wird, wieso verkaufen die alles ab, wenn so gut news gekommt ist, HEB hat kein geld mehr um zu überleben`?

[Aptamilla]

Klingt ja nicht gerade zuversichtlich was Du schreibst.Die 3.3 wird schnell wiederkehren.Da sind zwei ganz interessante Wirkstoffpräperate in der Pipline mit hohem Chancenpotenzial.Ampligen hat in zwei Zuammensetzungkombinationen(Tamiflu und Relenza)sensationelle Ergebnisse erzielt.Das ist Fakt.Fehlt nur noch ein starker Partner(er wird sicher bald kommen)und eine Zulassung der FDA.Dann wirds eine zweite "Viropharma"geben.Übrigens,was meinst Du mit Geld nicht auskommen?HEB hat noch genügend Optionen in etwaigen Geldangelegenheiten.Also,Kopf hoch und Geduld üben.MfG Aptamilla

[cyberhai]

Ich kann das bestätigen

Gruß Cyberhai

[Aptamilla]

Hallo cyberhai,schön Dich zu sehen!Was macht Novavax?Bist Du noch investiert?Und was gibt`s an Neuigkeiten im Sektor Vogelgrippe.Gruss Aptamilla

[cyberhai]

Hallo Aptamilla,

freut mich auch, dass Du wieder da bist. Ich hoffe Du hast Dich gut erholt

Bei Novavax gibts derzeit nichts neues außer dem heutigen Rebound von 19 % unter relativ großem Volumen, bin da ebenfalls noch investiert und denke, dass wir die 6 Dollar innerhalb der nächsten Wochen wieder sehen werden. Die haben immerhin bereits ein Medikament im Vertrieb, was aus meiner Sicht noch viel Potenial hat und in gewisser Weise als Polster herhalten kann.

Gruß Cyberhai

[Aptamilla]

Guten Morgen zusammen!In China ist ein erster Fall von Vogelgrippe festgestellt worden.Es sieht so aus,als ob sich der Virushype fortsetzen wird.Wieder einmal hohes Volumina an der AMEX.Global Value,wie siehst die weitere charttechnische Tendenz in den kommenden Tagen?Gruss Apta

[Aptamilla]

Denke,heute wird es an der AMEX wieder kräftig nach oben gehen.In Amerika ist der Tenor auf "Strong Buy" eingestellt.

[VNDong]

[posting]18.839.650 von Aptamilla am 16.11.05 14:41:51[/posting]aber bei HEB passiert gar nicht, nur NVAX und andere
irgend was falsch bei HEB?

[cyberhai]

HEB entwickelt sich ähnlich bzw. sogar teilweise sogar fast identisch wie NVAX (jedenfalls über mehrere Tage gesehen - ich kann das gut beurteilen, da ich ja in beiden drin bin). Hier z.B. heute:

NOVAVAX INC (RT-ECN)
Symbol: NVAX
Last Trade: 3.68 10:57AM ET
After Hours Change: N/A
Today`s Change: Up 0.19 (5.44%)
Bid: 3.67
Ask: 3.68

HEMISPHERX BIOPHARMA (RT-ECN)
Symbol: HEB
Last Trade: 2.95 9:37AM ET
After Hours Change: N/A
Today`s Change: Up 0.19 (6.88%)
Bid: 2.80
Ask: 3.10

Gruß Cyberhai

[cyberhai]

Da war wohl ein sogar zuviel

[Aptamilla]

Thank`s Cyberhai für die Info.Da Tamiflu und Relenza um Ampligen buhlen werden,räume ich HEB zukünftig gute Chancen ein.Novavax ist okay aber nicht sehr spannend.Trotzdem wünsche ich Dir gute Kurssteigerungen.Übrigens,wie errichte ich einen neuen Thread?Kannst Du mir helfen!?Gruss Apta

[cyberhai]

Hi Aptamilla,

gehe links auf Diskussionen, da steht oben dann Neuer Thread eröffnen.

Gruß Cyberhai

[Aptamilla]

Die FDA und EMEA verlangen von Roche einige Erklärungen über Tamiflu.In Japan seien einige Kinder nach Einnahme dieses Mittels gestorben.Für Hemispherx eröffnet dieser Aspekt neue Chancen mit Ampligen als Zusatzwirkstoff zu kooperieren.Seit geraumer Zeit hatte sich Ampligen auch mit Relenza gut kombinieren lassen.In Japan forscht man auch erfolgreich mit Ampligen.Das schliesst auf baldige Nachrichten,die bahnbrechende positive Folgen für HEB haben könnte.Spekulative Anleger sollten sich möglichst bald positionieren und sich einige Stücke ins Depot legen.

[VNDong]

[posting]18.866.715 von Aptamilla am 18.11.05 14:43:51[/posting]am Montag wird diese Nachrichten veröffentlichen

Studies on combinational treatments against Avian influenza are extended

2005 NOV 21 -- Hemispherx Biopharma, Inc., (HEB) has extended a preclinical report conducted by research affiliates of the U.S. National Institutes of Health at Utah State University to examine potential therapeutic synergies with more than 10 different drug combinations.
The ongoing research is comparing the relative protection conveyed by Tamiflu (oseltamivir, Roche) and Ampligen (dsRNA, Hemispherx), alone and in combination, against the avian flu virus (H5N1).


ich warte bis montag, überlegt ob ich mein limit hoch ziehen, kommt immer ein stopfishing manöver vor bull

[VNDong]

[Aptamilla]

[posting]18.868.589 von VNDong am 18.11.05 16:42:12[/posting]Hallo VNDong,Deine Chartdarstellung ist professionell aber mit der Nachricht vom 21.November kann ich nicht folgen.Die Homepage von Hemispherx sagt nichts über neue Nachrichten aus?!Gruss Apta

[VNDong]

oh aptamilla,

was ist das?
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx…

[tilt]

wenn hier nicht bald eine vernünftige meldung kommt sind die ersten angsthasen schon wieder raus
keine geduld die jugend von heute

mfg tilt

[Aptamilla]

[posting]18.933.364 von tilt am 22.11.05 09:12:53[/posting]Die News werden bald kommen.Bin zwar kein Prophet wie VNDong,der anscheinend in der Vergangenheit lebt.Aber zuletzt arbeiten viele Forschungsinstitute an dem Ampligenwirkstoff.Das wird der Aktie den nötigen Schub bescheren.Gruss Aptamilla

[VNDong]

[posting]18.933.861 von Aptamilla am 22.11.05 09:38:03[/posting]apta

HEB geht seit tagen abwärt, muss es bestimmt was dahinter stecken oder? irgendwas nicht in ordnung ins unternehmen, finanzierung, ..... etc....?

ich warte immer noch auf 2.25

[GlobalValue]

Hallo VNDong !
Ich wünsche dir ja alles Gute, aber die 2,25 müssen nicht unbedingt sein, obwohl das jetzt nicht mehr so unmöglich ist.
Leider sind wir nach unten durchgebrochen und haben mal gleich mehrere Wiederstände durchbrochen. Unterer Stop bei 2,25 also nicht unmöglich. Schöner wäre wenn wir vorher drehen und am Besten natürlich heute noch über 2,5 schließen. aber bei dem Volumen nach unten halte ich das für nicht glaubwürdig.
Ja, was fehlt sind Nachrichten und das treibt die meisten Kleinen raus, denn die Umsätze sind zwar hoch, aber die einzelnen Order alle klein.
Man wird sehen was die Woche noch bringt - ist eh bald um ( Feiertage in USA ).
Schönen Abend noch !
Gruß GV !

[VNDong]

[posting]18.943.844 von GlobalValue am 22.11.05 20:18:18[/posting]vielleicht wird meine order heute ausgeführt


Chart öffnen

[VNDong]

[/URL][/IMG]

[VNDong]

Chart öffnen

[VNDong]

vielleicht wird meine kaufsorder heute bei 2 und 2.25 ausgeführt

[VNDong]

ich bin on board mit euch
10 K bei 2.25 ausgeführt, habe 10 tage GTC order gewartet
andere 10 K order liegt bei 2

[GlobalValue]

Hallo VNDong !
Schön das du dabei bist.
Nun will mal hoffen, das die 2 nicht noch kommt.
Eigentlich müsste der Wiederstand bei 2,25 nun halten.
Langfristig ist der Wert auf alle Fälle vielversprechend.
Es fehlt halt die Zulassung der FDA , damit der Knoten platzt.

Dann erhöhe mal für die nächste Order lieber das Limit.

Gruß GV

[cyberhai]

VNDong, Glückwunsch - ich glaube Du hast den richtigen Zeitpunkt gewählt...

Gruß Cyberhai

[VNDong]

[posting]18.956.449 von cyberhai am 23.11.05 18:45:51[/posting]ich habe die order schon lange, seit 10 tagen
aber ob der 2.25 halten wird weiss ich nicht,
da liegt bei 2 noch eine order
wenn letzt order ausgeführt wurde, setze ich den stop bei 1.90 für die gesamte position

[Aptamilla]

Die Vogelgrippe breitet sich in Asien(China)aus.Ein Investment in Hemispherx ist immer noch sehr zu empfehlen.

[tilt]

wo gibt es meldungen das sich die vogelgrippe in china ausbreitet ?? habe weder davon gehört noch gelesen, außer ein paar einzelfälle.

mfg tilt

[VNDong]

[posting]19.055.445 von tilt am 28.11.05 20:31:18[/posting]ich glaube die hype ist schon vorbei, die meldung kommen sowieso täglich in asien seit jahren

[tonyjaa]

[posting]19.055.445 von tilt am 28.11.05 20:31:18[/posting]http://www.vogelgrippe-virus.de/vogelgrippe-news.php/39667

[tonyjaa]

Hemispherx Biopharma Enters Research Agreement with Defence R&D Canada
Tuesday November 29, 5:00 am ET
Efficacy Evaluation of Ampligen(R) and Alferon(R) for the Prophylaxis of Human Respiratory Influenza Virus Infection

PHILADELPHIA--(BUSINESS WIRE)--Nov. 29, 2005--Hemispherx Biopharma, Inc. (AMEX: HEB - News) announces that they have entered into an agreement with Defence R&D Canada - Suffield (DRDC), an agency of the Canadian Department of National Defence, to evaluate the antiviral efficacy of its experimental therapeutic Ampligen® and Alferon® for protection against human respiratory influenza virus infection in well validated animal models.

DRDC Suffield is conducting research and development of new drugs that could potentially become part of the arsenal of existing antiviral weapons to combat the bird flu. The initial study will focus on the testing of potential drugs against the respiratory influenza virus infection on a mouse-adapted strain of human influenza.

DRDC Suffield has already conducted extensive research in the use of liposome delivery technology to enhance the antiviral activity of a closely-allied Ampligen® analogue, Poly ICLC (an immunomodulating dsRNA) which is very similar to Ampligen®. Results suggest that ribo nucleic acid-based drugs have the ability to elicit protective broad-spectrum antiviral immunity against various pathogenic viruses. Hence, there is the potential for efficacy to be maintained against mutating strains of an influenza virus. Liposomes, a carrier system for nucleic acid-based drugs, have shown an ability to protect these drugs against in vivo degradation, delivering them to intracellular sites of infection, thereby reducing any toxicity and prolonging their therapeutic effectiveness. Protection can be afforded for 21 days with two doses of dsRNA. It is believed that in humans with active flu infection, Tamiflu, given twice daily, may ameliorate symptoms.

"We are very pleased to be included in the DRDC Suffield Study" commented Dr. William Carter, Hemispherx CEO. "Previous studies have shown that there are certain limitations using poly ICLC as an antiviral drug due to its inherent toxicity even though it has pronounced therapeutic activity. In contrast, Ampligen® and Alferon® have encouraging safety profiles to date and Ampligen® shares similar structure with Poly IC. The experimental combination has the potential to be a very promising therapy."

In addition to the DRDC Suffield collaboration, Hemispherx is also engaged in broad-based ongoing experimental studies assessing the efficacy of their products Ampligen®, Alferon N Injection® and Alferon LDO (Low Dose Oral)(TM) as an adjuvant or single agent antiviral with the National Institute of Infectious Diseases in Tokyo, the Princess Margaret Hospital in Hong Kong and various research affiliates of the National Institutes of Health in the United States.

Alferon N® is already commercially approved for another major viral infection, chronic refractory HPV, and Ampligen® has recently completed Phase III clinical testing in another viral associated disorder in the U.S.

About Defence R&D Canada

Defence R&D Canada (DRDC) is an agency of the Department of National Defence responding to the scientific and technological needs of the Canadian Forces. The agency is made up of six research centres located across Canada with a corporate office in Ottawa. DRDC has an annual budget of $300 million and employs 1500 people. With a broad scientific program, DRDC actively collaborates with industry, international allies, academia, other government departments and the national security community.

DRDC Suffield is the Canadian centre of expertise in chemical and biological defence and conducts world-class research and development to provide the Canadian Forces with advice, training and equipment to counter the hazards from chemical and biological threats. DRDC Suffield also carries out research and development in military robotics, countermine and the assessment of explosive threats. Scientific and technological activities are supported by a comprehensive biological and chemical laboratories and field experimental capabilities.

[Aptamilla]

Ich habe es geahnt,das irgendwann positive News ankommen!

[biotech_nett]

musst Dich nur für die News anmelden bei Hemispherx

... Apta, die Hemis kommen

[Aptamilla]

Hallo GlobalValue,wie sieht es Charttechnisch aus?Gruss Aptamilla

[Aptamilla]

Gewinnmitnahmen zum Wochenausklang.Keine nennenswerten News.Niedriges Volumen schliesst auf Schmerzensgeldversilberung.Heisst:erst die Schmerzen,dann das Geld.Happy Weekend ...Apta

[VNDong]

[posting]19.140.801 von Aptamilla am 02.12.05 21:38:38[/posting][URL]http://www.tradesignal.com/content.asp?p=wpa/tsb/default.asp&fcid=1332359[/URL]
[URLChart öffnen]http://www.tradesignal.com/content.asp?p=wpa/tsb/default.asp&fcid=1332359[/URL]

[Aptamilla]

Warum steigt Novavax und nicht Hemispherx?Dabei besitzt HEB die bessere Story und bleibt super spannend.Heute wieder niedrige Umsätze mit Tendenz zum Verkauf.Sieht aus,als ob sich die letzten Trader nun endlich verabschieden und der Kursverlauf zukünftig Stabilität verspricht. Apta

[Aptamilla]

Hollister-Stier und Ampligen.Gute News und Kursanstieg.

[cyberhai]

HEMISPHERX hat heute etwas von der gestrigen Performance von NVAX wettgemacht.

Gruß Cyberhai

[Aptamilla]

[posting]19.224.965 von cyberhai am 09.12.05 22:25:44[/posting]Hallo Cyberhai,lebst Du noch!

[cyberhai]

[posting]19.225.019 von Aptamilla am 09.12.05 22:29:26[/posting]Hi Aptamilla,

ich werde mich hier ordentlich verabschieden, wenn ich verkaufe - heute war ein besonderer Tag - mein Depot hat den Höchststand erreicht.

Ich hoffe, bei Dir läuft es auch gut...

Gruß + gute Nacht

Cyberhai

[tilt]

@ cyberhai
hier ist noch lange keine verabschiedung angesagt und das mit deinem depothöchststand ist auch bald nur noch makulatur.

last euch die news mal auf der zunge zergehen


9-Dec-2005

Entry into Material Agreement



Item 1.01 Entry into a Material Definitive Agreement.
We recently completed our negotiations and executed a Supply Agreement with Hollister-Stier for the production of Ampligen(R) for a five year term. Pursuant to the agreement, we will supply the key raw materials and Hollister-Stier will formulate and bottle the Ampligen. We have agreed to pay a one time start up fee and will provide funds to acquire certain equipment dedicated to Ampligen production


mfg tilt

[GlobalValue]

Hallo Apta !
Wenn ich mich mal über eine Zeit nicht melde hat das nichts mit HEB oder euch was zu tun, aber ich war in Österreich ( nicht im Ski- Urlaub ) und da schaue ich zwar mal kurz rein, aber befasse mich nicht so mit den Kursen (ist manchmal auch ganz gut so, da lebt sich´s einfach lockerer :laugh.
Habe mir mal den Chart gerade angeschaut und bin ganz froh, das die 2,25 also unsere untere Unterstützung gehalten hat und wir nicht die 2 ( und darunter ) gesehen haben.
Wir haben auch die alten Tiefs von Ende November nicht mehr wiedergesehen.
Dazu ist der ganze überkaufte Status abgebaut und der MACD wieder auf dem Stand wie bei 1,5 vor dem ersten Ausbruch nach oben.
RSI und Stochastik ebenfalls positiv. Aus technischer Sicht sind wir wieder Startbereit für einen neuen Schub nach oben.
Hallo VNDong falls du das liest. Mit den 2 ist nichts geworden und bei 2,42 gleich wieder auszusteigen und den Gewinn auch noch versteuern zu müssen ist uncool .
Bei mir liegen Aktien im Depot da liegt schon Staub drauf z.B. MO jetzt besser bekannt als Altria 2000 gekauft bei 20 Dollar ( wollte auch keiner haben ). Nun sind 5 Jahre um und ich hab zwar paar graue Haare mehr, aber schlafe auch ruhiger wie vor 5 Jahren.
Und da ich bei HEB auch durchhalte werde ich irgendwann auf den Malediven aufwachen ) !

Also Technisch ist alles zum Besten und noch ein paar gute Nachrichten ( z.B. hat am 29.11.05 Steven D Spence ( Director bei HEB ) 29000 Aktien zu 2,34 gekauft gesamt seit April 88086 Stück und es wird seinen Grund haben, wenn er jetzt kauft und nicht verkauft!

Also weiter HEB - HEB Hurra !

Gruß und schöne Woche an alle HEBIS
GV

[cyberhai]

[posting]19.235.297 von tilt am 10.12.05 16:46:25[/posting]Hallo tilt,

ich bleibe hier bis mind. Ende nächsten Jahres investiert, bis dahin will ich natürlich noch ordentlich Rendite sehen.

Bis ja auch recht Börsenerfahren.

Hier haben wir das Potential eines Vervielfachers, da lass ich mich nicht so schnell rausschütteln.

Gruß Cyberhai

[Aptamilla]

[posting]19.235.606 von GlobalValue am 10.12.05 17:17:19[/posting]Hallo und vielen Dank!Gruss Aptamilla

[VNDong]

ick sbreche nick deut, nur chert

]

[VNDong]

einstieg @ 2.30 - 35 bei second dip heute euphorish wieder raus average 2.68 sicher is sicher
die wahrscheinlichkeit ein break 2.7 und leitet zu 3.45 W formation oder umgekehr zu M formation 2 oder zurück 2.40 ist 50:50

viel glück für alle die gehalten sind
ich werde meine chance nutzen wenn heb in die 2 bzw 2.4 zone, sonst suche ich irgendwo anders zu trade

[GlobalValue]

Hallo VNDong !
Schön mal wieder jemanden kennen zu lernen, der von sich behaupten kann immer die Höchst und Tiefstkurse zu fassen.
Du wolltest ja eigentlich bei 2 rein beim letzten Mal, aber scheinbar bist du bei 2,35 rein - wieso hast du dann bei 2,42 vorher verkauft ? Nun bist du bei 2,68 raus !
Toll, hast du ja fast auf Tageshoch verkauft, bevor es 5 min später Bergab ging.
Ich bin kein Freund von diesem Früh rein Abends raus.
Meines Erachtens sind wirklich gute Gewinne damit auch nicht zu erzielen. Diese Erfahrung hatte ich vor 10 Jahren gemacht, wo ich analog gehandelt habe. Übrigens war ich scheinbar die totale Ausnahme. Bei mir hat es nicht funktioniert, das ich immer die Tiefst - und Höchstkurse erwischt habe.
Ich handle jetzt mehr nach der Methode entweder ein gutes Unternehmen das mal unter die Räder kommt billig einkaufen und dann liegen lassen ( MO ) oder ein Unternehmen mit langfristigen Potential was vom Markt als solches vielleicht noch nicht so erkannt wird kaufen und warten ( HEB ). Es muss nicht immer klappen, aber es klappt immer öfter .

Ich sende dir meinen besten Gruß und wünsche dir weiterhin die realen größten Gewinne !

MFG GV

[VNDong]

hi globalvalue, ich stimme dich zu, was du alles gesagt hast
es ist unmöglich

aber mein einstieg und ausstieg war nicht bei tief und hoch kurse

die unterschiedlich zwischen mein entscheidung und deine bei heb oder andere war, obwohl ich die heb nicht persönliche kenne, und nur seit anfang november 05 den heb blick werfen wegen überflutten von bird flu news in vietnam.
auf PR news, website ...handelsvolume und ihre kommentare hier in yahoo und wallstreet-online , sagt mir schon eindeutig was ich mit solche aktien umgehen soll
weiss du schon was ich meine, wenn du über 10 jahre börse erfahrung hast

---> ich bin nicht heb gläubiger also kein emotion beeinflussen, trade absolut nach TA
der PR news kommt fast immer vor der börse eröffnung, die nur um den kurs zu manipuliert

du oder andere glaubst an heb, ich nicht, für mich es ist nur ungewissenheit, ich analysiert taktik vergangenheit news und aktienkurs wenn ich ein aktien beobachte

[VNDong]

"Ich sende dir meinen besten Gruß und wünsche dir weiterhin die realen größten Gewinne !"

danke dir
aber was heisst real gewinn
wir sind hier um information, meinung austauschen
es geht hier nicht wer besser oder schlechter ist

wenn ich nicht persönliche heb kenne, es hilf mir nur mit stimmung + TA zu arbeiten, eure anwort auf mein aktivität sagt es mir auch etwas

ob ich real gewinn habe? brauche keine mir glauben
aber es ist zeitverschwendung wenn man nur um spass täglich hier ist

[VNDong]

[posting]19.270.284 von GlobalValue am 13.12.05 11:07:10[/posting]"globalvalue

Unternehmen mit langfristigen Potential was vom Markt als solches vielleicht noch nicht so erkannt wird kaufen und warten ( HEB )"

heb gabe es schon seit mehr als 30 jahre
verdient heb noch kein geld
gibt es bisher irgendein institution beobachtet?
gibt es andere news quelle ausser PR?
schau mal website an, wie sieht denn aus? wie kann man ein unternehmen so präsentiert, vergleich mit andere klein nvax, avii, sva web

[GlobalValue]

Hallo VNDong !
Danke für die zahlreichen Antworten auf die ich dann mal kurz antworten will.
Zu Nr.1 ) also wenn du deine Handlungsweise mit aus den paar hier und bei Yahoo Diskussionen ziehst ( ? ) schau dir mal die wirklich gepuschten Aktien an wo 5000 Kommentare drin stehen / übrigens bringen die meisten Unternehmen ihre Nachrichten vor Börseneröffnung
mit HEB Gläubigkeit hat das nichts zu tun, wenn man mit dem Durchbruch des Wirkstoffes rechnet ( wie gesagt es muss nicht aufgehen, es kann :cool
zu Nr.2 ) " Ich sende dir meinen besten Gruß und wünsche dir weiterhin die realen größten Gewinne !"

danke dir
aber was heisst real gewinn das sind die Gewinne die man hat, nach Steuern
wir sind hier um information, meinung austauschen
es geht hier nicht wer besser oder schlechter istsorry, aber ich schreibe hier nicht meine Einstiegs - Ausstiegskurse rein ( und dazu noch unklare ) am 06.12. wettest du mit Apta das du nach dem du bei 2,45 ausgestiegen bist, das du bei 2 wieder einsteigst und jetzt schreibst du das du bei 2,35 rein und bei 2,68 raus bist und das nachdem der Kurs schon den Sinkflug an dem Tag durchhatte -- na dann viel Spass mit dem realen Gewinn

wenn ich nicht persönliche heb kenne, es hilf mir nur mit stimmung + TA zu arbeiten, eure anwort auf mein aktivität sagt es mir auch etwas schön das dir die Antworten von drei kleinen HEBIS so viel geben

ob ich real gewinn habe? brauche keine mir glauben
aber es ist zeitverschwendung wenn man nur um spass täglich hier ist
natürlich bin ich zum Spass mit hier oder soll ich Trübsinn blasen, bei dem Wetter, nimm es einfach locker

zu 3 )natürlich gibt es tolle Webseiten anderer Unternehmen, aber das heißt nicht das die besser sind
an der Börse ist Heb nun erst seit 1996 und du müsstest wissen, das die Entwicklung von Wirkstoffen bis zur Feigabe bei der FDA es 10 Jahre dauert (Bsp: Amgen Mitte 83 an der Börse zu 2,5 notiert stand im Jahr 12/94 nach 11 Jahren bei 7 Dollar ) o.K. jetzt kommt der Einwand das HEB immer noch auf dem Niveau von 1996 bei 2,5 steht wie damals, aber es sind auch erst 9 Jahre um, womit uns noch 2 Jahre bleiben um auf AMGN Niveau zu kommen.
Auf was wir hier Wetten, denn das HEB eine Spekulation ist, wird nicht bestritten, ist die Zulassung der FDA und der Durchbruch am Markt ( wenn es klappt, dann ist mit Technik nichts mehr zu machen, denn dann geht´s halt nicht mehr billig rein )und die zweite Wette ist eine Übernahme durch einen Großen wie Roche ( und auch dann versagt jede Technik, denn wenn die Meldung kommt macht´s puff und der Kurs steht da wo er hingehört).

So nun leider doch etwas länger geworden, aber es geht halt um eine offene Diskussion.

Besten Gruß sendet Dir GV

[Aptamilla]

[posting]19.284.722 von GlobalValue am 14.12.05 12:30:56[/posting]Hallo GV,Du hast eine persönliche Nachricht.Gruss Apta

[VNDong]

braucht heb geld ?
http://www.sec.gov/Archives/edgar/data/946644/00009466440500…

bittet 9.6 millions share an, gibt genug neu investor die das haben will? Ja sicher wieso nicht

[Trappertoni]

@ all

Folgende Meldung von heute auf boerse.ard.de muss man sich mal auf der Zunge zergehen lassen, und dann entscheiden, welche Perspektiven für Hemispherx bestehen.

15.12.2005 13:28
Traum-Ehe in der Biotech-Branche
Das weltgrößte Biotech-Unternehmen Amgen will sich verstärken. Der profitable Konzern will für 2,2 Milliarden Dollar den Konkurrenten Abgenix kaufen. Die Anleger reagieren begeistert.

Amgen bietet 22,50 Dollar je Abgenix-Aktie und damit einen Aufschlag von 54 Prozent auf den Schlusskurs vom Mittwoch an der Computerbörse Nasdaq. Die Abgenix-Papiere zogen daraufhin im nachbörslichen US-Handel und an der Frankfurter Börse um rund 50 Prozent an.

Doch auch die Amgen-Aktie legte zu - um knapp drei Prozent. Eine ungewöhnliche Reaktion, denn meistens verlieren bei Übernahmen die Papiere der Käufer-Unternehmen zumindest kurzfristig an Wert. Das ist ein Zeichen dafür, dass die Anleger Vertrauen in die Akquisitionspolitik des Unternehmens haben.

Die Transaktion wäre die größte Übernahme von Amgen seit dem Kauf von Immunex im Jahr 2002 für 8,8 Milliarden Dollar. Mit der Übernahme sichert sich Amgen den Zugriff auf die zukünftigen Medikamente von Abgenix.
Krebs-Medikament in der Pipeline
Einer der Hoffnungsträger ist das Krebs-Medikament Panitumumab, das derzeit noch entwickelt wird, dessen Zulassung aber als sehr wahrscheinlich gilt. Amgen geht von einem maximalen jährlichen Umsatzpotenzial von zwei Milliarden Dollar aus.

Ein weiterer Nebeneffekt der Übernahme: In Zukunft müsste Amgen keine Umsatzbeteiligungen für das Osteoporose-Medikament Denosumab bezahlen, das derzeit mit Hilfe von Abgenix-Technik entwickelt wird. Für die Mittel rechnet Amgen mit jährlichen Spitzen-Umsätzen von rund zwei Milliarden Dollar.

Amgen ist mit einem Börsenwert von knapp 100 Milliarden Dollar das wertvollste Biotech-Unternehmen der Welt. Im vergangenen Jahr setzte das kalifornische Unternehmen gut zehn Milliarden Dollar um. Die Profitabilität ist beeindruckend: Die Netto-Umsatzrendite lag bei mehr als 22 Prozent. Das bedeutet von jeden Dollar Umsatz blieben nach Steuern rund 22 Cent hängen.



Interessant ist auch der Geschäftsbericht von Abgenix - hier wird durch Amgen eindeutig in die Zukunft mit neuen Präparaten investiert. Warum sollte dies nicht auch auf absehbare Zeit für Hemispherx gelten - bei der Pipeline.

Ist ja nur mal so`n Gedanke.

Grüße an alle investierten

Trappertoni

[Aptamilla]

[posting]19.284.722 von GlobalValue am 14.12.05 12:30:56[/posting]Danke für die prompte Antwort.Gruss Aptamilla

[Aptamilla]

[posting]19.293.740 von VNDong am 15.12.05 00:44:30[/posting]VDong,hast Du einen Clown gegessen oder gleich einen ganzen Zirkus?!Deine Postings sind so albern und realitätsfremd.Warum suchst Du Dir nicht einen anderen Wert?Mit HEB verzettelst Du Dich zusehends,was schon GlobalValue richtig erkannt hat.

[longlongwau]

hallo an alle hier,

habe soeben nach wochenlangem beobachten der aktie auch mal einen kaufauftrag reingestellt. mal sehen was draus wird. hoffentlich gehts nichtso wie bei nabi...

viel glueck an alle investierten

[cyberhai]

[posting]19.314.075 von longlongwau am 16.12.05 14:07:11[/posting]In Nabi will ich heute einsteigen - bist Du da noch drin?

[VNDong]

Hemispherx is a 34-year-old alleged drug company that has never filed a New Drug Application ("NDA") with the FDA or completed a Phase III trial, despite claiming potential efficacy based on pre-clinical and Phase II testing in many different diseases including CFS, hepatitis, cancer and HIV. Simultaneously with failing to file an NDA, Hemispherx has used irregular and non-reproducible medical studies, authored by individuals with ties to Hemispherx, to perpetuate the fraudulent promotion of a 30-year-old drug it calls Ampligen. Ampligen is a 1970s substance once studied, along with many other failed dRNAs, as a potential interferon inducer before interferon itself became available as a prescription drug.

.......

A U.S. House of Representatives Subcommittee investigated Carter and his associates for scientific fraud. Carter also has been charged with personally defrauding $1 million from an AIDS patient who sought admission to an Ampligen AIDS trial, which resoundingly failed and was halted. E.I. Du Pont de Nemours and Company (NYSE: DD), which sponsored the failed AIDS trial charged Carter and his colleagues in a lawsuit with scientific fraud.

Another part of Hemispherx’s fraud is the use of legal proceedings to fight opponents. Hemispherx and Dr. Carter have a history of making irregular medical claims and taking legal action against parties that question their claims. Hemispherx repeatedly have filed lawsuits claiming themselves as victims of a series of conspiracies.

[longlongwau]

@ hi cyberhai,

bin bei nabi eingesteigen zu 3,06 euro. da muss man ein bisschen geduld haben. das wird schon werden....

HEB habe ich heute gekauft und gleich gehts etwas runter... aber auch hier muss man eben ein bisschen geduld aufbringen.

auch interessant zur info: mivt berlin, human biosystems meines erachtens jetzt ein toller einstiegskurs.

viel erfolg an alle

[Masse]

Der Bericht ist von 2002 oder 2003. Asensio der sich mit HEB schon ewig bekriegt hat diesen Bericht auf seiner Homepage. Er behauptet, das die Produkte von HEB keinerlei Wirkung haben. Ich denke, das durch die Berichte in der letzten Zeit das Gegenteil bewiesen haben. Im übrigen hatte Herr Asensio den Prozess gegen HEB verloren ;-)

Gruß Masse

[Aptamilla]

[posting]19.314.075 von longlongwau am 16.12.05 14:07:11[/posting]Schön das Du Interesse an Hemispherx bekundest.Denke mit diesem Wert liegst Du richtig.Good News müssten täglich eintreffen.Spannung und Chancen liegen gleichauf.Obwohl die AMEX heute schwächelte summieren sich immer mehr Käufer.Das zeugt von Erwartung und Interesse.Ampligen ist ein Hoffnungsträger in vielerlei Hinsicht.Dies wird sich sehr bald bewahrheiten.Schönes Wochenende... Aptamilla

[longlongwau]

@aptamilla

das denke ich auch. ich sehe die chancen deutlich hoeher, als das risiko. ebenso bei mivt und auch bei human biosystems (das ist im moment auch ei sonderangebotspreis).

HEB wird seinen weg machen. schoenes wochenende an alle hier

[VNDong]

target 2.25 - 2.00 trading range -- wenn nicht halten, dann ....... ohohohohoho

[Trappertoni]

@ VNDong

Wieso beschleicht mich bei Dir blos immer das ungute Gefühl, daß ich Dich bereits unter einer anderen stimmungsmachenden ID kenne und Dein Ausländergetue simple Mache / Ablenkung ist?

Allen anderen Investierten wünsche ich gute Nachrichten und steigende Kurse.

Trappertoni

[longlongwau]

@ tappertoni

[GlobalValue]

Hallo Apta !
NEWS

PHILADELPHIA, Dec 20, 2005 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (HEB) announces that two papers on its lead biodefense products were accepted for presentation, after peer review, for the February 15th-18th 2006 Biodefense Meeting sponsored by the American Society of Microbiology in Washington, D.C. The conference brings together the scientists, public health researchers and policy makers that are shaping the future of biodefense research. They will discuss policy issues, legislation, and gaps related to biodefense.

Hemispherx will present the results from the experimental trials for Alferon N Low Dose Oral (LDO) that are taking place with internationally recognized researchers at the Cleveland Clinic Medical Centers in the United States and the Princess Margaret Hospital in Hong Kong. The experimental trials involve use of a cutting edge technology (a variation on DNA chips) to test whether Alferon N, an interferon inducing therapeutic already approved for the treatment of Human Papilloma Virus, given orally can trigger a broad-spectrum antiviral immune response. If successful, Hemispherx will have the capacity to produce 50-100 million doses of the experimental therapeutic from the GMP approved manufacturing facility in New Jersey.

The company will also present Ampligen(R), an experimental immune amplifier with broad-spectrum defense capabilities. Hemispherx recently completed a Phase III trial with Ampligen for the treatment of Chronic Fatigue Syndrome and has currently treated more than 750 patients under the government`s cost recovery program. With the threat of a bioterror attack and an Avian Flu outbreak looming, there has been a recent demand for an adjuvant that offers a broad-spectrum approach. As a result of this demand, Hemispherx is currently conducting studies in animals using Ampligen given alone or in combination with approved influenza vaccines and antivirals such as Tamiflu and Relenza. Under new emergency rules, drugs may be licensed for sale based on successful studies in two recognized animal models.

The results of new Hemispherx human and animal studies will be presented at the meeting.

About Hemispherx Biopharma


Gruss GV

[VNDong]

vielleicht in paar monat kommt bird flu news aus VN, aber
jetzt es ist vorbei, wir essen alle arten von geflügel und preis steigt

[Trappertoni]

@ VNDong

... und Dein getue, als wenn Du der deutschen Sprache nicht mächtig wärst, geht mir voll auf die Nerven.
Also lass doch einfach Deine überflüssigen Postings - wer immer Du auch wirklich bist - die keiner wirklich braucht und die substanziell absolut keinen ernstzunehmenden Inhalt besitzen und somit überflüssig sind.

Grüße

Trappertoni

[Aptamilla]

[posting]19.350.828 von GlobalValue am 20.12.05 15:14:33[/posting]Grüss Dich Global Value,habe gerade Feierabend und gleich Deine Nachricht gesehen.Die Übersetzung auf Deutsch habe ich nun drei mal intensiv gelesen.Sie ist gut und weckt grosse Hoffnungen auf baldige positive Ergebnisse.Mit Alferon und Ampligen füllen zwei Hoffnungsträger die HEB Pipline.Da mir die Effizienz und das gesamte Spektrum des aktiven Forschens von HEB sehr gefällt,bestätigen die wöchentlichen Schlagzeilen meine nährenden Spekulationen.Ich denke man ist so oder so nah dran,einen Blockbuster ins Rennen zu bekommen.Geduld sollte bald belohnt werden!@Trappertoni,in Sachen VNDong,bin ich absolut "DITO"!Gruss Aptamilla

[tilt]

lest euch doch mal #154 von VNDong durch.
ich bin schon der meinung das dieser inhalt ernst zu nehmen ist. andererseits besteht doch im internet die möglichkeit von überall auf der welt hier mal reinzuschauen, vielleicht solltet ihr ihn erstmal fragen woher er kommt bevor ihr ihn verurteilt.

mfg tilt

[Aptamilla]

Hallo tilt,natürlich schauen wir auch nach rechts und links.Doch mit VNDong haben wir hier ein Nerver im Thread.GlobalValue hatte letzlich noch über sein Verhaltensmuster hingewiesen.Wenn es stets nur um Einstiegsspekulationen geht und andererseits um Misstrauen,denke ich weitestgehend an Widersprüche in sich was VNDong betrifft.

[Aptamilla]

Zum Abschluss noch mal steigende Kurse.Allen Hemis-Fans frohe Festtage.Apta

[longlongwau]

ja, auch von mir schoene feiertage im kuehlen deutschland. schicke euch ein paar sonnenstrahlen......

[cyberhai]

Auch von mir besinnliche und frohe Weihnachten

Gruß Cyberhai

[Besitzer]

Ein schönes Fest für Alle

[tilt]

merry x-mas and a happy new year

mfg tilt

[VNDong]

chart sagt mehr als tausend worte

[tilt]

@ vndong

sieht ganz so aus als würde HEB aufgrund fehlender ergebnisse, wie in den letzten jahren, wieder abschmieren
irgendwie schaffen die es nicht mal etwas endgültiges auf die beine zu stellen

mfg tilt

p.s. hoffe natürlich das wir doch noch die biege kriegen

[VNDong]

[posting]19.436.701 von tilt am 28.12.05 20:32:25[/posting]ich will ausschliesslich müde mark der scam news gläubiger retten
leider wurde geschimpft
leider leider

Wed Dec 28,11:49 AM ET
WASHINGTON (Reuters) - Stock scams involving companies claiming to have products or services to fight bird flu have been hitting fax machines, e-mail inboxes and mobile phones, U.S. securities regulator NASD said on Wednesday.

NASD warned investors to be wary of solicitations that claim these companies will see large gains in the fight against a global pandemic, citing the enormous cost of preventing a widespread outbreak of avian flu.

One fax claimed its company`s stock was "positioned to gain 250 percent or more," and that the stock was "clearly missed by Wall Street," the regulator said.

"This is an age-old pump-and-dump scheme with a brand new disguise," John Gannon, NASD vice president of Investor Education, said in a statement. "Unfortunately, fraudsters are quick to exploit every new crisis or catastrophe to peddle their get-rich-quick scams to unsuspecting investors."

Scientists fear that the H5N1 bird flu virus -- which has killed 73 people in Asia -- could mutate from a disease that largely affects birds to one that can pass easily among people, leading to a human pandemic.

The NASD said potential bird-flu investment scams may include predictions of swift growth, references from respected news sources to bolster claims of a price surge, mention of associations with federal and international government agencies and a pressure to invest immediately.

The regulator said it has not initiated any enforcement proceedings related to the issue.

[VNDong]

[posting]19.436.701 von tilt am 28.12.05 20:32:25[/posting]http://www.asensio.com/Reports/WarStoriesHemispherx.aspx

Hemispherx is a 34-year-old alleged drug company that has never filed a New Drug Application ("NDA") with the FDA or completed a Phase III trial, despite claiming potential efficacy based on pre-clinical and Phase II testing in many different diseases including CFS, hepatitis, cancer and HIV. Simultaneously with failing to file an NDA, Hemispherx has used irregular and non-reproducible medical studies, authored by individuals with ties to Hemispherx, to perpetuate the fraudulent promotion of a 30-year-old drug it calls Ampligen. Ampligen is a 1970s substance once studied, along with many other failed dRNAs, as a potential interferon inducer before interferon itself became available as a prescription drug.


vorsicht wenn man investment in solche unternehmen, die in vergangenheit schlechter ruf hat ...

[longlongwau]

ich erinnere auch nochmal an diese news:

alles ist auch nicht immer tureb. wenn man natuerlich nur negatives sehen will,dann findet man das auch...

HEB: Highlighted in Study of Innate Immunity as a Defense Against Bio-terror Threats



Hemispherx Biopharma, Inc. (HEB) announces that research published by an academic consortium led by The National Defense University (U.S.A.) in the Journal of Allergy and Clinical Immunology (JACI) (December issue) titled "Innate Immunity for Biodefense: A Strategy whose Time has Come" have found that Hemispherx products Alferon N(R) and Ampligen(R), are among a small pool of agents that stimulate innate immunity for the defense against a bio-terror attack. The study concluded that an adequate defense would require a broad-spectrum approach to combat deadly pathogens, such as the H5N1 virus. Alferon N(R) and Ampligen(R) have shown the greatest ability to stimulate the innate immune system (also called "the first line of defense") therefore providing the best opportunity to fulfill this requirement.

[cyberhai]

Ist die Quelle für die negativen News als seriös einzustufen: http://www.asensio.com Was meint Ihr dazu?

[VNDong]

[posting]19.437.297 von cyberhai am 28.12.05 21:53:07[/posting]hi cyberhai, ich bin neutral, kennt selbst weder heb noch asensio, (vermute ihr seid genauso wie ich, nur information aus dem NET). Hier nenne ich folgende fragezeichen
1) wenn heb sauber wäre, hat asensio keine grund zu attackieren.
2) ein Unternehmen die seit 25 Jahre verbrennt nur Geld, HEB Managers leben nur von Aktionärs durch Kapitalserhöhung. Noch nie nennenwert Umsatz gemacht.
3) Wir finden nur eigene PR News, keine Institutions oder andere Finanzmedia HEB betrachten. (wahrscheinlich die Geschichte mit Japan, Canada etc. läuft so..HEB reicht die Antrag bzw. Ergebniss an deren Institut und bitte darum zusammen zu arbeiten. und sofort PR ah bla bla wir haben was ....Nie irgendein institut hat sich gemeldet bzw finanzmedia darüber berichtet)
4) Ist Ampligen sein gut, wieso hören wir nie etwas von ROCHE oder GSK? . Sondern GSK und ROCHE cooperieren aber andere mit Partner statt HEB.
5) Die versucht nur bei irgendwelche Hype wie Bird Flu, den Aktienkurs hoch pushen, um mehr Aktien mit Höher Kurs zu verkaufen ---> sonst wer HEB Manager Jahrenlang finanziert? reicht die 25 Jahre nicht?
6) schaun mal die WEBSITE an, wie präsentiert HEB im vergleich mit andere Unternehmen?
7) weil keine renommierte Pharma will HEB, HEB braucht Geld für HS produktion, aber ob das verkaufen kann weist niemals. und glaubt auch keine. HEB ist biotech und nicht Pharma mit verkaufsnetwerk .. marketing .. etc...

das war nur meine Gedanken mit Dir die Meinung austauschen

[cyberhai]

Hi VNDong,

danke für Deine ausführliche Stellungnahme.

Zu 1): Es könnten auch Firmen oder Leute sein, welche ein Interesse an sinkenden Kursen haben, da sie mit der Aktie short gegangen sind.
Zu 2): Ist bei fast allen Biotechfirmen ohne ein Produkt im Verkaufsstadium so. Innerhalb von ca. 1 Jahr müsste nun allerdings ein Ergebnis der Phase III da sein...
Zu 3+4): Das sehe ich ebenfalls sehr negativ und ist mir auch schon aufgefallen. Auf der anderen Seite sind einige Instis investiert (leider nur in sehr geringem Umfang): http://finance.yahoo.com/q/mh?s=HEB. Es gibt Analysen, von denen man mal eine kaufen müsste (werde dies bei Gelegenheit ausprobieren...): http://finance.yahoo.com/q/rr?s=HEB.
Zu 5-7): Ja, ist nicht sehr vertrauenserweckend, u.a. Roche müsste doch mitbekommen haben, dass es da Potential gibt - dann wäre eine Übernahme längst erfolgt.

Ich habe mir die Sache nochmals reiflich überlegt und bin jetzt zunächst mal ausgestiegen - jetzt kann die Rakete starten.

Gruß Cyberhai

[VNDong]

[posting]19.444.308 von cyberhai am 29.12.05 16:08:06[/posting]Ich habe mir die Sache nochmals reiflich überlegt und bin jetzt zunächst mal ausgestiegen - jetzt kann die Rakete starten.

Was meinst du damit?

[cyberhai]

[posting]19.445.618 von VNDong am 29.12.05 17:25:26[/posting]Meistens, wenn ich augestiegen bin, steigen die Aktien

Gruß Cyberhai

[longlongwau]

also ich habe die heb heute auch geschmissen und bin voll bei swkj und atct rein. da gehts naechste woche ab.... nabi habe ich behalten....

gruesse und guten rutsch

[tonyjaa]

bin mal gespannt

Hemispherx Biopharma Letter to Shareholders
Tuesday January 3, 8:30 am ET

PHILADELPHIA--(BUSINESS WIRE)--Jan. 3, 2006--Hemispherx Biopharma:

Dear Shareholders,

2005 has been an excellent year for Hemispherx. Years of research, development, clinical trials and perseverance have led to growing recognition of the value of our scientific approach and product portfolio and have facilitated important collaborations, acquisitions and financings, all key steps on the path to successful commercialization. Our strategy going forward is to focus all efforts on regulatory approval and advantageous alliances, with the ultimate goal being increased shareholder value. Every clinical trial initiated, alliance struck and investment made in the past year was undertaken with these objectives in mind. We have enhanced our asset base and enriched our professional resources to provide us with the resources, relationships and expertise to achieve our objectives.

The twenty million dollar equity credit line established with Fusion Capital has provided us the means to build out our manufacturing capability, strengthen our balance sheet and secure future growth with minimum dilution to our shareholders.

The expansion of our manufacturing facilities and staff in New Brunswick, New Jersey and the collaborative manufacturing relationship with HollisterStier Laboratories LLC for the production of Ampligen® are both ahead of schedule and due for completion and certification late in the 2nd quarter 2006. These efforts will significantly add to our production capacity and conclude the last steps necessary for the filing of a consolidated NDA for Ampligen® for the treatment of CFS.

The single shortfall of our 2005 objectives was the delay in the filing of our NDA for Ampligen® for the treatment of CFS. Our targeted filing by 2005 year-end was based on an anticipated grant of FDA permission to submit a rolling or staged NDA application, which would allow us to file the safety and clinical sections of the NDA application in advance of the manufacturing section. Even though FDA permission to submit a rolling or staged NDA application has yet to be received, since we are scheduled to complete our manufacturing certifications late in the 2nd quarter of 2006, we should, in any event, file our NDA for Ampligen® for the treatment of CFS no later than the first part of the 3rd quarter of 2006.

The disturbing threats of an influenza pandemic and bio-terror attacks have pushed researchers and government institutions to pursue creative alternatives to established vaccines and antivirals. This pursuit has led to a growing recognition of the value of our scientific approach and product portfolio as investigators have identified Hemispherx products as potentially adequate options as a broad-spectrum, first line of defense approach to combat deadly pathogens, such as the H5N1 influenza virus. Investigators, with whom we are now collaborating, have sought and are utilizing Hemispherx products in ongoing clinical trials in this vital area.

Our clinical trials and those of our collaborators in the United States, Canada, Hong Kong and Japan, if successful, will allow for NDA filings of our drugs as experimental stand-alone antivirals or as adjuvants (boosters) under the proposed new emergency guidelines whereby drugs may be licensed for sale based on successful studies in two recognized animal models. While we are committed to and are actively pursuing commercial approval of Ampligen® for the treatment of CFS, we are aware of, and believe we are uniquely positioned to take advantage of, the fact that the avian flu (prevention / treatment) market opportunity is far larger at present, rapidly growing and encompasses areas of the market opportunity (Europe and Asia) where CFS recognition and treatment is still in its infancy.

Our strategy now is to obtain regulatory approval and to leverage our laboratory successes in aggressively pursuing advantageous relationships. We are committed to these objectives and determined to deliver. The next two years will be significant in Hemispherx`s transition to a developer, manufacturer and distributor of value-added immune enhancing drugs.

At the Biodefense Research Meeting sponsored by the American Society of Microbiology in February 2006 (Washington, DC) we will unveil exciting new results in both the avian flu vaccine augmentation and the potential broad-spectrum antiviral activities of Alferon N(TM) and Ampligen®. Mark these dates on your calendar as important milestones for our Company.

It is critical to our success that our investors understand the path that we are taking and our progress down this path. In an effort to improve upon communication to the investor community we will commence quarterly investor conference calls in line with the filing of the first 10Q of 2006.

We thank you for your on-going support.

Sincerely,

Dr. William Carter

Chairman and Chief Executive Officer

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen® and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon® do not imply that the product will ever be specifically approved commercially for these other treatment indications.

[VNDong]

[posting]19.516.951 von tonyjaa am 03.01.06 16:54:20[/posting]oh ja diese gut news, leider immer das selber termin verschoben, unbestimmte tagen ... niemals interesssiert

fakten ist die kurs in minus minus
lass doch die betrügerei der HEB mal endlich beenden

[VNDong]

]

[biotech_nett]

... tja, Todesfall in der Türkei, Ihr seid langsam alle raus???


... habe auch ein paar steuerfrei verkauft, doch jetzt ist der Boden gefunden und es soll einfach die sogenannten falsch liegenden "Top-Analytiker" geben, doch interpretation ist halt relativ

Also, ich sehe die Aktie durchaus noch mit sehr viel Potential, etwas Zeit sollte man ihr auch geben, es ist doch alles offiziell, meine was gemeldet wurde, und H5N1, es soll schlechte Leute geben die am Leid der Welt noch wirklich Geld verdienen????

Also, solche Lümmel!!!

Danke für die vielen Kommentare und die positive Unterstützung hier im Board wollte ich noch sagen!!!!

Happy weekend

bio_nett

[VNDong]

[posting]19.554.901 von biotech_nett am 05.01.06 21:33:41[/posting]was hat heb mit bird flu todesfall in türkei zu tun?
alles mit ampligen oder wie die in der zukunft heissen soll ...> nur betrug betrug und noch mal betrug, lüge lüge und noch mal lüge mehr nicht

[Aptamilla]

VNDong,verschleich Dich und les mal sorgfältig nach und bezichtige einen AMEX Wert nicht als korrupt!

[Trappertoni]

Aus der China Post von heute

Scientists in uphill battle to fight bird flu

2006/1/7
By Tan Ee Lyn HONG KONG, Reuters


Fighting the deadly H5N1 bird flu virus is all the more difficult because experts are still figuring out how best to use Tamiflu, believed to be one of the very few defenses, scientists said.

Roche AG`s Tamiflu, generically called oseltamivir, is an anti-viral designed to fight human influenza. But tests have suggested it may be effective in reducing the severity of H5N1 and its complications if taken in higher doses.

Still, scientists have only just begun experimenting how best to use the drug in fighting the H5N1, which health experts fear will mutate into a form that is easily transmissible among people and unleash a pandemic, killing millions.

"The truth of the matter is, we don`t really know what is the correct dose, or how many days do you have to treat with Tamiflu and what is the dose required," said virologist Robert Webster of the St. Jude`s Children`s Hospital in Memphis, Tennessee.

"There is still space for research to be done ... on how many days to treat, what dose to use. The standard tablets may not contain enough drugs. Maybe it requires more because all of these things were determined for standard human flu."

Three children from the same family in Turkey have died of bird flu over the past week. They were the first human fatalities outside China and East Asia since 1997, when the H5N1 virus made its first known jump to humans in Hong Kong.

The disease has re-emerged in China and Southeast Asia since 2003, killing 74 people. Like the East Asian victims, the Turkish children are known to have lived in close proximity with poultry.

A recent article in the New England Journal of Medicine reported how four of eight patients in Vietnam died despite using Tamiflu. It sparked concern as it suggested that certain strains of the H5N1 might have become resistant to the drug.

It also showed that experts were just figuring out how best to use the drug.

In one patient, Tamiflu was used early on, as is recommended by experts and the drug maker -- but Webster, speaking in Hong Kong, said these guidelines were meant to fight human flu viruses, not bird flu viruses.

"These patients in Vietnam ... certainly received the dose that was recommended on the package, but those studies were done with standard H3N2, H1N1 (human flu) viruses," said Webster, who is trying to find out if the best way to fight H5N1 is through the use of a cocktail of drugs, including Tamiflu.
"We are still learning how best to use this drug. The studies from Vietnam tell us you have to think about early treatment. With late treatment, you will have a problem with resistance."

William Chui, a pharmacologist based in Hong Kong, agrees: "The speculation in the Vietnam cases is that the recommended dosage was not high enough. Whether it`s dosage, duration of treatment, they are all trial and error (for H5N1)."

Webster said Tamiflu could only be of use against H5N1 if it is taken within one to 1.5 days of infection -- and not within 48 hours of the patient showing symptoms as advised by many experts.

"The issue is when was the drug started in patients after they got infected. Published work on the use of Tamiflu shows it is only effective for the first day. You must begin treatment in the first day or maximally 1.5 days after initial infection. Not symptoms, that is the difficulty," Webster said.

Apart from Tamiflu, experts believe GlazoSmithKline`s Relenza, another anti-viral drug known generically as zanamivir, may work against the H5N1.

There is an experimental H5N1 human vaccine but it is based on the current H5N1 strain and experts have warned that it may just not match a future pandemic strain.


Also, die Probleme sind vielfach und ein alleinges wirksames Mittel gegen H5N1 gibt es offensichtlich nicht.

Es wurde aber bereits in anderen auch hier beschriebenen Studien festgestellt, daß u.a. Tamiflu unter Hinzugabe von Ampligen einen um das Mehrfache (300%)erhöhten Wirkungsgrad hat.
Ob das gut oder schlecht ist und welche Vorteile und Perspektiven sich daraus für Hemispherx ergeben, muß jeder für sich entscheiden.
Ich bleibe weiterhin investiert und harre der Dinge die da kommen.

Grüße an alle
Trappertoni

[VNDong]

[posting]19.590.797 von Trappertoni am 07.01.06 17:44:10[/posting]300% ????
ruf doch roche oder gsk an, sein nicht so naiv
sein meine warnung habt ihr doch ganze menge geld verlust sparen können

[VNDong]

welche studie behauptet? --> nur eigene PR news, niemal interessiert das
kapiert doch endlich

[Trappertoni]

@VNDong

Die Zukunft wird zeigen, was an der Aktie dran ist.

Unabhängig davon geht mir Dein permanentes Gezeter mit Berichten, Behauptungen oder Verdächtigungen ohne Quellenangabe und Zeitangaben tierisch auf die Nerven.

Wo jetzt objektiv der Sinn in Deinen Postings liegt, wo Du doch offensichtlich nicht investiert bist, bleibt mir auch weiterhin verborgen.

Aber man muss ja auch nicht alles so ernst nehmen, was hier gepostet wird.

So long, mein vermuteter Pseudoasiate

Trappertoni

P.S.: Es dürfte nach Nachrichtenlage aus der Türkei morgen ein durchaus interessanter Tag werden.

[Trappertoni]

Biota - WKN 887853 - Hersteller von Relenza

Kursdaten

Börse - Australien

Aktuell - 1,75 AUD

Zeit - 09.01.06 06:15

Diff. Vortag +14,38 %

Tages-Vol. 11,55 Mio.
Gehandelte Stück 7,2 Mio.
Geld 1,75
Brief 1,76
Zeit 09.01.06 06:26
Spread 0,57%
Geld Stk. 92.139
Brief Stk. 58.420

Wir werden sehen was wird.
Grüße Trappertoni

[tonyjaa]

mal sehen wie sich das auf heb auswirkt

Fünf neue Vogelgrippe-Erkrankungen in der Türkei
Nach dem Ausbruch der Vogelgrippe in der Türkei haben sich fünf weitere Menschen mit dem Erreger infiziert. In allen Fällen handelt es sich um Erkrankungen mit dem für den Menschen lebensgefährlichen Virus-Stamm H5N1. Das teilte ein ranghoher Vertreter des türkischen Gesundheitsministeriums am Montag mit. Daneben gibt es laut Behördenangaben rund einhundert Verdachtsfälle.

Vier der fünf Patienten kommen aus Provinzen im Schwarzmeergebiet, der fünfte aus der osttürkischen Provinz Van, berichtete die Nachrichtenagentur Anadolu. Bei den neuen Patienten handelt es sich ausschließlich um Kinder oder Jugendliche.

Damit ist die Zahl der mit Vogelgrippe infizierten Menschen in der Türkei auf nunmehr zwölf gestiegen. Darunter sind zwei Kinder und ein Erwachsener aus der Region der Hauptstadt Ankara. In der Universitätsklinik der osttürkischen Stadt Van werden nach jüngsten Angaben 41 Menschen mit Verdacht auf Vogelgrippe behandelt, darunter 32 Kinder.

Die Ende vergangenen Jahres im Osten des Landes aufgetretenen Vogelgrippe hat sich mittlerweile bis weit in den Westen ausgebreitet. Ein Fall von Vogelgrippe bei Hühnern wurde auch aus einen Außenbezirk von Istanbul im europäischen Teil der Türkei gemeldet.

Angesichts der in der Türkei grassierenden Vogelgrippe verschärft die EU ihre Einfuhrbestimmungen für Geflügelprodukte. Für Federn aus den Nachbarstaaten Armenien, Aserbaidschan, Georgien, Syrien, Iran und Irak gilt künftig ein Importverbot, wie die EU-Kommission am Montag mitteilte.

In Österreich besteht aber derzeit dennoch kein Anlass zur Sorge geboten, beschwichtigte am Montag Ulrich Herzog, Bereichsleiter für Verbrauchergesundheit im Gesundheitsministerium im APA-Gespräch. Es seien auch keine Anzeichen einer Übertragung von Mensch zu Mensch gegeben, weshalb man von einer Reisewarnung derzeit absehe, betonte er.
© APA - Austria Presse Agentur.

[Aptamilla]

[posting]19.612.649 von Trappertoni am 09.01.06 07:27:46[/posting]kannst Du mal mehr über Biota posten?Börsenplatz,Finanzen bzw.Bewertungen!Danke...Gruss Aptamilla

[Trappertoni]

Info`s zu Biota (WKN 887853)

Der Nachfolgende Artikel ist alles andere als neu - aber durchaus informativ.
Ansonsten verweise ich auf den Thread hier bei w:o.

Biotech-Kolumne: Australisches Medikament wirkt gegen Vogelgrippe
27.02.2004 08:57:00

Neben der Schweizer Roche AG und der US-amerikanischen Gilead Sciences, die mit Tamiflu noch vor kurzem als die einzigen Profiteure der sich ausbreitenden Vogelgrippe galten, tritt nun ein kleines australisches Unternehmen ins Blickfeld der Investoren und mit ihm auch der Vermarkter seines Produktes, das britische Pharmaunternehmen GlaxoSmithKline.

Dem australischen Unternehmen Biota Holdings Ltd. brachten die Labortests der Commonwealth Scientific and Industrial Research Organisation (CSIRO) mit seinem Grippewirkstoff Relenza erst vor wenigen Tagen ein dickes Kursplus von 51 Prozent ein. Wenn sich die in vitro Versuche auch am Menschen bestätigen lassen, dann dürfte aber auch der Vermarktungspartner GlaxoSmithKline davon profitieren.

In den von der Commonwealth Scientific and Industrial Research Organisation (CSIRO) durchgeführten Labortests konnte das Grippemedikament die Vermehrung des Vogelgrippe-Virus H5N1 unterdrücken. Bisher hat die in Asien ausgebrochene Vogelgrippe wenigstens 20 Asiaten und tausenden von Hühnern das Leben gekostet. Zwar ist das Virus noch nicht von Mensch zu Mensch übertragbar, doch sollte dies geschehen, dann wäre das Wissen um einen effektiven Wirkstoff immens beruhigend. Dass sich das Virus noch lange nicht zurückzieht, sondern seinen Wirtspool noch ausdehnt, dafür spricht nicht zuletzt, dass laut der Regierung von Bangkok erst jüngst zwei Hauskatzen dem Virus zum Opfer fielen. Und auch im US-Bundesstaat Texas wurden jetzt erste Fälle der Vogelgrippe gemeldet, allerdings soll das isolierte Virus nicht mit dem asiatischen Stamm identisch sein.

Das von GlaxoSmithKline im Rahmen einer Lizenzvereinbarung mit Biota hergestellte und vermarktete Relenza zeigte in Tests, die die Empfindlichkeit von Viren gegenüber Medikamenten ermitteln, die gleiche Effektivität wie gegen humane Grippeviren, für welche das Präparat bereits die Zulassung besitzt. Ein Ergebnis, das nach seiner Veröffentlichung die Aktie von Biota auf den höchsten Stand seit mehr als zwei Jahren katapultierte. Sollte sich die Wirksamkeit von Relenza tatsächlich auch im Menschen bestätigen lassen, dann wäre wohl noch mit weiteren Kursgewinnen zu rechnen.

Mit einer erneuten Kursexplosion könnte man rechnen, wenn es dem Virus gelänge in einen zwischen Menschen übertragbaren Erreger zu mutieren. Dieses Szenario ist zwar relativ unwahrscheinlich, aber dennoch nicht völlig auszuschließen. Solange die Übertragung des Virus vom Huhn auf den Menschen nicht zurückgedrängt werden kann, solange könnte wohl auch Relenza und mit ihm sein Entwickler Biota sowie sein Vermarkter GlaxoSmithKline für Gesprächstoff an den Börsen sorgen.

Die Biotech-Branche zählt zu den chancen- und zugleich risikoreichsten Sektoren, nur wer sich dieses Dualismus bewusst ist, wird langfristig Gewinne mit Biotech-Aktien erzielen können.

Mangel an Zeit und/oder fehlender Sachverstand sind zwar nicht die einzigen, jedoch die häufigsten Ursachen für erhebliche Kursverluste mit Biotech-Aktien.

Fakt ist: Auch Zeit und der nötige Sachverstand sind keine 100-prozentigen Garantien für ein erfolgreiches Biotech-Investment, doch sie tragen ganz signifikant zur Minimierung des Verlustrisikos sowie zur Maximierung von Gewinnchancen bei.

Frau Hörrlein war sechs Jahre in der medizinischen Forschung in den Bereichen Humangenetik, Molekularbiologie, Zellbiologie, Proteinchemie und Pharmakologie tätig. Infos: www.biotech-experte.de. Ein Service der BörseGo GmbH.

Der obige Text spiegelt die Meinung des jeweiligen Kolumnisten wider. Die Smarthouse Media GmbH übernimmt für dessen Richtigkeit keine Verantwortung und schließt jegliche Regressansprüche aus.

-------------------------------------------------------------------


Handelsplätze / Kurse / Veränderungen / Voluminas von heute:


Frankfurt 1,15 EUR 09.01. 10:34 +0,21 +22,34% Tendenz 1,17 1,12 10.975,00

München 1,16 EUR 09.01. 20:05 +0,22 +23,40% Tendenz 1,16 1,13 2.830,00

Berlin-Bremen 1,15 EUR 09.01. 14:30 +0,26 +29,21% Tendenz 1,17 1,04 1.404,00

Grüße und noch eine gute Nacht
Trappertoni

[Aptamilla]

[posting]19.626.440 von Trappertoni am 09.01.06 23:13:10[/posting]Danke Trapp!Gruss Apta

[Aptamilla]

Nanu...Novavax schwächelt,Combimatrix wird nicht gesucht-aber Hemispherx steigt!Gibt es da irgend etwas was ich wissen sollte?

[Aptamilla]

Hier noch ein sehr interessanter Link:www.tagesschau.de/aktuell/meldungen/0,1185,OID5126370.Apta

[biotech_nett]

[big]@VNDong [/big]

sag mir doch einmal bitte weshalb diese Aktie interessant ist? - Könnte es sein, böse Zungen behaupten dies, ich auch, ein Medikament welches bei der Eidämmung und Bekämpfung dieser Pandemie hilft???

Hast Du einmal eine Weltkarte betrachtet, dabei die Entwicklung und Verbreitung der Vogelgrippe skiziert??

... sorry, ich habe keine Zeit um so hirnrissige Fragen zu beantworten, Du besitzt aber keine Aktien, oder???

Grüsse an den Rest, jedenfalls an die denkenden,

biotech_nett

... und was hat es damit zu tun? - Der Kurs steigt, also eigentlich NULL - logisch

[Aptamilla]

Zum Thema Vogelgrippe gibt es eine Menge Stoff zu studieren.Ein User mit Nickname"nort."ist im Combimatrix Thread sehr fleissig.Schaut doch mal rein.Gruss Aptamilla

[Aptamilla]

Guten morgen an alle Hemi-Fans,gestern hohes Volumen an der AMEXHier tote HoseWas ist los?Denke,Hemispherx wird ein Wörtchen im Vogelgrippehype mitreden.Wohl dem der darüber nachdenkt.Gruss Apta

[Aptamilla]

Heute beherrschen geopolitische Ängste den Markt.Sollten den iranischen Captain mal eine eindeutige Botschaft rüberkommen lassen(boooooom).

[Aptamilla]

Leute,es ist soweit...auf der ersten Seite von T-Online Homepage folgende Themenüberschrift:Vogelgrippe-Virus gefährlich mutiert Tamiflu wird bald kein Thema mehr sein!" target="_blank" rel="nofollow ugc noopener">http://onnachrichten.t.online.de/c/66/65/87/6665870.html.Tamiflu wird bald kein Thema mehr sein! Gruss Apta

[ronaldus]

hemi steigt im amiland nur die euros schauen zu,nachrichten lesen,weiterdenken,birdflu wird im nächsten halbjahr zu einem extrem thema werden(die vögel kommen zurück).
das ist dieee chance,eine bessere wird nicht mehr kommen!!

[Oliver911]

Hallo,

trotz den neuen Nachrichten in den Medien zum Thema Vogelgrippe verliere ich langsam das Vertrauen, dass Hemi noch groß war über den 2€ reißen kann.

Könnte jemand bitte mal eine Übersichtliche Zusammenfassung machen, der Produkt-"Roadmap" von Hemi.
Welches Potenzial hat Hemi, wenn das Thema Vogelgrippe = 0 wäre, um den Kurs in den nächsten Monaten voranzutreiben?

Besten Dank
Olli

[Aptamilla]

[posting]19.708.552 von Oliver911 am 14.01.06 12:55:02[/posting]Hallo Olli...Hemispherx Homepage-R&D anklicken-Clinical Development anschauen.Dort findest Du die Produktkandidaten Ampligen und Alferon,die nicht nur der Vogelgrippe zugeordnet sind.Gruss Apta

[Aptamilla]

Eine Option für Ampligen könnte bald im Tamiflu-Einsatz kommen.Die Tests waren sehr vielversprechend.Bricht eine Pandemie in Europa aus wäre Hemispherx mit dabei.In Belgien vermutet man mittlerweile den ersten westeuropäischen Vogelgrippefall!Denke,der V.g-Hype dehnt sich mehr denn je beängstigend aus.

[Aptamilla]

Gestern im Aktionär eine erneute Kaufempfehlung mit Ziel 3.50 E.Sollte Ampligen einschlagen oder mit Roche kooperieren(was durchaus möglich ist)sind zweistellige Kurse Pflicht!

[tonyjaa]

da heisst es einfach warten

[Aptamilla]

Nun ein neuer Fall im Irak.Die Ausbreitung geht in alle Richtungen.Also...keine Entwarnung bzgl.Vogelgrippe!

[Aptamilla]

Hohes Handelsvolumen bei Hemispherx...Interesse!Bei Novavax und Combimatrix...Abschläge!Da kommt was,oder weiss jemand mehr???

[tonyjaa]

interessanter kursverlauf gestern:
bis 2.7 $ und dann ohne volumen auf 2.43 $ !
http://www.stockhouse.ca/comp_info.asp?drawChart=1&originalS…

[Aptamilla]

Welcher Heino schmeisst den da in Frankfurt???Da versteh doch einer die Börse...

[biotech_nett]

auf meinem Rest bleibe ich jetzt sitzen

GS=0,53 €

... passt nur gut auf die Vogelgrippe auf, doch ob das was mit dem Kursverlauf zu tun hat???? ... wie ein Kollege hier mal fragte

Happy year

biotech_nett

[Aptamilla]

[posting]19.789.122 von biotech_nett am 19.01.06 18:56:46[/posting]Denke,Hemispherx hat noch andere Eisen im Feuer.Sehr spannend ist der Wert allemal...weil so oder so jede Minute ein Volltreffer eintrudeln könnte.Dabei bleiben und warten heisst die Devise.Gruss Apta

[Trappertoni]

@all


Wieder ein Bericht zur Vogelgrippe und welche Wirkung Tamiflu oder Relenza dazu besitzen - oder auch nicht.
Der Phatasie zu Ampligen stehen also alle Türen offen.
Trotzdem sollte man Hemispherx nicht allein unter dem Gesichtspunkt von H5N1 sehen - das ist einfach zu simpel.



Nachrichten · Medizin
Studie warnt Behörden vor Überschätzung von Tamiflu
Donnerstag, 19. Januar 2006

London - Mediziner haben die Gesundheitsbehörden vor einer Überschätzung antiviraler Grippemittel wie Tamiflu oder Relenza beim Ausbruch einer weltweiten Vogelgrippen-Epidemie gewarnt. Zwar könnten diese Medikamente beim Kampf gegen Symptome und Komplikationen helfen, sie hätten aber nur eine niedrige Wirksamkeit, wenn es darum gehe, einen Grippe-Ausbruch unter Kontrolle zu bringen, heißt es „Lancet" (2006 DOI: 10.1016/S0140-6736(06)67970-1). Sie sollten deshalb „nur bei einer ernsten Epidemie oder Pandemie zusammen mit anderen Maßnahmen der öffentlichen Gesundheitsvorsorge eingesetzt werden, wie Masken, Schutzkleidung, Handschuhen, Quarantäne und Händewaschen.“

Für die Studie wertete ein Team unter Leitung von Tom Jefferson vom Mediziner-Netzwerk Cochrane Vaccines Field Untersuchungen über die Wirksamkeit von Tamiflu und Relenza (so genannte Neuraminidase-Hemmer) bei herkömmlichen Grippe-Formen beim Menschen und - soweit vorhanden - auch bei der Vogelgrippe aus. Demnach lindern beide Mittel Symptome, wenn sie bis 48 Stunden nach den ersten Anzeichen eingenommen wurden. Sie halfen auch, Zusatzerkrankungen wie Lungenentzündung und Bronchitis zu verhindern, die häufig bei Grippe auftreten.

Wichtig sei auch eine Verringerung der Flüssigkeitsabsonderung in der Nase, wodurch bei Niesen und Husten weit weniger Viren in die Umwelt entweichen und andere Menschen anstecken könnten, hieß es in dem Bericht weiter. Dies hat für die Vogelgrippe besondere Bedeutung: Nach einer Studie der Weltgesundheitsorganisation (WHO) gelangen in Fällen des H5N1-Virus bis zu zehn Mal mehr Viren durch Niesen in die Umwelt.

Einen weitgehenden Stopp der Virus-Verbreitung könnten beide Mittel nicht gewährleisten, erklärte Jefferson und seine Kollegen. Zudem wirke keines der Medikamente bei Infizierten ohne klar erkennbare Symptome, die damit die Krankheit unbewusst weiter verbreiten und Eindämmungsversuche der Behörden unterlaufen könnten. Bei den Studien zur Vogelgrippe fanden die Mediziner nach eigenem Bekunden keinen Beweis, dass Tamiflu bei H5N1-Infizierten in Asien die Todesrate senkte. Sie räumen allerdings ein, dass dies auch Folge einer zu späten Diagnose der Krankheit sein kann. Daneben gab es bei Fällen in Japan und Vietnam eine relativ hohe Zahl von Resistenzen gegen Tamiflu (16 Prozent).

„Wir konnten keinen glaubwürdigen Beweis für die Wirksamkeit von Neuraminidase-Hemmern bei Vogelgrippe finden", heißt es als Schlussfolgerung in dem Papier. Es sei deshalb bedenklich, wenn eine Abwehrstrategie zur Eindämmung der Krankheit weitgehend darauf setze. Andere Maßnahmen seien mindestens ebenso wichtig. /afp



Allen eine gute Nacht
Trappertoni

[Aptamilla]

Hi Trapp...interssanter Artikel.Das untermauert unsere Ansichten und weckt Begehrlichkeiten.

[tonyjaa]

diese nachrichten haben sicherlich positiven kurseffekt; was aber zählt sind ergebnisse und fakten.

genaueres werden wir höchstwahrscheinlich erst bei dem biodefense research meeting erfahren...
oder ?

[Aptamilla]

Die 2 Euronen werden bestimmt jetzt vom dicken Bernd F.getestet!Und VN Dong hat alles geschmissen

[Aptamilla]

VNDong...Du sollst doch nicht immer so kontraproduktiv die Kurse beeinflussen!Warst Du das etwa im Xetrahandel?Kleiner Schlingel,Du!!!

[biotech_nett]

*grübel* - der Stock Consultant sagt bullish für die nächste Woche voraus, ob das was hilft???

Wie hoch wollen wir denn???

Irgendwer irgendwelche Kursziele bisher???

Danke im voraus für die vielen Antworten!!!

biotech_nett wünscht noch ein schönes Wochenende

[Aptamilla]

VNDong,was Du das in Frankfurt?Wenn ja,dann hat Deine Miniorder ganz schön den Kurs nach unten gedrückt

[Aptamilla]

Laut Reuters hat der Vogelgrippevirus nun auch Bulgarien erreicht.

[tilt]

welches land die vogelgrippe erreicht ist belanglos für den kurs. wichtig sind positive meldungen von HEB und das bald, sonst hat auf einmal noch ein anderer pharmakonzern den fuß in der tür und wir schauen ganz dumm aus der wäsche.

mfg tilt

[Trappertoni]

Quelle - Swissinfo
Freitag 10.02.2006, MEZ 03:28



9. Februar 2006 22:16

Vogelgrippe breitet sich in Nigeria wie ein Buschfeuer aus

KADUNA - In Nigeria greift die Vogelgrippe bei Geflügel offenbar schnell um sich. Die Krankheit breite sich im nördlichen Bundesstaat Kano "wie ein Buschfeuer" aus, sagte der Geschäftsführer des zuständigen Geflügelzuchtverbandes.

Zehntausende Hühner seien bereits verendet. Allein heute hätten sich 20 000 Tiere infiziert. Der Vogelgrippeverdacht in dem Bundesstaat sei jedoch vom zuständigen Veterinärinstitut noch nicht bestätigt.

Am Mittwoch war auf einer Farm im benachbarten Bundesstaat Kaduna erstmals das auch für den Menschen gefährliche Virus H5N1 festgestellt worden. Damit hat der Erreger den afrikanischen Kontinent erreicht.

Lukas Jenni von der Vogelwarte Sempach schätzt die Chance, dass die Vogelgrippe aus Afrika in die Schweiz importiert wird, als "relativ gering" ein. In der Schweiz träten im Frühjahr nur wenige tausend der Enten aus Afrika auf, sagte Jenni in der "Tageschau" am Donnerstagabend. Ausserdem sei weiterhin unklar, ob das Virus überhaupt durch Zugvögel verbreitet werde.

Die Niederlande hingegen ordnete am Donnerstag für Anfang März eine Stallpflicht für das Geflügel an. Dies teilte eine Sprecherin des Landwirtschaftsministeriums am Donnerstag mit. Zuvor hatte bereits Deutschland ähnliche Massnahmen angekündigt.

In China erkrante erneut ein Mensch an der Vogelgrippe. Bei einer 26-jährigen Bäuerin in Zhangpu in der Küstenprovinz Fujian sei das gefährliche Virus H5N1 festgestellt worden, berichtete das Gesundheitsministerium in Peking.

Nach Angaben amtlicher Medien war in ihrer Gegend allerdings kein Ausbruch der Geflügelseuche bekannt geworden. Der gesundheitliche Zustand der Patientin sei stabil.

Das griechische Landwirtschaftsministerium gab am Donnerstag bekannt, dass bei drei verendeten Schwänen Viren vom Typ H5 entdeckt worden seien. Ob es sich um den auch für Menschen gefährlichen Erreger H5N1 handelt, soll nun das EU-Speziallabor in Grossbritannien klären.



So long
Trappertoni

[Aptamilla]

Die Messe ist noch nicht gesungen.Der Vogelgrippevirus breitet sich noch gefährlicher aus.Mit Hemispherx sollte und muss gerechnet werden.Wie gesagt:jeden Moment müsste eine Nachricht eintrudeln(mein Gefühl).Gruss Apta

[Aptamilla]

Na...das war doch wieder ganz ordentlich.Da wissen doch Insider mehr wie wir Kleinanleger.Auf gute Kurse...Apta

[Aptamilla]

Prima Eröffnung an der Amex..soll so weitergehen.Der Weg nach oben ist erkennbar.

[tonyjaa]

na, das sieht ja recht vielversprechend aus


nur kurz die meldungen von heute:
Today, Thu, Feb 16, 2006
• Hemispherx: Ampligen drug can be used for avian flu
at MarketWatch (Thu 10:14am)
• Hemispherx Biopharma`s Ampligen Boosts Tamiflu Potency
at Forbes.com (Thu 9:02am)
• InPlay: Hemispherx Biopharma says 3 new studies show HEB`s Ampligen and Alferon L.D.O. may provide defense against Avian Flu
Briefing.com (Thu 8:32am)
• 3 New Studies Show Hemispherx Biopharma`s Ampligen(R) and Alferon(R) LDO May Provide Defense against Avian Flu

[Aptamilla]

[posting]20.239.232 von tonyjaa am 16.02.06 16:34:47[/posting]Auf gut deutsch...Hemispherx hat die ideale Kombination herausgefunden und so die Konkurrenz düpiert.Folgt...müsste Roche nun reagieren.Ampligen und Alferon sind nun die auserkorenen Präperate mit Blockbusterstatus.

[Aptamilla]

Global Value...gibt es Dich noch?!

[Aptamilla]

Als Info folgendes:Um die Vorsorge zur Bekämpfung der Vogelgrippe zu gewährleisten,müsste man jährlich 6 Milliarden Menschen mit dem Medikament Tamiflu versorgen.Tatsächlich sind nur 300 Mio.bzw.unter Pandemieszenario 500 Mio.Packungen zu produzieren im Bereich des möglichen.Ein Manko,zudem z.B. Tamiflu einen mutierenden Wirt kein Paroli bieten kann.Jetzt kommt Ampligen ins Spiel und somit der Katalysator(Kombizwilling) überhaupt.Vermute stark,das Roche nun sehr bald reagiert und seine angekündigten kleinen Aquisitionen tätigt.Suggeriert man dieses Thema weiter stehen zweistellige Kurse im Raum. Aptamilla

[Aptamilla]

Naja,überfällige Konsolidierung mit gesunden Hintergrund!Gestern bei hohem Volumen plus 26%,momentan minus 9% bei hohem Volumen.Das ist nicht schlecht für die weitere Kursentwicklung und gibt einigen Nachzüglern die Gelegenheit auf Hemispherx zu setzen.Das Unternehmen stand noch nie so nah an einer Marktzulassung.Vermute,bei diesen Voluminas der letzten Tage eine besonders gute Nachricht.Ansonsten gibt es keinen Reim darauf.Apta

[Scheich2000]

Naja, mal sehen. Ich bin bei über 3 Euro drin und übelege jetzt schon die Notbremse zu ziehen.

[Aptamilla]

Leute cool bleiben.War gestern eine Konsolidierung im Gange,ist heute immer noch das Thema Vogelgrippe all gegenwärtig.Ein so hohes Volumina hatte Hemisperx Jahre nicht mehr und hinter diesem Hintergrund steckt immer eine Bedeutung.Es wunderte mich das Novavax und Combimatrix nicht so hohe Kurszuwächse hatten.Sie sind auch im Thema involviert.Fazit:da ist was auf dem Weg...und wir erfahren es immer zuletzt!Gruss Apta

[Lea_00]

also mein Einstand ist auch über 3,- Euro

bleibe aber trotzdem ruhig

die firma ist meiner meinung nach für die pipeline nicht hoch bewertet, könnte ein übernahmeziel sein, sieh genencor oder rosetta vor ein paar jahre

vogelgrippe bleibt aktuell, lass mal den ersten fall in de usa sein

selbst wenn die jetzt mal etwas runter geht, erwate auch dass sie heute in den usa noch weiter fällt ..bis 3,30

[Aptamilla]

[posting]20.337.894 von Lea_00 am 23.02.06 09:54:55[/posting]Glaube ich nicht,dafür ist ziemlich viel Musik im Unternehmen.Spekuliere auf ein Kontakt mit Roche,weil Ergebnisse von Tamiflu und Ampligen mehr als hervorragend ausfielen.Das ist die ideale Kombi schlechthin.Und übrigens,die Trittbrettfahrer sind gestern abgesprungen...haben den Kurs herunter gezogen.Das beruhigt den zukünftigen Kursverlauf.Es sei denn...eine Nachricht platzt hinein Apta

[tilt]

wenn ihr zeit mitbringt, bringt HEB die kohle mit. eine kleine konsolidierung schadet uns nicht und gibt die kraft für neue anstiege.
in der produktpipeline sind noch einige überraschungen vorhanden, die auf eine baldige zulassung durch die fda warten. von der symptomeigenschaft könnten es mind. 2 präparate zum blockbuster schaffen.

mfg tilt

[Aptamilla]

[posting]20.340.564 von tilt am 23.02.06 12:03:55[/posting]So wahr,so wahr tilt!Bin ganz Deiner Meinung.Stelle gerade fest,das der Kurs wieder Richtung Norden eingeschlagen hat.War eine erwartet gesunde Konsolidierung.Heute wieder fettes Volumen mit Tendenz der Kurserholung.Diese Tatsache nährt die Vermutung,das wir auf diesem Niveau neue Höhen erklimmen werden.Gruss Apta

[Trappertoni]

Letzter Kurs an der AMEX: 1.000 St. zu 3,28 $.
Da hat sich aber einer einen echten Spass erlaubt.

Helau und Alaaf
Trappertoni

[Aptamilla]

[posting]20.353.140 von Trappertoni am 23.02.06 22:46:22[/posting]Ja Trapp...es gibt Leute die sind echt jeck oder mittlerweile total besoffen!

[Aptamilla]

Das Thema Vogelgrippe ist noch immer in den Schlagzeilen vertreten.HEB ist nah dran eine gute Nachricht auszusenden.Viel zu hoch war das Interesse in Amerika.Die Voluminas waren sehr beeindruckend,sodas wir mit weiteren Kurssteigerungen rechnen dürften.

[Aptamilla]

Leute,Leute...das gibt`s doch gar nicht.Greift zu und legt Euch die Hemis ins Depot.Die Chancen stehen so gut wie nie zuvor.Mit Ampligen und Alferon sind zwei Raketen am Start,die jeden Moment zünden können.Apta

[Aptamilla]

In Deutschland übt man sich in Zurückhaltung.Dann muss eben mal wieder die AMEX den Kurs auf die Sprünge helfen.Bei diesen fetten Volumen am Freitag dürfte das ziemlich sicher sein...weil Konsolidierung nun endlich abgeschlossen ist.

[Aptamilla]

Es hat sich nichts geändert.Nach wie vor können breaking News eintrudeln und den Kurs bewegen.Momentan scheint ein Deckel drauf zu lasten.Würde mich momentan bewusst ruhig verhalten...nach dem Motto...in die Ruhe liegt die Kraft.Na denn!

[tonyjaa]

es geht weiter

[Lea_00]

oder auch nicht...

die geht noch runter bis 2,50 ..wenn keine news kommen, dann kann man wieder rein

[tonyjaa]

am anfang und am schluss grosse blöcke im umsatz !!!!
die nachricht wird kommen ...

[Scheich2000]

Hoffe erstmal das wir heute über 3 USD schließen.

[tonyjaa]

sieht so aus, als obs bald losgeht

[Aptamilla]

[posting]20.663.095 von tonyjaa am 13.03.06 16:29:15[/posting]In Amerika auf Tageshoch geschlossen.Nicht schlecht...der Kurs zieht wieder straff nach Norden!

[Scheich2000]

So kann es weitergehen!

[Simbasi]

so ist schön

[tonyjaa]

mit durchschnittlichem handel 9% im plus!!
ob uns da nicht bald was erwartet

[Aptamilla]

Ja...die Zeit ist reif,die Entwicklungsphasen sind durchlaufen.Fehlt nur noch die Nachricht...und die wird kommen!

[biotech_nett]

Einfach ein TOP-Investment, finde ich und halte weiter

Happy days

biotech_nett

[asics01]

bis jetzt ist das alles reine spekulation und gezocke.

[asics01]

wenn mir mal bei 10 oder höher stehen,dann war das ein top investment.
asics

[Aptamilla]

[posting]20.688.822 von asics01 am 15.03.06 09:34:28[/posting]asics01,Du kommst daher und sagst wir und ein Gezocke.Was denn nu?Wenn Du einmal genau hinschaust,erkennst Du einen gewissen Grad an Spekulation.Klar!Auf der anderen Seite eröffnen sich aber auch riesige Chancen.Das Potenzial ist da...fehlt nur noch die Nachricht einer Kooperation oder einer Zulassung.Dies ist jederzeit möglich.Ausserdem ist Hemispherx gut aufgestellt und an der AMEX gelistet.MfG Apta

[asics01]

ich habe nie behauptet das ihr gezocke seid,ich sagte nur die aktie wird gezockt.und auserdem bin auch ich investiert und zocke mit.
asics

[Aptamilla]

[posting]20.720.644 von asics01 am 16.03.06 06:57:59[/posting]Hi asics01,Deine letzen beiden Postings habe ich zusammen gefügt und diesen Satz formuliert.Wie dem auch sei,zockt hier nur eine gewisse Spezies.Berlin übertreibt momentan mal wieder.Im Grunde genommen ist HEB nichts anderes als eine gesunde Spekulation mit Tendenz eines Blockbusters.Das hat z.B. Biotech-nett schon frühzeitig erkannt.Long zu bleiben ist klug,zumal die Karten bereits auf den Tisch liegen.Es stellt sich einfach nur noch die Gretchenfrage wer mit wem oder wann und wo.Heisst:entweder mit Übernahmephantasie oder im Zulassungssektor.Jeder entscheidet für sich...das Kriterium dieses Unternehmens ist positiv.Der US Staat subventioniert den Vogelgrippehyp und die FDA räumt im Ausnahmestatus eine schnelle Zulassung ein.Die Japaner(Pharmariesen) sind brennend interessiert zu kooperieren.Roche und GKS könnten sich bald um HEB streiten(Studien absolut gut)(bei anstehender Pandemie ist z.B. Tamiflu schlicht und einfach wirkungslos).Und der Faktor H5N1 in den USA(er ist in wenigen Wochen auch dort),könnte den Kurs von HEB Flügel verleihen.All das steht sehr bald an.Ich bleibe fest überzeugt...andere sind ungeduldig und zocken.Na denn..MfG Apta

[asics01]

hey aptamilla
ich verfolge euren tread hier schon lange und bin auch schon seit 1,90€ dabei es hört sich alles gut an,aber man muß trotz aller euphorie realistisch sein und auch damit rechnen daß der schuss nach hinten losgehen kann.ich habe mir mit bios schon oft die finger verbrannt(maxim,genta,aphton...)da waren auch alle euphorisch,und wo stehen die heute???
asics

[Aptamilla]

Ist schon richtig,Biotechwerte sind ganz klar spekulativ.Aber bei HEB ist die Sache etwas anders.Da liegen die Fakten mit Ampligen und Alferon schon auf den Tisch.Es ist nur eine Frage wie sich beides nun vermarkten lässt.Andere Biotechs forschen und können versagen wenn das Ergebnis nicht stimmt.Wir haben aber ein Ergebnis eines Katalysators,der konkurrenzlos nur darauf wartet Verwendung zu finden.Es ist hier keine Pusherei sondern vielmehr eine Momentaufnahme eines Blockbusterpräperates.Hier haben wir grosse Chancen,dabei zu sein wenn sich was bewegen sollte.Dann fliegen sämtliche Deckel...ähnlich wie bei Viropharma seinerzeit.MfG Aptamilla

[Aptamilla]

NEWS NEWS NEWS!!!

[asics01]

na dann hoffen wir mal das beste.
asics

[götz]

New Research From Hemispherx Biopharma Leverages Recent Studies to Identify Factors in Breakdown of Immune System; May Help Prevent Spread of Avian Flu

Results to be presented at the VIII International Symposium on Respiratory Viral Infections March 16-19 in Hawaii

Japanese researchers initiate primate studies with co-administration of Hemispherx Biopharma’s Ampligen and H5N1 vaccine

Philadelphia, PA, March 16, 2006: The results of new studies to be presented at the VIII International Symposium on Respiratory Viral Infections on March 16-19 represent a major step forward in leveraging research that identifies the gene that is believed to have caused the immune system to shut down and led to the devastating Spanish flu epidemic of 1918, which is estimated to have killed 100 million people. These studies have critical implications because some researchers believe the current spread of the H5N1, or avian flu, virus may have similar underlying causes. The findings, to be presented by Dr William Mitchell, Professor of Pathology at Vanderbilt University and a member of the Board of Directors of Hemispherx Biopharma, provide further evidence that Hemispherx Biopharma’s Alferon LDO (Low-Dose Oral), a new delivery form of an anti-viral with prior regulatory approval for a category of sexually transmitted diseases, has tremendous potential in resisting the spread of avian flu by stimulating genes that induce the production of immune compounds that are key building blocks in the body’s defense system.

Researchers in this area have recently focused on TNF, a naturally occurring immune substance (or “lymphokine”) as the instigator of the massive tissue damage to lung cells.

The new research included analysis of avian flu virus specimens recently recovered in the frozen artic tundra from victims of the 1918 avian flu epidemic. These studies suggest that the interferon system, the body’s primary line of defense, broke down first, leading to the aberrant and ultimately self-destructive release of TNF.
In recent healthy human volunteer tests conducted in Hong Kong and Philadelphia, patients were given graded doses of Alferon LDO for two minutes’ exposure. Blood samples were then taken to determine which components of the immune system had been activated. It was found that the interferon gene activity normally suppressed or killed by the virus were instead enhanced several times over. By contrast, the TNF gene battery normally enhanced by viral infection was instead sharply suppressed by the brief Alferon LDO exposure.

“These new studies are highly significant to our understanding of how the body reacts to virus attacks, a critical component in building adequate defenses against the spread of avian flu,” said Dr William Mitchell. “We believe that taken collectively, the latest findings represent tremendous progress in this critical area.”

Dr. Mitchell will also be presenting ongoing findings from trials on The TLR3 Agonist, Poly I: Poly C12U, Provides Nasal Adjuvant Activity to a Vaccine Directed Against Highly Pathogenic H5N1 Avian Influenza Virus and Synerginistic Inhibition of Avian Influenza Virus (H5N1) by PolyI: Poly C12 U Combined with Oseltamivir or Zanamivir. (All three trials were recently presented at the ASM Biodefense Conference.)

Dr. Mitchell will announce that the co-administration of Hemispherx Biopharma’s experimental immunotherapeutic Ampligen, a specifically configured double-stranded RNA, may help enable substantial reductions in an H5N1 vaccine dose, as well as provide cross-protection against mutated strains of the H5N1 virus. These results come from a conclusive mouse study conducted in collaboration with the National Institute of Infectious Diseases in Japan. In collaboration with Hemispherx Biopharma, the Institute has initiated the next phase of studies with primates.

Finally, additional research to be presented suggests the effectiveness of Tamiflu and Relenza, the only two drugs formally recognized for combating bird flu, can be boosted up to 100 times. Lab studies reveal that 50 to 100 times less Tamiflu may be used in conjunction with Ampligen to achieve full inhibition with no multiplication of the virus, and no host cell damage.



“The latest research offers further evidence that we are on the right path to identifying the factors that cause the immune system to break down, which has grave implications in the event of a pandemic,” said Dr. William A. Carter, M.D., Chairman and CEO of Hemispherx Biopharma. “We’re also encouraged that our experimental immunotherapeutics Ampligen and Alferon offer tremendous potential against the global spread of the H5N1 virus.”

(kopiert aus dem yahoo-board).

Sieht verdammt gut aus.

[tonyjaa]

ja sieht verdammt gut aus...

[[KERN]Codex]

[Aptamilla]

Ich fass es einfach nicht!Da werden 4,05 Mio.Aktien im deutlich positiven Terrain gehandelt und in Deutschland übt man sich in vornehmer Zurückhaltung.Die News waren gut,sehr vielversprechend.Die Story bleibt extrem spannend und spekulativ.Übrigens sind 54,1 Mio.Aktien im Markt plaziert..davon gestern 13% gehandelt worden.Also man sieht ganz klar,das sich der Kurs stabilisiert und ansetzt neue Höhen zu erklimmen.

[Aptamilla]

Montag sollten wir wieder die 3 vorm Komma sehen.Mal schauen was es an weiteren Neuigkeiten gibt.

[[KERN]Codex]

Werde Morgen nachlegen

[schadu]

Nächste Zündung in Sicht!
Die Experten von Trendraketen haben diesen Wert noch einmal unter die Lupe genommen. Nach einer kurzen Konsolidierungsphase ist jetzt der Zeitpunkt zum Nachkaufen da.

Hemispherx hat mit Ampligen ein hochinteressantes und vor allem marktreifes Produkt in der Pipeline. Ampligen ist ein so genannter Immunmodulator, der die Wirksamkeit des Grippemittels Tamiflu nach der Injektion „markant erhöht“ schreibt Trendraketen. Die Experten gehen davon aus, dass die Aktie den Ausbruch über die Marke von 3.50 Dollar schafft und empfehlen, die Aktie jetzt nachzukaufen.

[Aptamilla]

[posting]20.869.320 von schadu am 20.03.06 14:47:14[/posting]Aufstocken!!!

[Aptamilla]

Auf Tageshoch mit Rekordvolumina geschlossen!Strong buy!!!

[Aptamilla]

In München glaubt jemand an den Osterhasen!

[Aptamilla]

Charttechnisch ist nun auch der Weg nach oben frei!

[tilt]

[posting]20.883.054 von Aptamilla am 21.03.06 11:50:49[/posting]nicht ganz, denn als nächste hürde liegt die 4,25 aus 2004 vor uns. sollte diese kippen haben wir die 5,90 aus 12/01 vor der brust. aber gemach bis jetzt können wir uns nicht beklagen. hoffentlich beherschen die amis den doppelpass, dann erleben wir ein knaller sk heute.

stay cool, stay long

mfgtilt

[Aptamilla]

[posting]20.886.464 von tilt am 21.03.06 13:18:30[/posting]Aber so grosses Volumina am Stück hatte HEB über Jahre nicht.Da fliegen schon bald die Deckel!MfG

[tilt]

wäre mir nur recht
also heißt das neue motto " laßt die deckel fliegen "

mfg tilt

[Simbasi]

jetzt gehts aber wieder so runter wie es heute hoch ging
eigentlich schade

[Aptamilla]

[posting]20.897.605 von Simbasi am 21.03.06 21:38:19[/posting]Simbasi,Du musst das nicht durch die rosa Brille sehen.Schau mal auf das Handelsvolumen!Das ist für HEB gigantisch hoch und positiv zu bewerten.Wenn wir heute im grünen Bereich schliessen ist das sehr gut.Der Abschwung resultiert aus der volatilen Tagesperformance der Indizes Dow und Nasdaq.Also,bleib cool!

[tonyjaa]

5 mio gehandelte stück !!! das ist ein 10tel vom gesamtvolumen. von dem her schon extrem top!!!


marktkapitalisierung ist derzeit auf 200 mio dollar.
--> da sollte längerfristig viel platz nach oben sein


http://www.stockhouse.ca/comp_info.asp?symbol=HEB&table=AMEX
der stock indicator steht auch auf very bullish

[[KERN]Codex]

Heute geht es weiter bergauf

[tonyjaa]

tja, alles wartet auf die amis

[Aptamilla]

[posting]20.907.156 von tonyjaa am 22.03.06 14:11:29[/posting]Bin sehr zuversichtlich.Die Story stimmt und die Instis haben nun endlich HEB auf der Watchlist.Ampligen wird uns noch eine Menge Freude bereiten.Dieses Präparat ist eine Goldgrube und könnte schon bald zum Blockbuster avanchieren.Mein Tip lautet:dabei bleiben!Apta

[[KERN]Codex]

[[KERN]Codex]

[[KERN]Codex]

Hemispherx Biopharma Avian Influenza Programs

Ampligen® as an Adjuvant for Avian Influenza Vaccines
One approach to fighting Avian Influenza has been the use of vaccines such as the one
developed by Sanofi-Aventis. Vaccines typically use additional agents, called adjuvants,
to increase their potency.
A number of studies have presented a strong case for the use of double-stranded RNA
(dsRNA) as an adjuvant for vaccines. There is significant data on both polyAolyU and
polyIolyC in a variety of animal models. Particularly significant is the ability of
dsRNA adjuvants to broaden the range of inflections which are susceptible to the vaccine
used. This is particularly important as new strains of influenza appear with ever
increasing frequency and exhibit the potential to evolve into a global pandemic.
The limitation to this approach has been that dsRNAs such as polyAolyU and
polyIolyC are experimental agents which have not been approved for human use and/or
have exhibited significant toxicity.
The one exception is the dsRNA product developed by Hemispherx Biopharma,
Ampligen®, polyIolyC12U. Ampligen has been studied for a variety of anti-viral and
anti-cancer applications in over 700 patients. In the various clinical studies, patients have
received two doses a week i.v. of 400 mg. for periods as long as three years. Hemispherx
has completed pivotal Phase II and Phase III trials in chronic fatigue syndrome and is
preparing to file an NDA. The investigational Ampligen® program for the potential
treatment of CFS has generated a set of efficacy parameters over a number of years in
clinical development. As of this date, over 500 CFS patients have received approximately
53,000 doses of the experimental drug. Non-CFS disease category patients have received
approximately 23,000 doses for a cumulative drug exposure of 76,000 doses.
Recently, Japanese researchers (Journal of Virology page 2910, 2005) have found that
dsRNAs increase the effectiveness of influenza vaccine by more than 300% and may also
convey “cross-protection ability against variant viruses” (mutated strains of influenza
virus). Hemispherx recently entered into collaboration with this research group at the
National Institute of Infectious Diseases in Tokyo, led by Hideki Hasegawa, M.D>, Ph.D.,
Chief of the Laboratory of Infectious Disease Pathology.
Co-Administration of Ampligen® with Tamiflu or Relenza
A second approach to fighting Avian Influenza is the use of an anti-viral agent such as
Roche’s Tamiflu or Glaxo’s Relenza.
The report on a preclinical study conducted by research affiliates of the National
Institutes of Health at Utah State University compared the relative protection conveyed
by Tamiflu (oseltamivir, Roche) and Ampligen®, alone and in combination against the
avian flu virus (H5N1). Cell destruction was measured in vitro using different drug
combinations. Both drugs, given alone, were effective in inhibiting cell destruction by
avian influenza, but viral “suppression with the combination was greater than either drug
alone”. The researchers reported, in summary: “The overall assessment is that there was
improvement in cell protection when Ampligen® was combined with oseltamivir
carboxylate” (Tamiflu). Further immediate experimental tests are planned, including the
testing of Ampligen in combination with Relenza.
At present, a narrow window of opportunity (approximately 48 hours) exists for effective
utilization of Tamiflu after exposure to influenza. By providing a new mechanism of
inhibition of Avian Influenza, (i.e. immunologic/host defensive immune cascades),
Ampligen® may afford a new approach to help combat influenza virus.
Ampligen® as a Single Agent
Ampligen is an anti-viral agent in its own right, as demonstrated by its success in treating
diseases of known or suspected viral origin such as HIV, CFS, and Hepatitis C. Other
dsRNA compounds have shown success in Hepatitis B. The Utah State study
demonstrated effectiveness against the Avian Influenza virus.
Alferon N Injection®
Alferon N, the first natural source, multi-species interferon, is a consistent mixture of
glycosylated alpha-interferon species which are the normal components of the body’s
first line of defense against viral infection. In addition, Alferon N does not induce
antibody formation, which is a problem associated with recombinant forms of nonglycosylated
alpha-interferon. Moreover, Alferon N has shown a broad spectrum
antiviral activity in chronic viral diseases including HIV disease, genital warts secondary
to human papilloma virus, and chronic hepatitis C. Indeed, for the most common
genotype of hepatitis C virus in the U.S., genotype 1, Alferon N was statistically superior
in clinical testing to recombinant interferon. In addition, Alferon N has also well
demonstrated activity against two newly emerging viruses, SARS and avian influenza.
Alferon N Injection® has been approved by the FDA for treatment of condylomata
acuminata (genital warts). It is effective at doses significantly lower than those used for
recombinant alpha interferon.
Alferon LDO™
Alferon® LDO (Low Dose Oral) is an experimental low-dose, oral liquid formulation of
Hemispherx Biopharma’s approved natural interferon product, Alferon N Injection®
[Interferon alfa-n3 (human leukocyte derived)].
It is expected to be a broad spectrum antiviral and immune modulator with the ability to
activate selectively the genes responsible for the interferon response components of
innate immunity in order to generate a systemic, prophylactic antiviral defense.
Several studies in different animal species suggest that low dose oral interferon therapy
suppresses virus replication and eliminates or reduces virus shedding and transmission,
which results in higher survival rates and improvement in weight gain.
Previous peer reviewed experimental research conducted has shown that low doses of
Alferon® N added to the water and food supply of the bird population reduced death rate
as well as produced healthier weight compared to birds that received placebo. Typically,
birds in close quarters being raised as a poultry crop are exposed to various stressful
conditions, which include outbreaks of viral infections and make them more susceptible
to disease. This well-controlled study demonstrated that Alferon® N can both decrease
the morbidity and death rates of birds living under these conditions as well as produce a
larger bird when trace amounts of Alferon® are added to the food supply.
The multiple actions of cocktails of human alpha interferons is the crux of Hemispherx’s
belief that Alferon LDO may be able to inactivate avian influenza by boosting the
immune system of both birds raised as poultry crop so as to prevent infection, as well as
act as both a short-term immune boost lending to a longer-term vaccine-like protection in
humans. Initial studies indicate that alpha interferons stimulate broad-spectrum antiviral
and immune system genes when given by injection, but such studies have not yet been
systematically conducted by oral delivery.
Hemispherx has started clinical trials in humans looking at relevant interferon gene
activation profiles after administration of Alferon LDO, using cutting edge technology
involving hundreds of genes analyzed by gene micro-arrays. Successful results would
impact the potential for use of Alferon LDO in a wide range of diseases, including Avian
Influenza. One of the trials will be conducted in healthy volunteers by Dr. Tommy Tang,
Senior Medical Officery at the Princess Margaret Hospital in Hong Kong.
Recent studies indicate that the disabling of these interferon genes may have led to the
pandemic in 1918/1919, which killed millions around the globe. If these disabled genes
can be protected, the molecular basis for the lethality of avian flu may be completely
avoided.
New Vaccine Manufacturing Technology
Hemispherx is beginning a new program to develop a modern vaccine manufacturing
technology which would short the time require to manufacture a new vaccine. No results
are available at this point but the approach is promising.

[[KERN]Codex]

Hemispherx Biopharma Avian Influenza Programs

Ampligen® as an Adjuvant for Avian Influenza Vaccines
One approach to fighting Avian Influenza has been the use of vaccines such as the one
developed by Sanofi-Aventis. Vaccines typically use additional agents, called adjuvants,
to increase their potency.
A number of studies have presented a strong case for the use of double-stranded RNA
(dsRNA) as an adjuvant for vaccines. There is significant data on both polyA: polyU and
polyI: polyC in a variety of animal models. Particularly significant is the ability of
dsRNA adjuvants to broaden the range of inflections which are susceptible to the vaccine
used. This is particularly important as new strains of influenza appear with ever
increasing frequency and exhibit the potential to evolve into a global pandemic.
The limitation to this approach has been that dsRNAs such as polyA: polyU and
polyI: polyC are experimental agents which have not been approved for human use and/or
have exhibited significant toxicity.
The one exception is the dsRNA product developed by Hemispherx Biopharma,
Ampligen®, polyI: polyC12U. Ampligen has been studied for a variety of anti-viral and
anti-cancer applications in over 700 patients. In the various clinical studies, patients have
received two doses a week i.v. of 400 mg. for periods as long as three years. Hemispherx
has completed pivotal Phase II and Phase III trials in chronic fatigue syndrome and is
preparing to file an NDA. The investigational Ampligen® program for the potential
treatment of CFS has generated a set of efficacy parameters over a number of years in
clinical development. As of this date, over 500 CFS patients have received approximately
53,000 doses of the experimental drug. Non-CFS disease category patients have received
approximately 23,000 doses for a cumulative drug exposure of 76,000 doses.
Recently, Japanese researchers (Journal of Virology page 2910, 2005) have found that
dsRNAs increase the effectiveness of influenza vaccine by more than 300% and may also
convey “cross-protection ability against variant viruses” (mutated strains of influenza
virus). Hemispherx recently entered into collaboration with this research group at the
National Institute of Infectious Diseases in Tokyo, led by Hideki Hasegawa, M.D>, Ph.D.,
Chief of the Laboratory of Infectious Disease Pathology.
Co-Administration of Ampligen® with Tamiflu or Relenza
A second approach to fighting Avian Influenza is the use of an anti-viral agent such as
Roche’s Tamiflu or Glaxo’s Relenza.
The report on a preclinical study conducted by research affiliates of the National
Institutes of Health at Utah State University compared the relative protection conveyed
by Tamiflu (oseltamivir, Roche) and Ampligen®, alone and in combination against the
avian flu virus (H5N1). Cell destruction was measured in vitro using different drug
combinations. Both drugs, given alone, were effective in inhibiting cell destruction by
avian influenza, but viral “suppression with the combination was greater than either drug
alone”. The researchers reported, in summary: “The overall assessment is that there was
improvement in cell protection when Ampligen® was combined with oseltamivir
carboxylate” (Tamiflu). Further immediate experimental tests are planned, including the
testing of Ampligen in combination with Relenza.
At present, a narrow window of opportunity (approximately 48 hours) exists for effective
utilization of Tamiflu after exposure to influenza. By providing a new mechanism of
inhibition of Avian Influenza, (i.e. immunologic/host defensive immune cascades),
Ampligen® may afford a new approach to help combat influenza virus.
Ampligen® as a Single Agent
Ampligen is an anti-viral agent in its own right, as demonstrated by its success in treating
diseases of known or suspected viral origin such as HIV, CFS, and Hepatitis C. Other
dsRNA compounds have shown success in Hepatitis B. The Utah State study
demonstrated effectiveness against the Avian Influenza virus.
Alferon N Injection®
Alferon N, the first natural source, multi-species interferon, is a consistent mixture of
glycosylated alpha-interferon species which are the normal components of the body’s
first line of defense against viral infection. In addition, Alferon N does not induce
antibody formation, which is a problem associated with recombinant forms of nonglycosylated
alpha-interferon. Moreover, Alferon N has shown a broad spectrum
antiviral activity in chronic viral diseases including HIV disease, genital warts secondary
to human papilloma virus, and chronic hepatitis C. Indeed, for the most common
genotype of hepatitis C virus in the U.S., genotype 1, Alferon N was statistically superior
in clinical testing to recombinant interferon. In addition, Alferon N has also well
demonstrated activity against two newly emerging viruses, SARS and avian influenza.
Alferon N Injection® has been approved by the FDA for treatment of condylomata
acuminata (genital warts). It is effective at doses significantly lower than those used for
recombinant alpha interferon.
Alferon LDO™
Alferon® LDO (Low Dose Oral) is an experimental low-dose, oral liquid formulation of
Hemispherx Biopharma’s approved natural interferon product, Alferon N Injection®
[Interferon alfa-n3 (human leukocyte derived)].
It is expected to be a broad spectrum antiviral and immune modulator with the ability to
activate selectively the genes responsible for the interferon response components of
innate immunity in order to generate a systemic, prophylactic antiviral defense.
Several studies in different animal species suggest that low dose oral interferon therapy
suppresses virus replication and eliminates or reduces virus shedding and transmission,
which results in higher survival rates and improvement in weight gain.
Previous peer reviewed experimental research conducted has shown that low doses of
Alferon® N added to the water and food supply of the bird population reduced death rate
as well as produced healthier weight compared to birds that received placebo. Typically,
birds in close quarters being raised as a poultry crop are exposed to various stressful
conditions, which include outbreaks of viral infections and make them more susceptible
to disease. This well-controlled study demonstrated that Alferon® N can both decrease
the morbidity and death rates of birds living under these conditions as well as produce a
larger bird when trace amounts of Alferon® are added to the food supply.
The multiple actions of cocktails of human alpha interferons is the crux of Hemispherx’s
belief that Alferon LDO may be able to inactivate avian influenza by boosting the
immune system of both birds raised as poultry crop so as to prevent infection, as well as
act as both a short-term immune boost lending to a longer-term vaccine-like protection in
humans. Initial studies indicate that alpha interferons stimulate broad-spectrum antiviral
and immune system genes when given by injection, but such studies have not yet been
systematically conducted by oral delivery.
Hemispherx has started clinical trials in humans looking at relevant interferon gene
activation profiles after administration of Alferon LDO, using cutting edge technology
involving hundreds of genes analyzed by gene micro-arrays. Successful results would
impact the potential for use of Alferon LDO in a wide range of diseases, including Avian
Influenza. One of the trials will be conducted in healthy volunteers by Dr. Tommy Tang,
Senior Medical Officery at the Princess Margaret Hospital in Hong Kong.
Recent studies indicate that the disabling of these interferon genes may have led to the
pandemic in 1918/1919, which killed millions around the globe. If these disabled genes
can be protected, the molecular basis for the lethality of avian flu may be completely
avoided.
New Vaccine Manufacturing Technology
Hemispherx is beginning a new program to develop a modern vaccine manufacturing
technology which would short the time require to manufacture a new vaccine. No results
are available at this point but the approach is promising.

[[KERN]Codex]

http://www.cdc.gov/ncidod/diseases/cfs/publications/causes.h…

[[KERN]Codex]

Moin Moin

Chronic fatigue syndrome (CFS) affects 400,000 to 900,000 adults in the United States [1,2]. At least a quarter of those suffering from CFS are unemployed or receiving disability because of the illness; the average affected family forgoes $20,000 annually in lost earnings and wages (approximately half of the average United States household income); and the annual value of lost productivity in the United States is approximately $9 billion [2-4]. Despite the public health burden imposed by CFS, effective diagnostic, treatment and prevention strategies are not available because the etiology, risk factors and pathophysiology of CFS remain unknown (reviewed in [5]).

To some extent, the inconsistent and often conflicting results from studies of CFS reflect referral bias. Most published studies concerning CFS recruited patients from tertiary referral clinics. Patients receiving care for CFS are neither similar across clinics [6,7] nor necessarily representative of the population of people who suffer from CFS. Studies of CFS in the general population of Chicago have found that only 66% of people with CFS have consulted a physician concerning their fatigue and only 19% of them received a diagnosis of CFS [1]. Studies in the general population of Wichita have similarly reported that only 16% of individuals with the illness have been diagnosed by or treated for CFS by a physician [2].

In addition, the lack of consistent findings concerning the etiology, pathophysiology and risk factors for CFS reflects lack of standardized reproducible diagnostic criteria for CFS. CFS is defined as persistent or relapsing fatigue of at least 6-months' duration, that is not alleviated by rest, and that causes substantial reduction in activities. The fatigue cannot be explained by medical or psychiatric conditions and must be accompanied by at least 4 of 8 case defining symptoms (unusual post exertional fatigue, impaired memory or concentration, unrefreshing sleep, headaches, muscle pain, joint pain, sore throat and tender cervical nodes) [9]. An International CFS Study Group recently published recommendations concerning application of the case definition [10]. The Group recommended the use of validated instruments to obtain standardized measures of the major symptom domains of the illness. They specifically recommended: (1) the Medical Outcomes Survey Short Form-36 (SF-36), to measure functional impairment [11]; (2) a comprehensive instrument, such as the Checklist Individual Strength (CIS) [12] or the Multidimensional Fatigue Inventory (MFI) [13], to obtain reproducible quantifiable measures of fatigue,; and (3) the CDC Symptom Inventory to document the occurrence, duration and severity of the symptom complex [14]. We are aware of no published studies that have utilized this comprehensive battery of standardized clinically empirical instruments to characterize persons with CFS, persons with other unexplained fatiguing illnesses and non-fatigued controls.

The objective of the present study was to implement recommendations of the International CFS Study Group [10] and define CFS based on scores from standardized and validated instruments that assess the major dimensions of the illness specified by the 1994 CFS case definition [9]. Data came from a 2-day in-patient study of 227 people with CFS, with other chronically fatiguing illnesses, and matched non-fatigued controls identified in the general population of Wichita, Kansas. We used standardized and validated instruments to characterize the major dimensions of CFS – functional impairment (SF-36) – fatigue characteristics (MFI) – frequency and severity of accompanying symptoms (Symptom Inventory).

http://www.biomedcentral.com/1741-7015/3/19

[[KERN]Codex]

Das Thema ist wirklich spannend

Chronic fatigue syndrome (CFS) is an illness characterized by severe disabling fatigue lasting for at least 6 months and made worse by minimal physical or mental exertion, for which there is no adequate medical explanation. There are no key features or typical symptoms, but a sore throat, depression and myalgia may all be present [1–3]. Factors causing the condition remain unclear, although there is some consensus that psychological and social factors influence outcome. Altered hypothalamus–pituitary–adrenal gland (HPA) axis activity has been identified as a feature, as has the frequent association of CFS with viral infections, suggesting that under certain circumstances virus infection is a prelude to the development of CFS [4–8].

In the light of observations in relation to viruses, a number of studies have sought evidence of abnormalities in immune function, but in general there has been no consistent pattern observed, and abnormalities rarely correlate with clinical status [9–13] even though immunological changes have been observed and reported frequently. Most recently, the Th1/Th2 paradigm of immune-mediated disease has been invoked and explored in relation to CFS [14–16]. One of the main supporting arguments for this proposal is the frequent reporting of a reduction in natural killer (NK) cell activity in CFS [10,17,18]. NK cells play a key role in the generation of Th1 type antiviral responses, and loss of their activity could result in a Th2 bias and persistent viral activation and chronic infection. More direct evidence of potential Th2 bias has been reported recently [15] in a study in which an increased level of interleukin (IL)-4 mRNA was associated with a CFS-like syndrome in Gulf War veterans.

Cytokines are the main parameters measured in assessing Th1/Th2 balance and information on cytokine levels and the nature of cellular production could provide important insights into the immune hypothesis in relation to CFS. To date few studies have examined Th1/Th2 balance directly in this disorder. Studies that have been performed have employed enzyme-linked immunosorbent assay (ELISA) or bioassay measurement of cytokines in supernatants from peripheral blood mononuclear cell culture [19] or from serum samples. However, these approaches are not able to provide a clear picture of Th1/Th2 balance. First, the relative contribution of individual cell subsets to cytokine production, and whether they are lymphocytes or macrophages, cannot be determined. Subtle changes in lymphocyte polarization could be masked by cytokine production by non-lymphoid cells. In addition, the presence of soluble natural inhibitors of cytokine function in serum is usually not determined simultaneously, and therefore the functional balance of the immune system remains obscured. Finally, cytokines are known to be sensitive to degradation in serum and are present typically only at the limits of detection of conventional assays [20]. In contrast with these approaches, in recent years direct visualization of cytokine production, using intracellular staining and flow cytometry, has become a powerful technique for examining the immune response, being both sensitive and cell-specific [21–23]. This method therefore allows direct enumeration of polarized, cytokine-producing effector cells. Additionally the use of a whole-blood system avoids potential subtle effects on lymphocyte function arising from gradient separations [22,24–26], and is also reported to yield greater cytokine production when compared with purified peripheral blood mononuclear cell (PBMC) preparations [27]. The choice of phorbol esters and ionomycin as stimulants that act independently of accessory cells is based on earlier work [23], showing their superiority in terms of their ability to induce intracellular cytokine secretion to lectins such as phytohaemagglutinin [21].

With these technical issues in mind, in the present study we examined the frequency of type 1 (interferon (IFN)-γ and IL-2-producing), type 2 (IL-4) and regulatory (IL-10) CD4 and CD8 T cells by direct visualization of intracellular cytokine production in CFS patients and healthy blood donors. Our results demonstrate an expansion of type 2 effector memory cells in CFS patients.

http://www.blackwell-synergy.com/doi/full/10.1111/j.1365-224…

[[KERN]Codex]

Das Thema wird uns noch eine ganze Weile beschäftigen!

Bird Flu News Feed
Due to severe pressure of work and the sheer volume of Bird Flu stories at present we are unable to edit this site at present. Below is our news research feed which contains the 100 latest stories from the internet



» Bird Flu Reported in Gaza Strip - Chosun Ilbo
23/03/06 06:15 from Google Search: bird flu
Chosun Ilbo Bird Flu Reported in Gaza Strip Chosun Ilbo, South Korea - 4 hours ago Tests on dead chickens indicate that the deadly H5N1 strain of bird flu or avian influenza has spread to the Gaza Strip. Israeli ... China, US lau..


» Schools Work On Preparedness For Avian Flu Outbreak - Tampa Tribune
23/03/06 05:43 from Google Search: avian flu
PR Web (press release) Schools Work On Preparedness For Avian Flu Outbreak Tampa Tribune, FL - 30 minutes ago School officials across the country are being asked by federal officials to shore up preparations for a possible outbre..


» Madonna Causes Bird Flu?
23/03/06 02:30 from Bird Flu Monitor
[ (parenthetical remarks) - blogging between the lines ] It's no secret that she's deeply immersed in Kabbalah, the once-obscure form of Jewish mysticism that, thanks in large part to the Material Girl (or Esther, to call her by ..


» European Commission assists Palestinians with Prevention of Avian ... - Palestine News Network
22/03/06 19:32 from Google Search: avian flu
European Commission assists Palestinians with Prevention of Avian ... Palestine News Network, Israel - 1 hour ago ... Instead, the European Commission has been an active partner in following up on the developments of the Avian Fl..


» Romania confirms more bird flu - Monsters and Critics.com
22/03/06 15:01 from Google Search: bird flu
Romania confirms more bird flu Monsters and Critics.com, UK - 4 hours ago ... A total number of bird flu outbreaks in Romania were about 50. Apart from thousands of birds already destroyed, the officials said ... Bird flu no big ..


» African Bird Flu Conference Fails to Discuss Human Infection - Voice of America
22/03/06 14:52 from Google Search: avian flu
Voice of America African Bird Flu Conference Fails to Discuss Human Infection Voice of America - 3 hours ago ... productive. He said the spread of the avian flu across most of the north of the country has seriously affected its agricu..


» Bird flu poses fresh threat to endangered species - Reuters AlertNet
22/03/06 14:08 from Google Search: avian flu
Bird flu poses fresh threat to endangered species Reuters AlertNet, UK - 4 hours ago ... about countries like Vietnam, which is home to both a rich variety of wild species and a large poultry industry that has been hit by avian f..


» US GOVT.URGES SCHOOLS TO PREPARE FOR BIRD FLU
22/03/06 13:31 from H5N1
It's extremely important to investigate every H5N1 case, said Dr. Timothy Uyeki of the federal Centers for Disease Control and Prevention. ... The deadly H5N1 strain of bird flu remains primarily a contagious bird disease. ...


» Egypt reports 4th suspected human bird flu case
22/03/06 13:28 from H5N1
Via Reuters: Egypt reports 4th suspected human bird flu case . Egypt reported a fourth suspected case of bird flu in humans on Tuesday, in a 17-year-old boy whose father had an outbreak of the disease on his chicken farm in the Nile Delta ..


» Pakistan: H5N1 confirmed
22/03/06 13:25 from H5N1
Via the Khaleej Times Online: Pakistan confirms first two cases of H5N1 . Pakistan's beleaguered poultry industry braced for a further drop in sales after the government announced on Tuesday the country's first two cases of the deadly H5N1..


» Avian Virus Mutates
22/03/06 13:15 from H5N1
... According to researchers, the virus responsible for the current bird flu outbreak has split into two distinct genetic subgroups. An analysis of more than 300 samples of the H5N1 virus taken from humans and birds has revealed that the v..


» Bird Flu Outbreak In The Gaza Strip
22/03/06 13:09 from H5N1
... The first outbreak of bird flu in the Palestinian territories has been detected, initial tests claim.The H5N1 strain of the virus may have killed 200 chickens in the Gaza Strip. ... News from the web


» Survey reveals bird flu complacency - Management-Issues
22/03/06 11:08 from Google Search: avian flu
Survey reveals bird flu complacency Management-Issues, UK - 2 hours ago Despite all the warnings about the potentially devastating effects of a global avian flu pandemic, only half of the world's major multinationals have yet..


» Seven people test positive for H5N1 in Azerbaijan
22/03/06 09:17 from Avian Flu - What we need to know
WHO said seven of 11 patients from Azerbaijan had tested positive for H5N1 in samples checked at a major laboratory in Britain. Five of those cases were fatal. The sources of infection were still under investigation, but officials suspecte..


» Burmese vets say avian flu spreads to Kantbalu and Taungtha - Democratic Voice of Burma
22/03/06 09:17 from Google Search: avian flu
Burmese vets say avian flu spreads to Kantbalu and Taungtha Democratic Voice of Burma, Norway - 4 hours ago Mar 21, 2006 (DVB) - Burmese vets, speaking on condition of anonymity, said that they have the suspicion that the deadly ..


» March 22 Flu Update
22/03/06 09:13 from The Coming Influenza Pandemic?
The big news today is a study that purports to explain why flu isn't easily transmissible between people. Scientists say they've found a reason bird flu isn't spreading easily from person to person: The virus concentrates itself too deep i..


» Avian flu: Is it time to panic? AQ and A with Orange County's ... - Times Herald-Record
22/03/06 09:11 from Google Search: avian flu
Avian flu : Is it time to panic? AQ and A with Orange County's ... Times Herald-Record, NY - 4 hours ago ... There were three pandemics in the 20th century - in 1918, 1957 and 1968. Is avian flu the same thing as a pandemic? ..


» Bird flu virus spreads from Mandalay to neighbouring areas - Democratic Voice of Burma
22/03/06 08:26 from Google Search: avian flu
Bird flu virus spreads from Mandalay to neighbouring areas Democratic Voice of Burma, Norway - 1 hour ago ... Organisation (FAO) in Bangkok, Laurence Gleeson, warned that the Burmese authorities were losing the battle to control ..


» Egypt, Azerbaijan and the task ahead
22/03/06 07:56 from Effect Measure
Egypt and Azerbaijan are both reporting more human cases of bird flu. First, Egypt . There are now a total of four cases, one fatal, all with histories of contact with sick poultry. Three more people are suspect cases and under observation..


» UK's warship just keeps on killing
22/03/06 07:39 from Effect Measure
Old soldiers never die, they just fade away, the old saying goes, but a veteran of the UK's Falkland conflict, the ship Sir Geraint , will go on killing even after death. No gentle fade for this asbestos-laden toxic scrap heap. It wasn't s..


» Bird flu confirmed in Pak - NDTV.com
22/03/06 03:38 from Google Search: avian flu
NewKerala.com Bird flu confirmed in Pak NDTV.com, India - 2 hours ago ... But apart from two farms, we have had no reports of avian flu from any other farm in Pakistan," said Mohammad Afzal, Commissioner, Livestock. ... Paki..


» Bank warns against airline stocks due to bird flu
22/03/06 01:36 from MSN Search News: bird flu
Daily Telegraph - Investment bank Bear Stearns has advised investors to start dumping airline and retail stocks in favour of blue-chip utilities as a hedge against bird flu, warning that a full human pandemic of the ...


http://tahilla.typepad.com/birdflu/

[Aptamilla]

Antwort auf Beitrag Nr.: 20.919.964 von [KERN]Codex am 23.03.06 12:54:27

Wenn der Virus die USA erreicht(und das wird er)bekommt der ganze Hype eine ganz andere Bedeutung.Dann fliegen sämtliche Deckel.HEB ist dann mit Ampligen vorne mit dabei!Das ist sicher.MfG Apta

[[KERN]Codex]

Antwort auf Beitrag Nr.: 20.920.652 von Aptamilla am 23.03.06 13:46:48

Sehe ich genauso, Hemispherx wird Novavax noch überholen

[[KERN]Codex]

Strong Buy!

[Aptamilla]

Antwort auf Beitrag Nr.: 20.940.480 von [KERN]Codex am 24.03.06 16:58:16

Kern,das sage ich schon ein halbes Jahr:strong buy...aber nur wenige verstehen unsere Botschaft!Im wirklichen Leben gibt es nun mal Menschen..die wollen gar nicht verstehenMfG Apta

[asics01]

ich habe doch auch verstanden und habe gestern noch mal nachgekauft.also schau mer mal.
asics

[[KERN]Codex]

[Lanzalover]

[[KERN]Codex]

how ampligen works in a vaccine for :
by: kdog007_2000 03/28/06 12:56 am
Msg: 76070 of 76070

those who are new,

without slingin around big words that none of us undrstand, the simple way to put it is this:

If a vaccine maker utilizes Ampligen while making any antiviral vaccince, ampligen allows 2 things, the vaccine maker to produce less vaccine, yet increase yields, and 2 allows the vaccine to cross mutate with the virus. So an exapmle:

every year poeple line up to get flu shots, to make a flu shot, the vaccine is grown in eggs. one egg=1 shot, minus non performing vaccines. that flu vaccine is targeted at a specific strain of flu. if a similiar flu comes around, then the vaccine should provide some security. if it is a different strain altogether, everyone who had a flu shot is NOT protected. now, fast forward to an ampligen enhanced flu shot. the vaccine maker buys ampligen from HEB, he takes the vaccine for strain x of the flu mixed in some ampligen, and produces more flushot. strain x comes around, but mutates into strain y and z. the ampligen modified shot allows the vaccine to mutate with the virus, since ampligen allows the vaccine to cross mutate, you are still protected. In terms of bird flu, imagine all the vaccines that will come outtargeting the H5n1 strain, then it morphes into something different. the vaccine u have for h5n1 is ineffective, but a vaccine made with ampligen will be effective. same with tamiflu. make tamiflu with ampligen, you boost the effect up to 300 times or whatever they said. for the nearly dead with bird flu, you can fill them up with ampligen alone, and that should trigger a massive immunoresponse like an overdose of penicicillian. same can be said for Alferon. the beauty of HEB is it is not a 1 trick pony, but it is a multiple areas approach to bird flu, and other diseases. so buy more when you can and hope HEB makes us money for something othere than a pandemic, but if there is one, this and a few other stocks are gonna be the only things that go up. we'd see the dow drop 5000 points or more if this thing mutates.

[[KERN]Codex]

Antwort auf Beitrag Nr.: 20.968.466 von [KERN]Codex am 28.03.06 07:58:37

3,25 USD sollten heute halten

[[KERN]Codex]

How A Pandemic Takes Wing
While Fear Of Avian Flu Is Spreading, The Disease Has Yet To Claim A Single U.S. Victim, Human Or Avian. All It Might Take To Change That Is A Single Cat

Subscribe to BusinessWeek
Springtime usually brings joy to Alaska after a long winter. This year, however, it is also likely to bring the avian flu virus, carried by infected wild birds migrating from Asia. If so, the virus could spread to birds in the lower 48 states in a matter of months.



At that point, the population that most worries the world's infectious disease trackers is not so much the nation's human population -- the virus has yet to evolve into a form that easily infects humans. It is not even domestic poultry, since most U.S. commercial bird flocks are sealed away in covered buildings, never coming in contact with wild birds.



What keeps some scientists up at night is the 75 million household cats, plus the 40 to 60 million feral cats roaming the countryside, some of which are sure to eat infected birds. "If it gets into cats in this country it will spread like crazy," warns Larry Glickman, a professor of epidemiology at Purdue University School of Veterinarian Medicine. "Many of these cats sleep in bed with their owners. The potential that they could spread it to humans is very large."



CASH SHORTAGE.

The federal government is well aware of the potential dangers of an avian flu outbreak in humans. So it is dramatically stepping up efforts to monitor migratory birds, particularly in Alaska.



Health & Human Services Secretary Michael Leavitt says the H5N1 virus that causes avian flu could reach the U.S. by summer or fall -- a reasonable assumption, given that it has spread to at least five new countries in March alone. In addition, the Centers for Disease Control & Prevention [CDC] just reported that a new variant of the virus has evolved with genetic characteristics that increase the risk of infection in humans.



At this point, surveillance efforts in the U.S. and overseas are focused on birds and the people who come in contact with them. There is no official effort to monitor household pets for infection. And while Purdue's vet school has, in fact, developed such a system under a grant from the CDC, no one has stepped forward to finance its implementation.



BIRDS, PIGS, PEOPLE.

Meanwhile, epidemiologists have confirmed that the virus has killed three cats, a dog, and a weasel in Europe in recent weeks. "This is what we're most worried about," says Walter Boyce, director of the Wildlife Health Center at University of California-Davis's School of Veterinary Medicine. "Every time this virus jumps into a new species, it has a chance to undergo more evolution."



In the virus world, evolution can lead to a scary narrative. As long as H5N1 is passed primarily among birds, a human pandemic is not in the cards. The virus has so far been found in 178 people, 101 of whom died. All got it from handling live or recently killed poultry.



As the virus finds new hosts, however, the opportunity arises for it to swap tiny bits of its DNA with a virus that can be exchanged among humans. Recent studies have suggested, for example, that the Spanish flu pandemic of 1918 was the result of an avian virus that mingled with bits of a virus found in pigs. The end result was a microbe that was both deadly and highly transmissible.



MONITORING SAMPLES.

Nobody knows whether or not the current strain of H5N1 will eventually cause a human pandemic. Boyce says we should be thinking of how to handle the intermediate stage: "What do we need to do when the virus is found in geese or even cats, but not in humans? How do we keep people from panicking?"



To keep tabs on the cat population, Glickman and other researchers at Purdue have designed a computerized surveillance system that analyzes veterinarian records for unusual clusters of symptoms that might indicate an infectious outbreak.



The data flows in from more than 500 animal hospitals spread throughout the U.S. They are operated by Portland [Ore.]-based Banfield the Pet Hospital, which, unlike most hospitals for human patients, keeps sophisticated, systemwide electronic records. The data can be extracted on a daily, or even hourly, basis. "By routinely testing blood samples from cats and pet birds that come to the Banfield hospitals, we can monitor the emergence and movement of the avian flu virus," says Glickman.



RATIONAL FEARS?

Other researchers share concerns about animal populations. Tracey McNamara, a veterinary pathologist at New York's Bronx Zoo, worries about the feces of infected wild birds, a common reservoir for the virus. Geese produce a pound of feces a day and some studies have found that viruses can survive there for up to a week. William Karesh, director of the field vet program for the Wildlife Conservation Society, says birds smuggled in from nations where the virus is well-established form the most likely path of transmission to North America. He calls for stepped up monitoring of the ports.



There is, of course, an optimistic cohort of researchers who believe the virus will never mutate to become an infectious human disease. Or perhaps, if it does, it will turn out to be more benign than everyone expects. The Hong Kong flu pandemic of 1964, for example, killed about 34,000 people in the U.S. That's actually fewer than die during a normal flu season. But since the course of this disease cannot be predicted, our best defensive action is to monitor the animals that are the first to succumb.




Copyright 2006 , by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use | Privacy Policy

[[KERN]Codex]

March 27, 2006

At least 29 nations have reported initial cases of avian influenza during the past seven weeks, reflecting the ineffectiveness of bird culling.

The viral disease has been newly reported in Nigeria, Israel, India, Sweden and elsewhere, with scientists in the United States estimating bird flu is likely to arrive in North America this year.

"We expected it to move, but not any of us thought it would move quite like this," said Dr. David Nabarro, the U.N. coordinator on bird flu efforts, told The Los Angeles Times.

Researchers initially thought culling millions of chickens, ducks and other birds would contain or even eradicate the virus. It has not.

The virus has so far infected 186 humans, causing 105 deaths, according to the World Health Organization. The fear is the virus will mutate, becoming easily spread between humans and creating a pandemic that potentially could kill millions of people.

"Each morning I sit down at the computer ... there's another country, another outbreak or another human case," Nancy Cox, chief of the influenza branch at the U.S. Centers for Disease Control and Prevention, told the Los Angeles Times. "It keeps us breathless," she said.

[Aptamilla]

Hallo Kern...filigrane und sehr aufschlussreiche Postings von Dir.Denke,das viele im Thread genauso denken.Die Vogelgrippe zieht ihre Kreise und wird auch in den nächsten Wochen die USA erreichen.Da bin ich mir sicher.Die Kursverluste gestern resultieren aus Gewinnmitnahmen.Der Wert ist gut gelaufen und da gibt es nun mal die Shorties,die den Kurs belasten.Trost:auf diesem Niveau wird es nicht mehr viele davon geben.Laut Analyse werden die Abschläge von starken Händen aufgefangen,so das wir zuversichtlich seien können.HEB hat eine intakte Story die weiterhin ein Investment wert sein dürfte.Gruss Aptamilla

[[KERN]Codex]

Influenza pandemics are recurring events.

An influenza pandemic is a rare but recurrent event. Three pandemics occurred in the previous century: “Spanish influenza” in 1918, “Asian influenza” in 1957, and “Hong Kong influenza” in 1968. The 1918 pandemic killed an estimated 40–50 million people worldwide. That pandemic, which was exceptional, is considered one of the deadliest disease events in human history. Subsequent pandemics were much milder, with an estimated 2 million deaths in 1957 and 1 million deaths in 1968.

A pandemic occurs when a new influenza virus emerges and starts spreading as easily as normal influenza – by coughing and sneezing. Because the virus is new, the human immune system will have no pre-existing immunity. This makes it likely that people who contract pandemic influenza will experience more serious disease than that caused by normal influenza.

Ten things you need to know about pandemic influenza

14 October 2005

1. Pandemic influenza is different from avian influenza.

Avian influenza refers to a large group of different influenza viruses that primarily affect birds. On rare occasions, these bird viruses can infect other species, including pigs and humans. The vast majority of avian influenza viruses do not infect humans. An influenza pandemic happens when a new subtype emerges that has not previously circulated in humans.

For this reason, avian H5N1 is a strain with pandemic potential, since it might ultimately adapt into a strain that is contagious among humans. Once this adaptation occurs, it will no longer be a bird virus--it will be a human influenza virus. Influenza pandemics are caused by new influenza viruses that have adapted to humans.

2. Influenza pandemics are recurring events.

An influenza pandemic is a rare but recurrent event. Three pandemics occurred in the previous century: “Spanish influenza” in 1918, “Asian influenza” in 1957, and “Hong Kong influenza” in 1968. The 1918 pandemic killed an estimated 40–50 million people worldwide. That pandemic, which was exceptional, is considered one of the deadliest disease events in human history. Subsequent pandemics were much milder, with an estimated 2 million deaths in 1957 and 1 million deaths in 1968.

A pandemic occurs when a new influenza virus emerges and starts spreading as easily as normal influenza – by coughing and sneezing. Because the virus is new, the human immune system will have no pre-existing immunity. This makes it likely that people who contract pandemic influenza will experience more serious disease than that caused by normal influenza.


3. The world may be on the brink of another pandemic.

Health experts have been monitoring a new and extremely severe influenza virus – the H5N1 strain – for almost eight years. The H5N1 strain first infected humans in Hong Kong in 1997, causing 18 cases, including six deaths. Since mid-2003, this virus has caused the largest and most severe outbreaks in poultry on record. In December 2003, infections in people exposed to sick birds were identified.

Since then, over 100 human cases have been laboratory confirmed in four Asian countries (Cambodia, Indonesia, Thailand, and Viet Nam), and more than half of these people have died. Most cases have occurred in previously healthy children and young adults. Fortunately, the virus does not jump easily from birds to humans or spread readily and sustainably among humans. Should H5N1 evolve to a form as contagious as normal influenza, a pandemic could begin.

4. All countries will be affected.

Once a fully contagious virus emerges, its global spread is considered inevitable. Countries might, through measures such as border closures and travel restrictions, delay arrival of the virus, but cannot stop it. The pandemics of the previous century encircled the globe in 6 to 9 months, even when most international travel was by ship. Given the speed and volume of international air travel today, the virus could spread more rapidly, possibly reaching all continents in less than 3 months.

5. Widespread illness will occur.

Because most people will have no immunity to the pandemic virus, infection and illness rates are expected to be higher than during seasonal epidemics of normal influenza. Current projections for the next pandemic estimate that a substantial percentage of the world’s population will require some form of medical care. Few countries have the staff, facilities, equipment, and hospital beds needed to cope with large numbers of people who suddenly fall ill.

6. Medical supplies will be inadequate.

Supplies of vaccines and antiviral drugs – the two most important medical interventions for reducing illness and deaths during a pandemic – will be inadequate in all countries at the start of a pandemic and for many months thereafter. Inadequate supplies of vaccines are of particular concern, as vaccines are considered the first line of defence for protecting populations. On present trends, many developing countries will have no access to vaccines throughout the duration of a pandemic.

7. Large numbers of deaths will occur.

Historically, the number of deaths during a pandemic has varied greatly. Death rates are largely determined by four factors: the number of people who become infected, the virulence of the virus, the underlying characteristics and vulnerability of affected populations, and the effectiveness of preventive measures. Accurate predictions of mortality cannot be made before the pandemic virus emerges and begins to spread. All estimates of the number of deaths are purely speculative.

WHO has used a relatively conservative estimate – from 2 million to 7.4 million deaths – because it provides a useful and plausible planning target. This estimate is based on the comparatively mild 1957 pandemic. Estimates based on a more virulent virus, closer to the one seen in 1918, have been made and are much higher. However, the 1918 pandemic was considered exceptional.

8. Economic and social disruption will be great.

High rates of illness and worker absenteeism are expected, and these will contribute to social and economic disruption. Past pandemics have spread globally in two and sometimes three waves. Not all parts of the world or of a single country are expected to be severely affected at the same time. Social and economic disruptions could be temporary, but may be amplified in today’s closely interrelated and interdependent systems of trade and commerce. Social disruption may be greatest when rates of absenteeism impair essential services, such as power, transportation, and communications.

9. Every country must be prepared.

WHO has issued a series of recommended strategic actions for responding to the influenza pandemic threat. The actions are designed to provide different layers of defence that reflect the complexity of the evolving situation. Recommended actions are different for the present phase of pandemic alert, the emergence of a pandemic virus, and the declaration of a pandemic and its subsequent international spread.

10. WHO will alert the world when the pandemic threat increases.

WHO works closely with ministries of health and various public health organizations to support countries' surveillance of circulating influenza strains. A sensitive surveillance system that can detect emerging influenza strains is essential for the rapid detection of a pandemic virus.

Six distinct phases have been defined to facilitate pandemic preparedness planning, with roles defined for governments, industry, and WHO. The present situation is categorized as phase 3: a virus new to humans is causing infections, but does not spread easily from one person to another.

[[KERN]Codex]

Avian influenza Birdflu News and Updates

Experts warn bird flu more diverse

No country is fully prepared for bird flu, which is much more genetically diverse than previously thought, according to a global team of researchers.

One of the bird flu experts, Dr. Malik Peiris, professor of microbiology at Hong Kong University, told CNN Wednesday the deadly disease deserved all the attention it was getting.

Bird flu has claimed at least 86 lives around the world since 2003 and is the major concern this year of Asian populations, according to a December 2005 CNN/TIME survey.

With the disease spreading beyond Asia to the fringes of Europe in recent months, a senior World Health Organization official in Tokyo last month warned that the threat of a pandemic was "growing every day." (Full story)

Peiris is one of a team of 29 scientists who have just published a report on bird flu, in which they claim that there are four types of the deadly H5N1 virus.

The report appears in the online medical journal, "U.S. Proceedings of the National Academy of Sciences."

The scientists say in their report that the H5N1 virus -- which the World Health Organization says is responsible for more than 160 infections and the deaths of 86 people around the world since 2003 -- is more genetically diverse and can survive in birds showing no signs of illness.

Peiris said the problem of diversity and the disease's circulation in apparently healthy birds was a surprise and meant treatment options had to be looked at much more widely.

He told CNN that regional virus types meant there was a need to look for "broad cross-protection" rather than a single vaccine.

Peiris said that while wild birds may contribute to the introduction and spread of bird flu, the perpetuation of the disease was through stocks of domestic poultry.

He said no country was fully prepared to combat the disease, which needed to be tracked back and tackled at its source.

Defensive push
The diversity claim by the scientists has major implications for pharmaceutical companies and governments seeking to develop defenses against the spread of bird flu.

The scientists warn in their report that no single vaccine is likely to provide protection because the virus has developed into four distinct gene families, known as Z, V, W and the Mekong delta type.

They also say H5N1 has been endemic in southern China for almost 10 years, and can exist in apparently healthy birds.

The report says the best way to avert the bird flu threat is to control the infection at its source -- domestic poultry.

"Control of the regional epizootic (outbreak) and its attendant pandemic threat requires that the source of the virus in southern China be contained," it says.

In the past few days, Hong Kong has put its customs officers on high alert and tightened surveillance to stop people smuggling in birds and poultry.

Last week, a chicken brought illegally into Hong Kong from China was found to have had the H5N1 virus.

Most human deaths have been in Vietnam, Thailand, Indonesia and China, but in recent months the disease has spread beyond Asia to the Middle East and the fringes of eastern Europe.

Iraq reported its first human death from bird flu late last month, while at least 21 human cases -- including four deaths -- have been reported in Turkey since the start of the year. Infected birds have been detected in parts of Croatia, Romania and Russia.

About 200 million birds have died or been culled around the world since the disease first appeared in China's Guangdong province -- which adjoins Hong Kong -- in 1996.

Researchers have been particularly worried that the virus may mutate into a form capable of spreading rapidly from human to human.

Both the European Union and the United States have pledged large amounts of money in recent weeks to combat bird flu. In the U.S., Congress has approved $3.3 billion this year, of the $7.1 billion sought by President George W. Bush.

[[KERN]Codex]

Antwort auf Beitrag Nr.: 20.971.706 von [KERN]Codex am 28.03.06 11:59:15

aptamilla

Punktlandung auf 3,25 USD, schöner Mehrfachboden, HEB ist einfach der Hammer, das sollte jedem klar sein, die könnten ne Steigung hinlegen wie Viropharma

[[KERN]Codex]

Antwort auf Beitrag Nr.: 20.981.463 von [KERN]Codex am 28.03.06 20:39:46

Pandemic flu — communicating the risks

WHO
Dr Margaret Chan

Dr Margaret Chan is from China. She obtained her MD degree from the University of Western Ontario, Canada, in 1977, and joined the Hong Kong Department of Health in 1978, where she began her career in public health. She was appointed Director of Health of Hong Kong in June 1994. After two decades of working closely with WHO, Chan joined the organization as Director of the Department of Protection of the Human Environment in 2003. In June 2005, she became Assistant Director-General for the Communicable Diseases cluster of departments and took up the newly-created post of Representative of the Director-General for Pandemic Influenza.

No public health issue has caught the public imagination over the last year as vividly as avian flu. Governments are scrambling to be prepared for a human flu pandemic that could kill millions of people. But public misconceptions abound about the nature of the threat to human health and how to respond to it. WHO hosted a meeting of public health experts in Geneva on 6–8 December to discuss how governments should communicate the risks posed by avian flu and the threat of a human flu pandemic to members of the public.



Q: WHO has convened a series of meetings over the last few months on avian influenza and the threat of a human influenza pandemic. Was it necessary to hold “yet another” meeting?

A: The December meeting was the first WHO meeting that focused exclusively on pandemic communications. It was the first step in building a global communication infrastructure to respond to the myriad challenges posed by a human influenza pandemic.

Q: Health ministries in many countries are concerned that they may be communicating uncertainty to the public when it comes to public information on avian influenza and human pandemic influenza? What is WHO advising them to do?

A: In accordance with WHO Outbreak Communication guidelines, WHO advises Member States to be as open and transparent as possible in their public communications regarding disease threats, including avian and pandemic influenza. Unfortunately, there is considerable uncertainty simply because there are many unknowns about the next influenza pandemic. There is no way for anyone to accurately predict things like when the next pandemic might strike, or how many people might be killed. While WHO recognizes that talking openly about a pandemic threat may raise concerns worldwide, we would not be fulfilling our public health mandate if we did not warn the world of this evolving threat.

"Investing in pandemic preparedness is essentially like investing in an insurance policy."


Q: Can Member States take a one-size-fits-all approach to communicating these risks? Or do public information campaigns need to be tailored to cultural and other specifics? How can WHO help to develop such information campaigns?

A: These are some of the issues that were addressed at the 6-8 December meeting. Once working groups are established to move ahead on such issues, we will have some communications guidance available [for governments]. WHO will provide technical and communications advice regarding public information campaigns specifically on avian and pandemic influenza.

A: WHO does not recommend that individuals stockpile oseltamivir because this is a drug whose consumption requires medical supervision. National stockpiles of oseltamivir, like WHO stockpiles of oseltamivir, have a very specific public health purpose — to contain the emergence of a new pandemic strain, if possible, and to lessen the burden of death and disease. Widespread personal use of oseltamivir could provoke the emergence of a resistant strain, which then might have serious public health implications. There is still much uncertainty regarding the potential efficacy of oseltamivir in the next pandemic. No one knows if it will be effective against the pandemic strain and it should not be regarded as a silver bullet. National authorities will have to decide which populations will be eligible to receive it according to their own criteria.

Q: How can governments justify to the public the WHO recommendation that individuals should not stockpile the antiviral drug, Tamiflu (oseltamivir), and in the event of a human influenza pandemic, how can governments justify selecting those who receive doses and those who do not? If governments get this message across in advance, will they not be more likely to have public cooperation and success in the event of a pandemic?

Q: Do you think there is too much “hype” about avian influenza and a possible human pandemic? What happens if there is no pandemic in the next six months? Will that not detract from the credibility of WHO and the United Nations?

"... there is no such thing as a localized outbreak. An outbreak in one country one day can very rapidly become a problem for countries on the other side of the world."


A: As a global public health agency, WHO has a responsibility to alert the international community when it appears that the world is moving closer to a pandemic. It may be years before a pandemic hits the world, and it may ultimately be sparked by a virus other than [avian influenza virus] H5N1. Investing in pandemic preparedness is essentially like investing in an insurance policy, and while we hope that we never have to make a claim, we also know that whatever investment we make now in strengthening global public health infrastructures will have benefits for our responses to all future infectious disease threats. The preparations that we make for a pandemic are not disease specific; they will increase our capacity to respond to all future outbreaks, including SARS (severe acute respiratory syndrome) and other new and emerging diseases.

Q: Some members of the public in some countries believe vaccines for a human pandemic influenza will be available as soon as a pandemic is announced. How can governments dispel the public’s unrealistic expectations about vaccine availability?

A: WHO advises governments to address such issues openly and rapidly. Because the pandemic strain has not yet emerged, there is no such vaccine currently available. Since a pandemic vaccine needs to be a close match to the pandemic virus, commercial production cannot begin prior to the emergence and characterization of the pandemic virus. It is likely that vaccine production, in any significant amounts, will take at least six months. It is therefore highly unlikely that there will be any large quantities of pandemic vaccine available during the first wave of a pandemic.

Q: SARS was a lesson in openness and transparency. If you are not open right away, it haunts you. Do you think governments have learned from the experience of SARS, that if they are not open and transparent from the start they may be heading for disaster?

A: Yes, SARS was an excellent example in demonstrating to countries that because infectious diseases do not respect borders, there is no such thing as a localized outbreak. An outbreak in one country one day can very rapidly become a problem for countries on the other side of the world. WHO hopes that countries realize that while they may be reluctant to report disease outbreaks, if they do so quickly and transparently, WHO can provide them with technical guidance and support, if it is needed, to contain such outbreaks.

Q: How is WHO advising governments on the use of masks in the event of a human influenza pandemic or other infectious diseases?

A: Because the pandemic virus has not yet emerged, there is no such specific guidance at the moment. While WHO has existing recommendations for issues, such as personal hygiene and mask usage primarily for health healthcare workers, such guidance is based on general transmission patterns of seasonal human influenza. It is not known how effective this guidance would be in slowing the spread of a pandemic. Thus, any recommendations that WHO provides in the pre-pandemic period, and even once the pandemic starts, may be modified once more information about the pandemic strain is obtained, such as its infection rate and its lethality.

Q: How do you bring members of the medical profession on board so that those who don’t believe what public health people are saying do not contradict public health messages?

A: WHO recognizes the need to work closely with medical professionals, since they are a very valuable ally in containing outbreaks and implementing control measures.


Hoffentlich kommen alle hinterher mit dem Lesen! Ist einfach ein verdammt spannendes Thema

[[KERN]Codex]

20 march beginnt der frühling in alaska, heisst dann kommen die vöglein auch nach amerika, das ist einfach unvermeintlich, wenn das der fall ist gehts erst richtig los,

achja und es gibt in den usa 70 mio katzen die alle töte vögel essen und mit ihren herchen in einem bett schlafen, die brüten das schon irgendwie aus

[Masse]

Hier noch eine Quelle in deutsch:
http://www.sueddeutsche.de/wissen/artikel/791/70721/
Ist schon ein paar Tage alt, aber sehr informativ.

Gruß Masse

[Aptamilla]

Antwort auf Beitrag Nr.: 20.983.648 von Masse am 28.03.06 22:50:52

Gefällt mir gut die Anregung zum V.G.Spektrum.HEB wird über kurz oder lang sensationelle Nachrichten heraus bringen.Alles andere wäre unlogisch,weil die Studien mit Ampligen sehr gut waren.

[[KERN]Codex]

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.000.993 von [KERN]Codex am 29.03.06 22:33:17

Bei meiner Stückzahl macht der heutige Anstieg schon was aus

Schön Schön

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.001.011 von [KERN]Codex am 29.03.06 22:34:06

p.s. vom Tief aus gesehen

[Aptamilla]

Antwort auf Beitrag Nr.: 21.001.022 von [KERN]Codex am 29.03.06 22:34:32

In Amerika auf Tageshoch geschlossen.Sieht ganz danach aus,das Du mit Deiner Charttechnik Recht behälst.Bin super gespannt auf die nächsten News.HEB wird zu einem Highflyer mit zweistelligen Dollar Kursen mutieren .Vielleicht noch in diesem Jahr... meine ich vorsichtig optimistisch.

[asics01]

Antwort auf Beitrag Nr.: 21.001.011 von [KERN]Codex am 29.03.06 22:34:06

wieviele hast du denn ???

[[KERN]Codex]

DJ Avian Flu Expected In US This Spring, Prudential Says



By Ciara Linnane



U.S. government officials monitoring the spread of avian influenza are expecting the first case to reach Alaska in about three weeks and to hit the West Coast by autumn, Prudential Equity Group said Wednesday.

The H5 pathogen has been confirmed in 51 or more countries, according to the Paris-based World Organization for Animal Health, causing the culling of millions of birds across Asia, Europe and, more recently, the Middle East.

The first cases in the U.S. won´t necessarily make humans ill - only the bird version of the disease is expected here, at least initially, said Kim Monk, a Prudential senior health-care-policy analyst.

"The virus might only spread bird to bird or, rarely, bird to human, and it may or may not ever mutate into a human-to-human virus," said Monk. "So for now, the only real threat is to the poultry industry."

More than 100 people have died since the H5 virus first occurred in Asia in 2003, most of them after direct contact with infected birds.

But scientists are worried the pathogen could mutate and become transmissible among humans, potentially creating a pandemic to rival the outbreak of Spanish Flu in 1918. That virus killed about 50 million people.

The Bush administration, like other governments, is bracing for a potential pandemic. It is seeking up to $7 billion to fund programs to develop and stock supplies of vaccines.

Among the companies most likely to benefit from the effort are Roche Holding AG (RHHBY), the biggest manufacturer of Tamiflu; GlaxoSmithKline PLC (GSK), which makes the antiviral Relenza; and makers of cell-based vaccines such as Chiron Corp. (CHIR), Solvay and Sanofi-Aventis (SNY).

The analyst said 3M Co. (MMM) could gain attention if there is increased demand for protective paper masks.

Trend Macroanalytics, a research firm serving institutional investors, has taken its analysis a step further and created an "avian-flu index" comprising 17 stocks in the health-care sector that can be expected to see a surge in demand for their products should the flu become a threat to humans.

The index includes stocks like Embrex Inc. (EMBX), a leader in "in ovo" technology for the poultry industry; Hemispherx Biopharma Inc. (HEB), whose interferon inducer Ampligen is considered a strong candidate as a flu treatment, and BioCryst Pharmaceuticals Inc. (BCRX) and Generex Biotechnology Corp. (GNBT), which are both producing antivirals.

Donald Luskin, chief investment officer at Trend Macro, said the index has gained 105% since its inception last Aug. 31 and is up 40.5% so far in 2006.

Luskin said he considers the chance of mutation and a pandemic small.

"The reason why investors should buy these stocks, though, is because it is the vaccines, therapeutics and diagnostics of the companies in this sector that are making sure the pandemic doesn´t happen," he said.

"Lots of money will be spent by governments - spent with these companies - to be sure to prevent the worst case."

He likened the bird-flu situation to Y2K, when companies spent billions of dollars upgrading technology to ensure computers could cope with the switch to the new millennium. "The worst case didn´t happen because people were warned," he recalled.

Among the companies outside the health-care sector that might attract a sales spurt from avian flu is Pall Corp. (PLL), which makes filtration systems that can also be used in vaccine production as well as breathing ventilators that can be used to discourage the spread of viruses such as SARS and certain flu strains.

-Ciara Linnane; 415-439-6456; [e-mail]



(END) Dow Jones Newswires

March 29, 2006 14:16 ET (19:16 GMT)

Copyright (c) 2006 Dow Jones & Company, Inc

[[KERN]Codex]

1st Bird-Flu Vaccine Only Partly Effective By LAURAN NEERGAARD, AP Medical Writer

Wed Mar 29, 9:08 PM ET

WASHINGTON - The nation's first vaccine against bird flu is only modestly effective, producing apparent protection in slightly over half the people who receive two mega-dose shots, initial testing shows. The worrisome findings underscore the urgency of brewing a better vaccine.

The government had signaled that this vaccine had serious flaws even as it ordered $162 million worth of shots last summer to stockpile in case the bird flu mutated to spread easily from person to person.

But results of the first human testing, being published Thursday in The New England Journal of Medicine, show the extent of the problem: The vaccine sparked a protective immune response in disappointingly few people — 54 percent of those who got two shots, 28 days apart, of the highest dose.

Regular winter flu shots, in contrast, protect 75 percent to 90 percent of young healthy people, the same group that first tested the experimental bird-flu vaccine. The elderly typically fare worse; how they respond to the bird flu shots still is being analyzed.

The results weren't too surprising, said lead researcher Dr. John Treanor of the University of Rochester. Humans have never been exposed to the deadly bird-flu strain called H5N1, and it takes the immune system awhile to ramp up to fight unique types of influenza.

The good news: The vaccine seems safe even at doses 12 times stronger than are used in the regular winter flu shot. The main side effect was pain at the site of the injection.

Researchers are giving the study's 451 volunteers a third dose, to see if that spurs more protection. More promising are other studies under way that add immune-enhancing chemicals to the shots to try to boost their power, in hopes people could be protected with lower doses.

"We have a long way to go," acknowledged Dr. Anthony Fauci, infectious disease chief at the National Institutes of Health, which funded the research.

Indeed, because each shot requires such a high dose, the government's vaccine stockpile contains enough for just 4 million people, far below its initial goal of 20 million. Those shots would be reserved for health care providers and workers in flu vaccine factories if a human epidemic of H5N1 began any time soon, Fauci said.

The world's vaccine factories are now brewing regular flu shots for next winter. They would make only bird-flu vaccine if a pandemic began. But at these high doses, the maximum that could be produced would fully immunize just 75 million people — 1.25 percent of the world's population — half of whom wouldn't be adequately protected, Mayo Clinic flu specialist Dr. Gregory Poland wrote in an accompanying editorial.

Still, "my impression is we are better off having stockpiled this vaccine than none," said Dr. William Schaffner of Vanderbilt University, a member of an independent panel that closely monitored the shots' safety during this first human testing.

"My concern is the public will see (the findings) as the jar half empty," he said, adding that he preferred that it be viewed as "the first strong step in a long journey."

More than 180 people worldwide, mostly in Asia, are known to have been infected with the H5N1 virus since 2003; more than 100 of them have died. Virtually all were infected by close contact with sick poultry. But flu viruses are prone to genetic mutations, and as H5N1 is now rapidly continent-hopping via migrating birds, there is increasing fear that it may eventually become easily spread from person-to-person, sparking a global epidemic.

Scientists don't know how much of an immune response — the creation of infection-fighting antibodies — a vaccine must prompt to protect people against bird flu. So in this first human study, Treanor and colleagues tested whether the H5N1 vaccine would prompt as much antibody protection as do regular winter flu shots.

Those annual flu shots contain 15 micrograms of antigen, the key element. For the H5N1 vaccine, it took two shots that each contained 90 micrograms of antigen to spur a protective immune response in slightly over half of recipients, Treanor found.

However, 70 percent of recipients had a slightly lower immune response — and scientists couldn't say whether they might have some protection against bird flu.

"Our guess about what will be a protective response may be very conservative," Treanor cautioned.

Vaccine manufacturers Sanofi-Pasteur and Chiron Corp. now are adding immune-enhancing compounds, called alum and MF59 respectively, to the experimental vaccine in hopes they would spark protection with doses closer to 15 micrograms, thus stretching limited supplies. Pilot studies are optimistic; Fauci said results may come in the fall.

Further complicating matters: This first H5N1 vaccine is already outdated, based on a version of the virus culled in Vietnam in 2004. Scientists now are creating a vaccine based on a slightly different Indonesian version that emerged last year; they don't yet know how much protection the older vaccine would spur against the newer virus.

[[KERN]Codex]

Bird Flu on Its Way: First Stop, Alaska

March 13, 2006 — The approach of spring brings not only the return of wild migratory birds to American shores but also the threat of avian influenza.

And this is the man whose job it is to spot it. Working on the Bering Sea at the tip of Alaska, Paul Flint, a Research Wildlife Biologist with the U.S. Geological Survey, is the point man in America's campaign against bird flu.

"We're targeting them as soon as we can from when they arrive from Asia to here," says Flint. "We're going to be on the ground in front of the bird migration waiting for the birds to arrive."

Along with Izenbek Wildlife Refuge manager Sandra Siekaniec of the U.S. Fish and Wildlife Service, and other federal and state agencies, Flint's assignment is to identify the first infected birds carrying the virus from Asia during the spring migration, and to sound the alarm.

"Alaska is one of the forefronts where it is most likely to arrive first because of its unique position as a crossroads of two international flyways: one on the Asian side of things and the other one on the North American side of things," explains Flint.

U.S. spy satellites have tracked the infected flocks, which started migrating from Asia and are now heading north to Siberia and Alaska, where they will soon mingle with flocks from the North American flyways.

"You can't build a cage around the United States," says Agriculture Secretary Michael Johanns, of the inevitably of the virus' arrival in America. "That's not possible."

Johanns tells ABC News that a bird flu outbreak in Alaska could come in as little as three weeks. That could mean further outbreaks in the lower 48 states by August.

The spread of the disease by wild migratory birds — traveling from Asia to Africa and Europe — has been much more rapid than first predicted. In four months, the virus has spread from 16 to 37 countries. Scientists now predict Great Britain will be next.

"We are losing our ability to forecast what's going on," says Laurie Garrett, the senior fellow for global health at the Council on Foreign Relations.

U.S. officials therefore count heavily on the early-warning system in place in Alaska, where suspect birds, including the Eastern Yellow Wagtail and the Dunlin, will be captured and tested.

Scientists here say, however, that given Alaska's remote location, it will take at least a month to confirm any outbreak, which reduces the lead time the rest of the country has to get ready.

While the virus is still not easily transmitted to humans, a report released today by Health and Human Services Secretary Michael Leavitt confirms that H5N1, a mutating type of avian influenza virus, continues to spread and change in unexpected ways. Even though the government had ordered millions of doses of vaccine, the emergence of a second, more lethal strain means another vaccine will now have to be developed.


ABC News' Maddy Sauer and Rhonda Schwartz contributed to this report.

[Aptamilla]

Hallo Kern,Top Arbeit Deine Postings...sehr aufschlussreich!Wie lautet Dein mittelfristiges Kursziel?Gruss Apta

[[KERN]Codex]

5 USD bis Sommer

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.017.959 von [KERN]Codex am 30.03.06 21:11:41

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.018.558 von [KERN]Codex am 30.03.06 21:47:17

BirdFlu Stocks laufen Heute mal wieder prächtig

[Aptamilla]

Und wieder auf Tageshoch geschlossen.Sieht so aus,als ob sich nun eine Range abbildet.Denke,das wir bei einer freundlichen Börsenwoche noch höhere Kurse sehen werden.

[[KERN]Codex]

NICE ONE

[Aptamilla]

Antwort auf Beitrag Nr.: 21.019.799 von [KERN]Codex am 30.03.06 23:06:23

Hi Kern,bald überflügeln wir mit HEB auch AVI!!!

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.019.959 von Aptamilla am 30.03.06 23:16:15

Auf jeden Fall

[[KERN]Codex]

Vorbörslich 3.80 USD!!

[Aptamilla]

YES:SIEHT GUT AUS!!!

[Aptamilla]

Geringe Stückzahlen reissen den Kurs in Amerika herunter.

[[KERN]Codex]

Echt der Hammer wie wenig da gehandelt wird

[asics01]

hey jungs cool bleiben (wenns auch schwer fällt).

[biotech_nett]

Antwort auf Beitrag Nr.: 21.059.298 von asics01 am 03.04.06 19:57:30

Mit den News über falsche Angaben in der Bilanz bezüglich der letzten Abschlüsse fallen wir ja nicht mal hart, soft landing?

- vielleicht geht es erst morgen richtig runter???

oder hoch???



biotech_nett

[asics01]

Antwort auf Beitrag Nr.: 21.059.665 von biotech_nett am 03.04.06 20:22:37

ich denke mal die werden heute noch gerupft.

[Aptamilla]

Also so aufregend fand ich die Bilanzierung nicht.Die SEC hat kein Interesse aufzuklären.Denke,das alles entscheidene sind Ampligen in Verbindung mit der Vogelgrippe.Und diese News werden kommen!

[[KERN]Codex]

Glaube nicht dass es sonderlich runtergeht

[Aptamilla]

Antwort auf Beitrag Nr.: 21.068.378 von [KERN]Codex am 04.04.06 14:30:53

Geht es doch!Aber mich irritiert das geringe Verkaufsvolumen der den Kurs so herunter zieht.Da stimmt doch was nicht.Entweder kommt bald ein Knaller der eine Vogelgrippemeldung aus den USA.

[tilt]

Hemispherx delays 2005 statement
Monday April 3, 2:06 pm ET


Hemispherx Biopharma Inc. said Monday the filing of its final form 10-K, containing its 2005 financial results, will be delayed.
The Philadelphia biopharmaceutical company said after discussions with its audit committee and BDO Seidman, its outside auditors, it determined that an incorrect accounting principle was applied to certain debentures and warrants issued between March 2003 and August 2005.

ADVERTISEMENT





The company said the error affects Hemispherx's financial statements between March 2003 and September 2005, specifically, the initial recording of the embedded conversion feature of the debentures and the related fair value of related warrants.

Hemispherx (AMEX: HEB - News) officials said the issues relate to accounting for convertible debt, additional paid-in capital and related noncash financing charges. They said the noncash charges do not affect the company's revenues, cash flows from past or future operations or its liquidity.

The company said its previously issued financial statements filed with the Securities and Exchange Commission for the periods ended from March 31, 2003, to December 31, 2005, should not be relied upon.

Hemispherx has filed its form 10-K for the year ended Dec. 31, 2005, without audited financial statements. The anticipated restatements of the company's financial statements for the past three years are contained in the report.

Company officials said because audited financial statements are not contained in the report, the report does not satisfy all requirements under the Securities Exchange Act and, therefore, is deficient.

Hemispherx anticipates that it will file an amendment to the report containing audited financial statements within the next 30 days.

Hemishpherx was trading down 9 percent Monday at $3.26 per share.

Published April 3, 2006 by the Philadelphia Business Journal

[tilt]

Hemispherx Biopharma says errors in results, to delay filing
Mon Apr 3, 2006 10:28 AM ET
April 3 (Reuters) - Hemispherx Biopharma Inc. (HEB.A: Quote, Profile, Research) on Monday said it identified accounting errors in its financial statements for the first three quarters of 2004 and 2005, and would delay the filing of its 2005 annual report beyond the extended March 31 due date.

The company said in a statement incorrect accounting principle was applied to certain debentures and warrants issued between March 2003 and August 2005, which affected its financial statements between March 2003 and September 2005. (Reporting by Deepak Kumar in Bangalore)

FACT BOX

HEB.A (Hemispherx BioPharma Inc)
Last: $3.12
Change: -0.12
Up/Down: -3.70%


AprJulOctJan
Quote
Full Chart
Company Profile
Analyst Research
News for HEB.A
Hemispherx Biopharma says errors in results, to delay filing
© Reuters 2006. All Rights Reserved.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq and all other quotes delayed by at least 15 minutes.
Reuters does not endorse the views or opinions given by any third party content provider.

[tilt]

Global Demand Supports Development of Avian Flu Treatments and Antiviral Drugs
Monday April 3, 9:00 am ET


Biotech and Healthcare Companies Present Potential Solutions to the Bird Flu


POINT ROBERTS, WA and DELTA, BC--(MARKET WIRE)--Apr 3, 2006 -- www.China-AsiaStocks.com (CAS) and www.BiotechIndustryStocks.com (BIS) , investor and industry news portals for the China-Asia and biotechnology sectors, feature "Global Demand Boosts Avian Flu Vaccine Market," for investors and industry following developments in the vaccine market. Biotech and Healthcare companies: Bridgetech Holdings International Inc., Generex Biotech, AVI Biopharma Inc., Hemispherx Biopharma, Inc, Carrington Laboratories and Aethlon Medical discuss unique approaches to this potential global dilemma and offer insight to possible solutions.
Dr. Carlton Turner, President and CEO of Carrington Laboratories, gave an overview on the market, commenting that, "Policymakers from around the world are responding as best they can to the threat of an H5 Avian Flu pandemic. The challenge lies in trying to find the right antigen, producing enough of it to protect the world's population and then finding a way to deliver it to large populations efficiently."

Michael Chermak, CEO for Bridgetech Holdings International Inc (Other OTC:BGTH.PK - News), has provided insights with respect to the effect the Avian Flu has had on China's healthcare market, "The impact of the Avian Flu outbreak on the Chinese healthcare system has been profound. The resulting self examination has created a sense of urgency, regarding the modernization and improvement of the entire system."

Vice President of Generex (NasdaqSC:GNBT - News) and President of Antigen Express, Dr. Eric Vonhofe, expressed great confidence in their product, explaining that," Last fall, the government paid about $100 million for an egg-based vaccine, but that will probably be enough for only about 3 million people. In contrast, our vaccine which is synthetic can be made on a 100 kg scale quickly, efficiently and at a relatively inexpensive rate."

AVI Biopharma Inc., a producer of antiviral drugs, has established avian influenza H5N1 as a priority within the company. Michael Hubbard, Director of Investor Relations for the company, said that, "We are moving as quickly as we can on Avian Flu, given the urgency. As soon as we have the safety data, we can apply for a new drug application with the FDA, which we hope to do before year's end." Dr. David Strayer, Medical Director at Hemispherx Biopharma, Inc. (AMEX:HEB - News), also pointed out that, "This area could move very rapidly because there is an urgent need for a better way to treat and prevent Avian influenza. I think there is great potential here for our company."

However, antiviral drugs currently being stockpiled as part of a global strategy to treat Avian Flu may have little therapeutic value once the deadly cytokine store has been triggered. As explained by James A. Joyce, Chairman and CEO at Aethlon Medican Inc. (OTC BB:AEMD.OB - News), "Once a cytokine storm has been triggered, the Hemopurifier could serve as the first, and perhaps only option for treating H5N1 infected patients."

To Read "Global Demand Boosts Avian Flu Vaccine Market" In Full Click Here: http://www.China-AsiaStocks.com/Articles/Avian_Flu.asp

About our CAS and BIS Portals:

www.China-AsiaStocks.com and www.BiotechIndustryStocks.com portals within the InvestorIdeas.com content umbrella, offer investors research, news and links to public companies within the China-Asia and Biotechnology sectors. CAS and BIS do not make recommendations, but offer unique free information portals to research news, articles, interviews and a growing list of participating public companies in the China-Asia and biotech industry.

China-AsiaStocks.com includes a comprehensive and growing list of China Asia Stocks: http://www.China-AsiaStocks.com/Companies/China-AsiaStocks/S…

To visit our China-Asia portal in Chinese click here: http://www.china-asiastocks.com/CAS/

Featured Sponsor Participating in the China Asia Market: (CAS is compensated by Bridgetech Holding International as disclosed in disclaimer.)

Bridgetech Holdings International Inc (Other OTC:BGTH.PK - News) a leading distributor of western-based healthcare products and medical technology in China. For more info: http://www.china-asiastocks.com/CO/BGTH/Default.asp or visit the company's website at www.bthi.com.

Investorideas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by its "featured companies." Bridgetech Holdings International, Inc five thousand dollars per month and ten thousand shares of 144 stock as a one time fee .Additionally , Aethlon Medical was a former featured company on Investorideas.com, please review previous clients disclaimer.



Contact:
For More Information Contact:
Dawn Van Zant
800-665-0411
Email: Email Contact
Fei Wang
866-948-0848
Email: Email Contact
Web Site: http://www.InvestorIdeas.com

[tilt]

AVI BioPharma Up Bird Flu Trial Plan
Thursday March 30, 1:54 pm ET
AVI BioPharma Inc. Shares Rise on Plans to Apply to the FDA for a Flu Drug Trial This Year


PORTLAND, Ore. (AP) -- Shares of AVI BioPharma Inc. jumped Thursday after the biotech company said it plans to file papers with the Food and Drug Administration this year to begin clinical trials of its Neugene line of antisense drugs.
ADVERTISEMENT


AVI BioPharma rose 79 cents, or 12 percent, to $7.38 in afternoon trading on the Nasdaq at more than double their average volume. Shares have traded between $2.05 and $9.20 over the past 52 weeks.

The company said it will base the application on lab studies showing that Neugene antisense drugs are effective in stopping the replication of influenza viruses, including the bird flu virus strain H5N1. Antisense drugs interfere with genetic processes to stop the manufacture of harmful proteins.

Shares of other biotechnology companies developing products to fight bird flu, such as Hemispherx Biopharma Inc. and Novavax Inc., also rose.

Shares of Hemispherx BioPharma rose 10 cents, or 2.8 percent, to $3.66 on the American Stock Exchange, and Novavax shares grew by 33 cents, or 4.4 percent, to $7.84 on the Nasdaq.

[[KERN]Codex]

U.N. Notes Quick Spread of Bird Flu

Tuesday April 4, 2006 6:31 PM


AP Photo XHG108

By MARGIE MASON

AP Medical Writer

BEIJING (AP) - The deadly bird flu virus has spread at lightning speed over the past three months, infecting birds in 30 new countries - double the number previously stricken since 2003, the U.N.'s bird flu point man said Tuesday.

``This is a really serious global situation,'' Dr. David Nabarro the U.N.'s chief coordinator for avian influenza, told reporters in Beijing. ``During the last three months globally, there has been an enormous and rapid spread of H5N1.''

Thirty new countries and territories in Africa, Europe, the Indian subcontinent and the Middle East have reported H5N1 infections in birds this year, he said. That rapid acceleration compares with the previous two and half years, when only 15 countries - mostly in Asia - reported bird flu.

China was Nabarro's first stop on a tour that includes Laos, Vietnam, Thailand, and Indonesia - countries where the H5N1 virus is considered endemic in poultry stocks.

In Beijing, he met with Vice Premier Hui Liangyu, who heads the country's bird flu command center, along with officials from the ministries of health and agriculture. He said China has pledged full cooperation in working with the international community to help control the spread of the disease.

Nabarro added that some of the $1.9 billion pledged by the international community in January for bird flu and pandemic preparedness has started reaching countries hit hard by the virus.

``A lot of that money is now being spent in Indonesia, Vietnam Cambodia, countries in central and eastern Europe, Turkey, Nigeria and Central Asia,'' he said.

In addition, the World Bank recently signed off on a record-fast $50 million loan for Nigeria to battle bird flu, he said. Bank official Jacques Baudouy said earlier Tuesday that the funding came from money earmarked for the disease prior to the $1.9 billion pledge.

Meanwhile, a U.S. health expert attending a Beijing health conference called for more infectious disease research in Asian countries, and scientists need to more closely track changes in the H5N1 virus to prepare for a potential pandemic.

``I think of it as the earthquake in San Francisco. You know it's on the fault. You know it's going to occur, but you can't tell if it's going to occur this year or next year or the year after,'' said Dr. Roger Glass, the new director of the Fogarty International Center at the U.S. National Institutes of Health.

``But it's clearly going to happen and the only way you can prepare is to build your houses with structure,'' he said on the sidelines of a four-day conference launching the Disease Control Priorities Project, which includes three books focusing on cost-effective strategies for improving global health.

Also Tuesday, regional officials met at a separate symposium to discuss new infectious diseases as a follow-up to talks during last fall's Asia Pacific Economic Cooperation forum.

Bird flu resurfaced in Asia in 2003 and has killed at least 108 people. It remains hard for humans to catch, but health experts fear it will mutate into a form easily spread among people, potentially sparking a pandemic.

[Aptamilla]

H5N1 nun auch auf Nutztiere in Deutschland übergesprungen.Das Thema wird uns noch lange beschäftigen.Bald wird der Virus auch in Amerika auftauchen...so flüstert man!HEB bleibt hochinteressant.

[[KERN]Codex]

HEB wird erst so richtig zünden, wenn sich das birdflu karussel noch schneller dreht, Ägypten hat schon 11 infizierte MENSCHEN, der Hammer

Dranbleiben!

Heute rauf auf 3,30 USD

Nachbörslich 3,31 / 3,34 USD - Morgen 3,50 USD, viel Spaß beim nachkaufen

[[KERN]Codex]

[[KERN]Codex]

Hemispherx Biopharma encouraged by ‘broad implications’ of recent tests, CEO
3/30/2006 3:16:08 PM
By Robert Ilich Associate Editor




Dr. William Carter
Chairman and CEO

As government experts predict the avian flu to spread to Alaska in upcoming weeks, a collection of pharmaceutical companies are reaping the rewards of newfound investor interest.

Count Hemispherx Biopharma Incorporated (AMEX: HEB Quotes, News, Charts) as one of them.

The Philadelphia-based company, whose patented drug “Ampligen” is considered a strong candidate as a bird flu treatment, appears to be on the verge of a profit bonanza if the bird flu becomes a threat to humans.

“There were two major studies just reported,” said Dr. William Carter, the Company’s Chairman and Chief Executive Officer. “One out of Japan shows that our drug ‘Ampligen’ can dramatically increase the potency of the Avian Influenza vaccines. This has broad economic implications.

The second study is a study out of Hong Kong, which also has broad implications, and suggests that we have found a way to use our already commercialized available ‘N Alferon’ orally in a matter to prevent the lethality that occurs in a
bout 60 percent of people who get Avian Influenza. So these are two very critical studies, which we believe will result in new marketing applications during calendar year 2006.”

According to MarketWatch.com, Ampligen may combine with flu remedies from other pharmaceutical companies to combat the bird flu. "You could take a supply for four million people and make it a supply for several hundred million people," said Carter, citing GlaxoSmithKline's Relenza as an example. Ampligen could enhance the effectiveness of Relenza by 300 to 500 times, and Roche AG’s Tamiflu by 100 times, Carter said.

Shares of Hemispherx have been up as much as 145 percent in the last seven months.

“The present sales of drugs to create repositories for treatment of influenza are somewhere between $5 billion and $10 billion,” said Carter. “We expect to have a significant portion of those potential earnings beginning sometime in 2006.”

[heartofgold]

Danke für die Info! War schon unsicher, ob sie noch weiter runtergehen würden.
Grüße heartofgold

[e.1]

hallo,
heute wirklich unerfreulich. eigentlich dachte ich es ginge weiter aufwärts und nicht abwärts.
kann jemand etwas zur charttechnik sagen, wie hier das bild aussieht, für evtl. nachkaufkurse.

gruß

e.1

[[KERN]Codex]

Hemispherx Biopharma to Host Conference Call to Review Company's Accomplishments, Update on Influenza Related Studies and Outline Future Goals

Tuesday April 11, 8:30 am ET


PHILADELPHIA--(BUSINESS WIRE)--April 11, 2006--Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (AMEX: HEB - News) will hold a telephone conference call at 10:00 a.m. ET on Thursday, April 13, 2006 to review the Company's accomplishments, update on influenza related studies and outline future goals.


Dr. William A. Carter, Chairman & CEO, will host the call, which will include a management discussion followed by questions and answers. Robert Peterson, Chief Financial Officer, Doug Hulse, President and COO, and Dr. David Strayer, Medical Director, will also participate in the call.

Hemispherx invites stakeholders interested in hearing management's discussion to join the call by dialing 1-800-346-7359. International callers may access the call by dialing 973-528-0008. Participants will be asked to provide a conference entry code (CED) which is 410653. A replay of the conference call will be available through May 6, 2006 and can be accessed by dialing 1-800-332-6854 for domestic participants and 973-973-528-0005 for international participants. Participants for the replay will be asked to provide the conference entry code which is 410653.

About Hemispherx Biopharma

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Hemispherx Biopharma's flagship products include Alferon® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens(TM). Alferon® is approved for a category of STD infection, and Ampligen® and Oragens(TM) represent experimental nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon® N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen®, Alferon® LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon® do not imply that the product will ever be specifically approved commercially for these other treatment indications.



Einfach KAUFEN und liegen lassen, its not a matter of how its a matter of when the impact on usa will begin

[e.1]

na ja zur zeit warte ich eher ab, geht ja doch noch um einiges bergab.
hoffen, dass es bald zu ende ist und wieder aufwärts geht.

gruß
e.1

[e.1]

hallo guten morgen,

wie geht es weiter?
auch die konferenz, hat zumindest gestern, nicht viel gebracht.
momentan werden alle aktien, welche einen bezug zur vogelgrippe haben zerfleddert. schade

auf bessere kurse

e.1

[[KERN]Codex]

CC ist erst Morgen


Bird flu to fly into Colo. by fall
Virus is expected in migratory species

By Associated Press
April 12, 2006

DENVER — Migratory birds that arrive in Colorado this fall after mingling in Alaska with birds from Asia are likely to bring avian flu with them, wildlife officials said.

State and federal officials are setting up monitoring and screening systems, including a telephone hot line for the public to report dead birds but stressed the arrival of the virus or the death of some birds is no cause for panic.





"Remember that avian influenza is an animal disease, it's not a human disease," acting state veterinarian Keith Roehr told The Denver Post.

Scientists fear the virus, which has infected about 200 people, killing about half, could mutate to spread easily among humans, possibly triggering a pandemic. For now, however, it is primarily a bird disease, Roehr said.

"With common hygiene and protection, people are at low risk," he said.

In Asia, Africa and Europe, the H5N1 virus first detected in Hong Kong in 1997 has killed millions of wild and domestic birds, and spread to several other species, including pigs and cats.

In Colorado, agencies participating in the Avian Influenza and Surveillance Education Task Force are preparing to increase their activities in hopes of detecting the virus as soon as possible after it arrives in the state.

The effort, including testing backyard chicken flocks and wild birds, has been under way for about a year. In June, the task force will begin screening Canada geese along the Front Range, said Division of Wildlife veterinarian Laurie Baeten.

Once the virus' arrival is confirmed, officials will turn their attention to protecting commercial poultry farms and backyard flocks.

"There is no way to prevent wild birds from migrating into the United States, but we have fairly good biosecurity in place to prevent mixing of wild birds with domestic poultry," Baeten said.

[[KERN]Codex]

Ich werde Morgen aufrüsten, wenn der Conference Call positiv wird, ich spekuliere seit Anfang an auf den ersten Grippevogel in den USA, dann werden die Aktien wieder hypen, jede Wette

[Aptamilla]

Absolut Deiner Meinung...Kern!!!Gestern Abend war übrigens im ZDF eine interessante Doku-Sendung über die Vogelgrippe zu sehen.Dort wurden sämtliche Szenarien aufgezeigt.Hat aufgeklärt und Angst gemacht.HEB ist first choice!!!

[asics01]

das sieht aber nicht gut aus.

[e.1]

was sieht deiner meinung nach nicht gut aus.
im moment schmelzen die heutigen verluste schon etwas.
vielleicht das erste zarte pflänzchen des aufstiegs.

gruß
e.1

[[KERN]Codex]

Bei hemispherx kann es auch ganz schnell wieder up gehen, in 2 oder 3 Tagen sind wir wieder bei 4 USD, falls die Ergebnisse Morgen sehenswert sind

[asics01]

Antwort auf Beitrag Nr.: 21.180.784 von [KERN]Codex am 12.04.06 19:02:05

ich bin momentan nicht auf dem laufenden,was soll es morgen für news geben ??

[[KERN]Codex]

HEB will hold a telephone conference call at 10:00 a.m. ET on Thursday, April 13, 2006 to review the Company\'s accomplishments, update on influenza related studies and outline future goals

[asics01]

Antwort auf Beitrag Nr.: 21.181.135 von [KERN]Codex am 12.04.06 19:21:33

das wird so sein wie immer, im vorfeld wissen wieder ein paar mehr und hauen ihre teile raus.vermutlich wird es morgen nichts neues bzw.schlechte news geben, der abgang die letzten tage lässt sowas vermuten.ich hoffe aber trotzdem da auch ich investiert bin das es nicht so kommt.

[[KERN]Codex]

newswelle ist im anmarsch, ich sags immer wieder

[[KERN]Codex]

ups falscher thread, aber gibt bestimmt trotzdem gute news, die leute die es wissen haben sich schon längst eingedeckt, denke ich

[asics01]

Antwort auf Beitrag Nr.: 21.181.903 von [KERN]Codex am 12.04.06 19:58:33

oder verabschieden sich heute und die letzten tage.

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.181.975 von asics01 am 12.04.06 20:02:06

Strong Buy, Ziel Morgen 3,30-3,50 USD - mal sehen

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.183.415 von [KERN]Codex am 12.04.06 21:37:51

naja eher 3,20 bis 3,30 USD, es geht bei HEB bekanntlich ja immer langsamer hoch

bin sehr gespannt auf den morgigen CC

[[KERN]Codex]

Hemispherx Biopharma, Inc. (“Hemispherx” or the “Company”) (AMEX: HEB) will hold a telephone conference call at 10:00 a.m. ET on Thursday, April 13, 2006 to review the Company’s accomplishments, update on influenza related studies and outline future goals.


Dr. William A. Carter, Chairman & CEO, will host the call, which will include a management discussion followed by questions and answers. Robert Peterson, Chief Financial Officer, Doug Hulse, President and COO, and Dr. David Strayer, Medical Director, will also participate in the call.

Hemispherx invites stakeholders interested in hearing management’s discussion to join the call by dialing 1-800-346-7359. International callers may access the call by dialing 973-528-0008. Participants will be asked to provide a conference entry code (CED) which is 410653. A replay of the conference call will be available through May 6, 2006 and can be accessed by dialing

1-800-332-6854 for domestic participants and 973-528-0005 for international participants. Participants for the replay will be asked to provide the conference entry code which is 410653.

[[KERN]Codex]

nachbörslich gehts rauf auf 3,14 +6,8%

[schadu]

Hallo HEMISPHERX jetzt auch in form eines Fonds zu haben ....

933803 DAC BIOTECH-FONDS 5,74%

http://fonds.onvista.de/filter-suche/top-holding.html?WKN=90…

grüße

[zillus]

wie hast Du das denn rausgekriegt !!!-----Bin auch dabei !!!--Gut Ding will ..... !!!!!----Viel Glück----wenn`s hier losgeht,--dann richtig !!!

[tonyjaa]

Letter to Shareholders of Hemispherx Biopharma, Inc. from William A. Carter, M.D., Chairman of the Board and Chief Executive Officer
Thursday April 13, 8:30 am ET

PHILADELPHIA--(BUSINESS WIRE)--April 13, 2006--Hemispherx Biopharma, Inc.:

Dear Shareholders,

I would like to take this opportunity to review what has been accomplished in the 1st Quarter of 2006 and lay out for you some of the objectives targeted for the rest of the year.

The initial results of three avian influenza related studies initiated in the summer of 2005 were presented at two conferences, the ASM Biodefense Research Meeting in Washington, D.C. and the VIII International Symposium on Respiratory Viral Infections in Hawaii.

* New tests provided further evidence that Alferon LDO (Low Dose Oral), a new delivery for an anti-viral with prior regulatory approval for a category of sexually transmitted diseases, offers tremendous potential in resisting the spread of avian flu by stimulating genes that induce the production of immune compounds that are key building blocks in the body's defense system.
* Additional research suggests that the activity of Tamiflu and Relenza, the only two drugs formally recognized for combating bird flu, can be boosted up to 100 times when co-administered with Ampligen®. Lab studies reveal that 50 to 100 times less Tamiflu may be used in conjunction with Ampligen® to achieve full inhibition with no multiplication of the virus, and no host cell damage.
* Finally, in animal studies conducted in collaboration with the National Institute of Infectious Diseases in Japan, it was found that the co-administration of our experimental immunostimulant Ampligen®, a specifically configured double-stranded RNA, may help enable substantial reductions in an H5N1 vaccine dose, as well as provide cross-protection against mutated strains of the H5N1 virus.

In further collaboration with the National Institute of Infectious Disease in Japan, we have commenced primate studies in the co-administration of Ampligen® with H5N1 vaccines in Japan. The studies are uniquely focused on the cross protection that Ampligen® provides to vaccines across mutated strains. These studies should be concluded and results presented in the 2nd Quarter of 2006. Our collaboration with our Japanese associates has proven to be highly productive. Our ambition is to continue and expand upon this relationship over time.

Studies are continuing along each of the three paths regarding avian influenza and progressing to what we anticipate will be NDA filings. If expedited guidelines are implemented by the FDA in response to the avian influenza threat, our time line to an NDA for this indication could be moved up significantly.

Irrespective of the threatened avian influenza pandemic or anticipated expedited approval guidelines, the ongoing trials have heightened the awareness of our drugs' activity as immunostimulants. Recognition of our drugs' capabilities as stand-alone antivirals and activity when co-administered with a vaccine have highlighted the broad spectrum of opportunities in our future.

While we have and are pursuing the extremely promising avian influenza studies through the efforts of our contract partners, our primary internal resources have been, and continue to be, focused on completing and filing our NDA for CFS. In the 1st Quarter we completed the construction of a facility within our New Brunswick plant to produce raw materials for the manufacture of Ampligen®. This in house capability will aid in fulfilling the manufacturing requirements of the Ampligen® CFS NDA. The pre-clinical section of the Ampligen® CFS NDA is on schedule to be completed by the end of this month. We anticipate having a pre NDA meeting with the FDA in late June of this year to obtain FDA input and thoughts on our Ampligen® CFS NDA filing and thereby allow us to maximize the presentation of our filing, which is on target to be completed and filed by year end.

The audited results of our Phase III trials with Ampligen® for Chronic Fatigue Syndrome (CFS) will be presented at the 5th International Conference on HHV-6&7 in Barcelona, Spain, April 30 - May 6, 2006.

The status of our trials and our path to commercialization will be presented at Rodman and Renshaw conferences in Monaco (May 15 and 16) and in New York City (June 9).

Our balance sheet and liquidity are stronger than ever. No small part of this accomplishment is due to our July 2005 financing agreement with Fusion Capital. We completed our $20 million agreement with Fusion in the first quarter of 2006. In addition to strengthening our balance sheet, access to this capital allowed us to enhance our manufacturing capabilities in compliance with federal guidelines. We have entered into a new financing agreement with Fusion Capital that provides us with the option to obtain up to an additional $50 million. We feel very fortunate to have the availability of this financing at the very time we are on the cusp of commercialization as it will provide us with significant flexibility in pursuing optimal commercial success. The Fusion Capital $50 million financing agreement will be on the agenda for approval by stockholders at the annual stockholders meeting on June 21, 2006.

During the preparation of our annual report on Form 10-K for 2005, it was determined that the 2003 interpretation of the accounting guidelines to account for our convertible debentures was incorrect resulting in financials that should not be relied on. As a result, the filing of our 10-K with audited financial statements has been delayed and we are restating our historical financial statements to account for non-cash expenses reflected in our interim financial statements from 2003 through 2005 and our annual financial statements for 2003 and 2004. This accounting problem reflected a weakness in our internal control process pursuant to Section 404 of the Sarbanes Oxley Act.

These non-cash charges do not affect our revenues, cash flows, or liquidity. We emphasize that the delayed filing in no way reflects upon our financial stability or accounting ethics and, based upon the representations of our independent accountants expect to complete the 10-K filing with audited financial statements within 30 days of April 3, 2006. We have always adhered to the most conservative and ethical standards of accounting and governance.

Our focus has firmly been upon building solid science that will deliver peer support, regulatory approval and lead to commercial, revenue generating relationships. We are well on the path to accomplishing our objectives.

Sincerely,

William A. Carter, M.D.

Chairman of the Board and
Chief Executive Officer

[Aptamilla]

Antwort auf Beitrag Nr.: 21.194.024 von tonyjaa am 13.04.06 16:14:53

Mal kurz und informativ auf deutsch bitte.Danke!

[Masse]

Antwort auf Beitrag Nr.: 21.197.244 von Aptamilla am 13.04.06 19:05:37

Anbei eine kurze Zusammenfassung:

HEB blickt zurück auf erreichtes und gibt einen vielversprechenden Ausblick in die Zukunft.

Erreichtes:
1. Alferon LDO Schlüsselbausteine im Verteidigungsystem des Körpers sind.
2. Laborstudien zeigen, daß 50 bis 100mal weniger Tamiflu in Verbindung mit Ampligen verwendet werden kann, um die volle Hemmung ohne Vermehrung des Virus erzielen zu können, und keine Wirtszellebeschädigung auf.
3. Schließlich haben Untersuchungen an Tieren, die gemeinsam mit dem nationalen Institut der ansteckenden Krankheiten in Japan geleitet wurden, gezeigt, daß die Co-Leitung von unserem experimentellen immunostimulant Ampligen, eine spezifisch zusammengebaute double-stranded RNS, helfen kann erheblichen, Verringerungen einer vaccine Dosis H5N1 zu ermöglichen, sowie einen Kreuz-Schutz gegen veränderte Belastungen des Virus H5N1 zur Verfügung stellt.

Es wird eine weitere Zusammenarbeit mit dem nationalen Institut der ansteckenden Krankheit in Japan geben, bei dem der Fokos auf die Wirkung von Ampligen mit Impfstoffen H5N1 in Japan getetst wird. Die Studien werden sich ausschließlich auf den Kreuzschutz richten, den Ampligen zu den Impfstoffen über veränderten Belastungen voraussetzt. Die Resultate dieser Studien sollen im 2. Quartal 2006 dargestellt werden. Die Zusammenarbeit mit den japanischen Teilnehmern ist in hohem Grade produktiv gewesen. Diese Zusammenarbeit soll über die Zeit fortfahren und erweitern werden.

Ziel ist es einen beschleunigte Zulassung durch die FDA zu erhalten.

Im 1. Quartal wurde die Basis geschaffen Ampligen in Großproduktion herstellen zu können.

Die revidierten Resultate der Versuche der Phase III mit Ampligen für chronisches Ermüdungsyndrom (CFS-) werden bei der 5. internationalen Konferenz auf Hhv-6&7 in Barcelona, Spanien, April 30 - Mai 6, 2006 dargestellt.

Um das alle finanzieren zu können sollen weitere 50 Mil. Aktien ausgegeben werden. Die Finanzierenvereinbarung von $50 Million ist auf der Tagesordnung jährlichen Aktionärsversammlung, die an Juni 21, 2006 treffen.

Ich hoffe ich habe es richtig wiedergegeben.

Gruß Masse

[Masse]

Ich denke es sieht ganz gut für die HEB-Aktionäre aus, wenn Geduld ausreichend vorhanden ist (ich bin selbst seit ca. 7 Jahren investiert). Da kommt es auf ein oder zwei Jahre auch nicht mehr an ;-)

HEB strebt das beschleunigte Verfahren an und braucht noch Geld um das alles finanzieren zu können.

Gruß Masse

[Aptamilla]

Danke Masse und frohe Ostertage.Gruss Apta

[zillus]

Super Zusammenfassung--Danke !!!----was glaubt Ihr---wie geht`s weiter ? ---wie sieht diese Kapitalerhöhung wohl aus ? 1 :1 / bei 1 Dollar --mit Sperrfrist --versteht sich !!!----das würde meiner Meinung nach steigende Kurse erklären !!! ----Meinungen ??? ---Frohe Ostern !

[Masse]

Antwort auf Beitrag Nr.: 21.201.032 von zillus am 14.04.06 08:20:12

100%ig habe ich es auch nicht verstanden.

Ich habe verstanden, das HEB 50 Mil. neue Anteile herausgeben wird. Der Investor kann zum Tagesminimum oder zum Preis des arithmetische Mittel der drei niedrigsten Tagesstände der letzten 12 Handelstage. Maximal kann er 100.000 Aktien je Tag erwerben.
Der Vorteil ist, das der Investor nahe am Tagespreis kaufen muss.

Gruß Masse

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.200.345 von Masse am 13.04.06 23:15:12

danke, frohe ostern

[[KERN]Codex]

[[KERN]Codex]

A new mode of bird-flu fighting: A small Malvern drugmaker has devised a way that may make vaccine faster, cheaper and more potent [The Philadelphia Inquirer]


Apr. 16--Rick Bright and his former colleagues at the Centers for Disease Control and Prevention have seen many companies jump on the avian-flu bandwagon, with a slew of potential treatments if a pandemic breaks out.

"I've heard so many things, so many wild ideas. I've seen it all," said Bright, a virologist and immunologist at the CDC's influenza branch for nine years.

But it is a small Malvern company, called Novavax Inc., that Bright says may have a viable solution to bird flu. The researcher recently left the CDC to take the helm of Novavax's vaccine research.

Drugmakers are racing to come up with new approaches to bird flu, as the lethal H5N1 strain has killed millions of birds and spread from Asia to Europe, Africa and the Middle East, killing more than 100 people. The virus is not yet transmissible among people.

Just eight months ago, Novavax had a money-losing estrogen lotion and shares trading at less than $1. But the drugmaker has had a remarkable change of fortune. For that it can thank avian-flu fears and a technology that may hold the promise of making an avian-flu vaccine faster, cheaper and more potent than conventional influenza vaccines.

"We are very excited about Novavax's approach," said Terry Tumpey, senior microbiologist at the CDC, which is working with more than a dozen smaller companies on new technologies to narrow the time it takes to make an avian-influenza vaccine.

Novavax has a different way of making flu vaccine, using virus-like-particle technology (VLP) that extracts protein genes from influenza virus and turns them into particles that mimic the virus and trick the immune system into creating antibodies.

The recombinant particles can be customized into a vaccine in about two to three months, instead of the six to nine months it takes to create a conventional flu vaccine in chicken eggs.

Other companies are developing VLP vaccines for AIDS, severe acute respiratory syndrome (SARS), and human papilloma virus. But no other company is using the technology for flu, and Novavax has pending patents, said president and chief executive officer Rahul Singhvi.

Since 2001, Novavax scientists have been working on an avian-flu vaccine with the CDC, using a grant of about $1 million from the National Institutes of Health.

In August, when preclinical results were published in the online edition of the journal Vaccine, Wall Street investors noticed. The stock rose from 87 cents Aug. 15 to $7.98 March 31, hitting a 52-week high of $8.31 March 20.

The study reported strong immune protection in mice at low doses against the H9N2 strain, which first appeared in Hong Kong in 1998, without adding immune-boosting chemicals. Novavax plans to test the vaccine this fall in human clinical trials.

The company is in the process of making a vaccine against H5N1, the strain that worries health experts the most. The CDC is preparing to test the H5N1 vaccine in animals.

Novavax's VLP vaccine has "a lot of potential" because it can be made quickly and will be "cost-effective" since the company intends to use a portable manufacturing process, said the CDC's Tumpey.

Flu manufacturers now make vaccines in stainless-steel tanks in multimillion-dollar plants. Novavax plans to use disposable equipment, which can be "scaled up" to make large quantities in case of a pandemic.

The company is collaborating with Wave Biotech L.L.C., of Somerset, N.J., to develop a commercial-scale production process. Manufacturing will be in sterile medical-grade plastic bags, using disposable cartridges and filters that can be thrown away and incinerated after each batch.

The portable manufacturing could go into any "clean room" in the world where there is electricity. "We did an experiment and found it worked beautifully," said Singhvi, a chemical engineer from the Massachusetts Institute of Technology who spent 10 years in vaccine development and manufacturing at Merck & Co. Inc.

"No other vaccine manufacturer in flu is using this approach yet," said Bright, who worked with avian influenza at the CDC from 1997 until February.

Novavax's product probably will not be approved for mass distribution until 2008, but potentially could be ready in winter 2007 if there were a pandemic, Singhvi said.

--

Only eight months ago, the company's prospects looked dim. The stock hit a year low Aug. 10 of 74 cents.

When Singhvi became CEO on Aug. 9, Novavax had about $5 million in cash and was carrying $35 million in debt. Sales of its Estrasorb estrogen lotion were tepid, and the company was losing $2 million to $2.5 million a month.

In his first act as CEO, Singhvi fired the sales and marketing staff of 40 to 45, shrinking the company by half. Today, Novavax employs 52 full-time and five part-time employees.

A turning point came in October, when Novavax licensed rights to Estrasorb to Esprit Pharma Inc. for $12.5 million up-front, plus double-digit royalties on sales and milestone payments. In addition, Novavax continued to manufacture the product at its Northeast Philadelphia plant.

Capitalizing on investor enthusiasm and its rising stock price, Novavax raised $18 million in November through a public stock offering.

In February, the company received an additional $20 million from two Silicon Valley venture firms: Kleiner Perkins Caufield & Byers, which has backed Google Inc., AOL and Genentech Inc., and Prospect Venture Partners.

Not everyone thinks the company's avian-flu vaccine program is a panacea. Shares, which had become a trader's favorite in recent months, lost ground recently after RBC Capital Markets cut its rating on the company's stock to "underperform," saying bird-flu-vaccine expectations were overblown. Shares have fallen 19 percent since their Nasdaq close at $6.68 on April 5. Shares closed Thursday at $5.38.

"The expectations for Novavax are way ahead of the company's ability to deliver a safe, functioning vaccine that has been tested in humans with validated, commercial-scale manufacturing," RBC analyst Ken Trbovich wrote in a research note. "We believe the valuation is running so far in front of so many other small companies with a focus on flu and other vaccines that the stock has the potential for a significant sell-off when the bird-flu-scare cools."

Trbovich said in an interview that the technology was "intriguing" and "a novel approach," but that "until they have real data from their vaccine, it's almost impossible to draw conclusions."

"In the end," he said, "the new management team has done a good job in repositioning this company. But it's a long way away from ringing the cash registers."

In February, Kleiner Perkins announced a $200 million fund to invest in innovative companies working on vaccines and drugs for emerging infectious diseases, including pandemic flu.

"Time and again people said, 'You've got to go see this company Novavax,' " said Kleiner Perkins managing partner Brook Byers, who said his firm invested $12.5 million in Novavax based on the management team, which came from Merck and other companies with expertise in vaccines and in scientific technology.

"VLPs are the hot thing in vaccines now," Byers said. "Using viruslike particles, you can make a vaccine for five or 10 targets, all in the same vaccine. So the coverage of protection from the vaccine could be broad. Novavax, we believe, is one of the leaders in VLP technology."

In September 2004, Novavax moved its headquarters to Malvern from Columbia, Md., but kept its vaccines division and about 20 scientists in Rockville, Md.

With the company's recent focus on bird flu, Novavax is in talks with Maryland economic-development officials about securing incentives to expand vaccine operations in Maryland -- and possibly move the headquarters back there.

"The corporate headquarters move is still up in the air," Singhvi said, "but what is definite is, we are going to a bigger facility in Maryland for our vaccine operations."

Even if the company does relocate, the Philadelphia-area operations will remain. Only "two or three" of Malvern's 15 employees will move, Singhvi said. And a 24,000-square-foot manufacturing facility that employs 20 in Northeast Philadelphia will stay open "and may expand," he said.

What happens if the dreaded global epidemic never pans out? The company is not putting all its efforts into avian flu.

"The second program we are going after is a seasonal-flu vaccine," Singhvi said. "Beyond that, we have another program in HIV vaccine that is currently being supported by NIH grants. We are planning to add more to our pipeline as we get more people."

Novavax Changes Direction

June 30: Shares of Malvern-based Novavax Inc. close at $1.32. It has $4.4 million in cash and cash equivalents and a money-losing estrogen cream, Estrasorb.

Aug. 9: Former chief executive officer Nelson Sims retires and is replaced by Rahul Singhvi, whose first move is to lay off the sales and marketing staff, cutting the workforce in half to reduce costs.

Aug. 25: Novavax reports positive preclinical results of its H9N2 avian-flu vaccine, as detailed in the journal Vaccine. Shares begin a steady move upward.

Sept. 13: Novavax announces collaboration with Wave Biotech L.L.C. to develop a process for commercial-scale production for pandemic-flu vaccine, using disposable manufacturing equipment.

Oct. 18: The company announces a licensing agreement for Estrasorb with Esprit Pharma, of East Brunswick, N.J., for $12.5 million, plus double-digit sales royalties and milestone payments.

Nov. 2: Novavax raises $18 million in a secondary stock offering, selling 4.2 million shares at $4.30 a share.

Feb. 2: Rick Bright, immunologist and virologist at the Centers for Disease Control and Prevention, joins the company as vice president of vaccine research.

Feb. 15: Novavax begins collaboration with the University of Pittsburgh School of Medicine to test its flu vaccines and a proprietary vaccine adjuvant.

Feb. 27: The company receives $20 million from two California venture-capital firms -- Kleiner Perkins Caufield & Byers and Prospect Venture Partners -- by selling 4.6 million shares at $4.35 per share.

Feb. 28: Novavax forms alliance with PacificGMP, of San Diego, to manufacture large quantities of avian-flu vaccine.

March 6: Novavax and Bharat Biotech International Ltd. announce alliance to develop pandemic-influenza vaccine for India and other south Asian countries.

March 20: Shares reach a 52-week high of $8.31.

March 21: Company sells 5.2 million shares of common stock at $7.30 a share, raising $36.1 million.

March 31: Holders of Novavax convertible notes choose to convert $7 million in notes to 1.3 million shares of common stock at a price of $5.46 a share.

April 13: Shares close at $5.38.

Fighting Flu on Many Fronts

Amid fear of an avian-flu outbreak in humans, many firms are developing therapeutics, antivirals and vaccines. Here are what several in the Philadelphia area are doing:

Sanofi Pasteur of Swiftwater, Pa., has a $100 million contract to supply experimental H5N1 avian-flu vaccine to a U.S. government stockpile. In 2004, Sanofi began supplying the U.S. government with two million vaccine doses. In addition, the French-based drugmaker is under contract to provide a year-round supply of chicken eggs for U.S. vaccine production, and is working on a new cell-culture influenza vaccine.

GlaxoSmithKline P.L.C. has begun human testing of two vaccines against the H5N1 strain, with the aim of having a vaccine in production before the end of the year. With a U.S. headquarters in Philadelphia, GlaxoSmithKline has committed $2 billion to expand manufacturing capacity for seasonal-flu vaccine and its antiviral drug, Relenza. The company has submitted an application to European regulators for a pandemic vaccine for strains H2N2 and H9N2. GlaxoSmithKline also acquired Canadian vaccine-maker ID Biomedical Corp. for $1.4 billion.

Hemispherx Biopharma Inc. of Philadelphia said lab tests showed that its immune-system drugs Ampligen and Alferon might strengthen the power of current treatments against avian influenza. The company said its experimental Ampligen drug boosted effectiveness of Roche Holding AG's Tamiflu and GlaxoSmithKline's Relenza antivirals in lab testing and in mice. An oral form of Alferon, tested in healthy humans, may stimulate genes that play a role in building the body's defense system. Alferon is approved as an injectable treatment for genital warts.

Quigley Pharma of Doylestown announced plans to test its antiviral compound QR-441A against the H5N1 virus in poultry.

Elsewhere, companies working on avian-flu treatments include: Chiron Corp., Emeryville, Calif.; BioCryst Pharmaceuticals, Birmingham, Ala.; Alnylam Pharmaceuticals, Cambridge, Mass.; Generex Biotechnology Corp., Toronto; AVI Biopharma Inc., Portland, Ore.; Peregrine Pharmaceuticals Inc., Tustin, Calif.; and MultiCell Technologies Inc., Lincoln, R.I.

Contact staff writer Linda Loyd at 215-854-2831 or [e-mail].

Copyright (c) 2006, The Philadelphia Inquirer

Distributed by Knight Ridder/Tribune Business News. For information on republishing this content, contact us at [phone] (U.S.), [phone] (worldwide), fax [phone], or e-mail [e-mail].

[Aptamilla]

Ich mach mir nicht bange.Demnächst knallen die Korken!!!

[[KERN]Codex]

Gestern auf TH geschlossen!

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.265.514 von [KERN]Codex am 21.04.06 07:59:39

Die Zeitungen sind voll von CFS

April 21, 2006, 12:53AM
Genes appear to play role in chronic fatigue syndrome, study finds
Research could aid treatment and diagnosis, predict who is more likely to develop disorder


By MIKE STOBBE
Associated Press

ATLANTA - Chronic fatigue syndrome appears to result from something in people's genetic makeup that reduces their ability to deal with physical and psychological stress, researchers reported Thursday.

The research is being called some of the first credible scientific evidence that genetics, when combined with stress, can bring on chronic fatigue syndrome — a condition so hard to diagnose and so poorly understood that some question whether it is a real ailment.

Researchers said the findings could help lead to better means of diagnosing and treating chronic fatigue syndrome, and predicting those who are likely to develop the disorder, which is characterized by extreme, persistent exhaustion.

"The results are ground-breaking," said Dr. William Reeves of the Centers for Disease Control and Prevention.

Reeves said the study demonstrates that people with chronic fatigue syndrome are unable to deal with everyday challenges and adversity. That could include injuries, illnesses, divorce, even stressful jobs, the researchers said.

The CDC estimates more than 1 million Americans have the condition, with women suffering at four times the rate than men. The research is contained in a collection of 14 articles published in this month's issue of Pharmacogenomics.

The centerpiece is a study of 227 people with chronic fatigue syndrome in Wichita, Kan. Over two days, doctors performed psychiatric evaluations, assessed their physical limitations, looked at their medications, and tested their blood and urine for abnormalities.

Chronic fatigue patients tested with high levels of allostatic load, a stress measure of hormone secretions, blood pressure, and other signs of wear and tear on the body. The patients were about twice as likely to have a high allostatic load index as people who did not have chronic fatigue syndrome.

[[KERN]Codex]

10 to 15 minutes old

Chronic fatigue result of genetics Press-Telegram, California 07:05


15 to 30 minutes old

Genetics may be factor in chronic fatigue syndrome: U.S. researchers People's Daily 06:55


30 minutes to 1 hour old

Study: Genes appear to play role in chronic fatigue syndrome Houston Chronicle 06:47

Genetics may be factor in chronic fatigue syndrome: US researchers China View 06:29

Chronic fatigue syndrome is caused by genetic mutations, CDC finds Minneapolis Star Tribune, Minnesota 06:24


1 to 2 hours old

Chronic fatigue may all be in the genes The Melbourne Age 05:36


2 to 4 hours old

Chronic Fatigue's Genetic Component The Washington Post 04:17


4 to 6 hours old

Genetics trigger chronic fatigue Telegraph.co.uk 02:15


Earlier Today

Some people may be genetically susceptible to chronic fatigue Reuters Health 01:10

Lack Of Research Forcing Elderly To Cope With Chronic Pain Medical News Today 01:01

Chronic fatigue may all be in the genes, U.S. says Manorama online 00:24

[zillus]

Hi Kern ,---ich versteh nur "Bahnhof "!!! --kannst Du mir und den anderen Hemisfans mal kurz schreiben um was es in den Artikeln geht ?! In Dankbarkeit --Zillus

[[KERN]Codex]

Frequently Asked Questions about Ampligen
What is Ampligen? Ampligen is a drug manufactured by HEMISPHERx Biopharma, Inc. (NASDAQ:HEMX), Philadelphia, Pa. It is an antiviral and immune modulatory drug under the nucleic acid class of drugs (NAs). Nucleic acid drugs are designed to mimic the body's own digitalized informational molecules (called DNA and RNA) which, in some laboratory and animal studies, reprogram certain diseased cells to enhance their intrinsic disease capabilities.

To date, HEMISPHERx and its subsidiaries have received over 200 patents internationally to protect its proprietary position in NA and related drug technologies.

What is the generic name of Ampligen? Ampligen is the drug poly I: poly C12U, which is a specific form of mismatched double-stranded ribonucleic acid (dsRNA) where uridylic acid (U) substitutions in the polycytidylic acid chain create periodic regions of non-hydrogen bonding in the helical configuration. These changes, developed by HEMISPHERx, have resulted in unique double-stranded RNA s, termed mismatched double-stranded RNA s. Double-stranded RNA s act as modulators or molecules that mediate cellular immune and antiviral activities.

How does Ampligen work? Ampligen inhibits viruses and tumor-cell growth through pleiotropic, or multiple interrelated, mechanisms. Ampligen up-regulates or down-regulates, as needed, two important enzyme systems; (1) the 2 ,5 oligoadenylate synthetase/RNase L (2-5A synthetase/RNase L) pathway; and (2) the P68 protein kinase pathway. Ampligen can induce the production of 2-5A synthetase independent of interferon induction. It also can activate both 2-5A and p68 protein kinase, while IFNs can only induce production, but not activate, these enzymes, an important biological distinction. Ampligen can also inhibit 2-phosphodiesterase, an enzyme which destroys the product of 2-5A synthetase, biactive 2-5A. These differences in mechanisms between IFNs and Ampligen result in clinical and biological activities in interferon intolerant or resistant states and synergistic interactions between Ampligen and interferon. (Once these pathways are stimulated correctly, the cell responds with the production of cytokines and lymphokines, the chemical messengers immune cells used to communicate the memory response of antigen specific CD8+ cells, the type of white blood cells thought to play the major role in cell-mediated immunity.)

2-5A Synthetase/RNase L Pathway: Once 2-5A mRNA has been transcribed by the genes in the nucleus (which earlier had been stimulated by messages from the cAMP signal transition pathway), latent 2-5A synthetase is created. Ampligen then activates this latent 2-5A synthetase and activated 2-5A is created. Activated 2-5A, in turn, activates an enzyme called RNase-L, which destroys viral RNA. (Oragen compounds directly stimulate the production of active 2-5A.) 2-5A itself also can control the growth of certain human tumor cells and inhibits reverse transcriptase, the enzyme both HIV and HBV use for reproduction.

The RNase-L pathway is one of the immune system s standard response to viral infection (termed intracellular immunity ). Some viruses, however, such as HIV, herpes, and HBV overcome intracellular immunity by producing substances that deactivate RNase-L, thereby releasing the virus to multiply largely unchecked within the intracellular environment and clinical deterioration occurs.


Protein Kinase (p68) Pathway: The protein kinase (p68) pathway is also affected in a similar manner. Once p68 kinase mRNA is transcribed from DNA templates in the nucleus of the cell, p68 kinase is formed by translation of the RNA message. Ampligen then induces the autophosphorylation of p68 kinase (essentially an activation of p68 kinase) that leads through two other steps, elF2a and elf25-P to the inhibition of viral protein syntheses.

Who invented Ampligen? William A. Carter, M.D., the co-inventor of Ampligen, was a pioneer in the clinical development of interferon, a protein therapy now approved for more than a dozen viral diseases and commanding a market in excess of $2 billion.

Where is Ampligen manufactured? Ampligen is currently manufactured in the United States. To prepare a shipment of the drug, the Company receives certain raw materials from Pharmacia/Upjohn functioning as a subcontractor and then processes this material to develop the final finished drug using HEMISPHERx facilities in Rockville, Maryland. Dosage units are then prepared and tested for quality assurance.

Also, on December 18, 1995, Bioclones Proprietary (an affiliated company of the South African Breweries Limited) as part of a strategic alliance with HEMISPHERx, successfully completed the first production runs at a larger nucleic acid manufacturing plant near Johannesburg, South Africa.

It is expected that the combined facilities of the partnership will, with the passage of time, increase efficiency and thus lower the overall manufacturing costs of this drug.

How much does Ampligen cost? The cost of manufacturing Ampligen for the treatment programs in Belgium and Canada is relatively high (U.S. $12-18,000) due to the low volume.

Who responds well to Ampligen? The results of Ampligen trials in the United States and Belgium suggest that Ampligen may be an effective treatment for a certain subset of Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) patients, namely those with severe debilitation. The patients who entered the Ampligen trials met the strict case study definition of ME/CFS established by the Center for Disease Control and Prevention (CDC).

Where is Ampligen available? As of this writing (December 1996), Ampligen is available to patients in Canada and Belgium under cost recovery programs.

Belgium: A trial initiated in Belgium in May, 1996 by Kenny DeMeirleir, M.D., Ph.D., from the University of Brussels, and by David Strayer, M.D., Professor of Medicine at Allegheny University, PA and Medical Director for HEMISPHERx, was significantly expanded in November, 1996.

The expanded enrollment came at the request of the Belgian investigator, who reported that after six months of Ampligen therapy, approximately 80% of the treated patients thereafter experienced an apparent complete clinical recovery, which meant that the patient could go back to school or to work. The typical patient had been bedridden because of CFIDS for between 3 and 7 years prior to the initiation of the six-month treatment program.

The results of the Belgium clinical study were reported in San Francisco, Calif., on October 14, 1996, at the scientific meeting of the American Association for Chronic Fatigue Syndrome (AACFS). The improvements observed in the two key measurements of physical performance used for the 24-week long Belgium study confirmed and extended earlier findings obtained from open-label and placebo-controlled American trials. The two measures of physical performance were Karnofsky Performance Score (KPS), used to measure activities of daily living; and exercise performance on a bicycle. KPS improved 43% from a severely debilitating level of 53 to a level of 76. A KPS score of 80 describes an individual who can perform normal activities with effort, but continues to have limited signs of the illness. On the bicycle testing, Belgium patients improved oxygen uptake significantly, from 1.16 liters/minute before the twice-weekly Ampligen administration of 200 to 400 mg, to 1.48 liters/minute after treatment.

In addition to physical improvement, significant cognitive improvements were documented among patients on the three Ampligen trials, using the cognitive subscale of the SCL 90-R or neuropsychological function tests. The Ampligen treatments were generally well tolerated.


By contrast, spontaneous recovery of untreated patients suffering from CFIDS is low. Earlier studies indicate that only 2% of the CFIDS population report spontaneous improvement to normal function and activity levels.

Canada: On May 3, 1996 Canada's Health Protection Board made Ampligen available to sufferers of Chronic Fatigue and Immune Dysfunction Syndrome ( CFIDS ), an extremely debilitating chronic viral condition with no previously approved treatments in the U.S. and Canada.

On October 1, 1996, HEMISPHERx BioPharma, Inc. announced that it began shipment of Ampligen to Rivex Pharma in Aurora, Ontario, a wholly-owned subsidiary of Helix BioPharma Corp. Ampligen is administered in Canada at the request of Canadian physicians.


Submitted by: [e-mail]
December 10, 1996

[[KERN]Codex]

H5N1 Pandemic Level 4 Declared by Research Team Citing 23 Clusters and Case Histories





Using the World Health Organizations own guidelines for determining pandemic level status, an independent research team has gathered enough factual H5N1 data to substantiate the need to declare a "Pandemic Level 4" response to Avian Flu. The Information that supports this claim is derived from scientific and medical papers, laboratory reports, government, geneticist, virologist and other experts around the world.

(PRWEB) April 23, 2006 -- Using the World Health Organizations own guidelines for determining pandemic level status, an independent research team has gathered enough factual H5N1 data to substantiate the need to declare a "Pandemic Level 4" response to Avian Flu. The Information that supports this claim is derived from scientific and medical papers, laboratory reports, government, geneticist, virologist and other experts around the world. The combined effort focused on a three year period from 2003 to the 2006, listing 23 documented clusters of H2H. The report is based on millions of Internet searches and thousands of hours verifying data.

"Clusters of H5N1 infections," says one research member "They may indicate human to human transmission of H5N1 influenza or alternatively indicate common exposure to the virus from an environmental source, presumably avian. A cluster here is defined as two or more individuals: 1. Who are in close physical contact, 2. Who become very sick with a respiratory disease, and 3. at least one of whom is a confirmed H5N1 influenza case.

China - 2003 February
A family of 5 from Hong Kong visited Fujian province in Mainland China early in 2003. A mother went with two daughters and one son on January 25, 2003. The 7 year old girl developed respiratory symptoms and a high fever on January 27/28. She developed pneumonia on January 28 2003. The father joined his family in Fujian province on January 31. His 7 year old daughter died on February 4, 2003. She was not tested for H5N1 and was buried in Mainland China. Her 33 year old father became ill on February 7 with fever, cough and blood in sputum. The family returned to Hong Kong on February 9 2003. The father was admitted to a hospital in Hong Kong on February 11. He died on February 17. He was tested and was found to have been infected with H5N1. The 8 year old boy in the family became ill with a cough and fever on February 9, 2003. He was tested and was also found to be positive for H5N1, but recovered. Peiris et al 2004

Viet Nam - 2003 December
A 12 year old girl from Ha Nam became ill on December 25 2003 and was admitted to a Hanoi hospital on December 27 2004. She died on December 30 2003. This is first confirmed death from H5N1 in Viet Nam. Her 30 year old mother became ill on January 1 2004 and died of H5N1 influenza on Jan 9 2004. Corresponds to Olsen et al. cluster 1

A 7 year old girl Nam Dinh died on December 29 2003 of acute respiratory distress. No samples were tested from this girl. Her 5 year old brother was admitted to the hospital on December 29 2003. He died 17 days after becoming ill. H5N1 infection was confirmed. Corresponds to Olsen et al. cluster 2

Viet Nam - 2004 January
A family cluster of H5N1 infections was observed in Thai Binh province in January 2004 (see also WHO update 15). A 31 year old man was hospitalized on January 7 2004 with severe respiratory illness. He died on January 12. No samples from this patient were tested for H5N1. His 28 year old wife became ill with a severe respiratory illness on January 10, but recovered. H5N1 infection was confirmed. The man’s two sisters, 23 and 30 years old, became ill on January 11 and January 10, respectively. Both died on January 23. H5N1 infection was confirmed in both sisters. Corresponds to Olsen et al. cluster 3

Viet Nam - 2004 January-February
A 9 year old girl in Dong Thap province became ill with diarrhea, but no respiratory symptoms on January 28 2004. She died of acute encephalitis on February 2 2004. She was not tested for H5N1 influenza. Her 4 year old brother became ill with diarrhea on February 10 2004, also with no respiratory symptoms. He developed encephalitis and died of respiratory failure on February 17 2004. This 4 year old boy was tested for H5N1 influenza and found to be positive.

Viet Nam - 2004 July
A 19 year old man in Hai Giang province became ill on July 23, 2004 with symptoms of fever, breathing difficulties and hemorrhage. His 22 year old female cousin exhibited the same symptoms. They both died on July 30. They were not tested for H5N1 infection. The man’s 25 year old sister became ill with the same symptoms on July 31 2004. She died on August 2 2004. H5N1 infection was confirmed. Corresponds to Olsen et al. cluster 5

Thailand - 2004 September
A family cluster of H5N1 and severe respiratory illness was observed in September 2004 in Kamphaeng Phet province. A 11 year old girl from Kamphaeng Phet province became ill on September 2 2004 and died of pneumonia on September 8 2004. She was not tested for H5N1 infection, but was considered to be a probable H5N1 fatality. Her 26 year old mother lived in Bangkok but visited her daughter to take of her while she was ill. The mother became ill on September 11 2004 and died on September 20. H5N1 infection was confirmed. The girl lived with her 32 year old Aunt. The Aunt became ill on September 16 2004 but recovered. H5N1 infection was confirmed. The Aunt’s son became ill with a respiratory infection. This cluster is considered one of the most convincing cases of human-to-human transmission of H5N1 because the mother lived in an area which had no infected birds, Bangkok, and was exposed to H5N1 by her daughter (who did have exposure to sick chickens). Corresponds to Olsen et al. cluster 6

Viet Nam - 2005 January
A 45 year old man from Thai Binh became ill with a respiratory illness on December 26 2004 and died on January 9 2005. H5N1 influenza was confirmed. His 42 year old brother, from Hanoi, was hospitalized on January 10 but recovered. He was also confirmed to be infected with H5 influenza. A third 36 year old brother was reported to be positive for H5N1 infection, but did not exhibit any symptoms Corresponds to Olsen et al. cluster 7

A 17 year old boy from Bac Lieu was hospitalized on January 10 2005. He died of H5N1 influenza on January 14 2005. His 22 year old sister also had respiratory symptoms and was hospitalized. Her fate and H5N1 status were not reported.Corresponds to Olsen et al. cluster 8

A 35 year old woman from Dong Thap became ill on January 14 2005. She died of H5N1 influenza on January 21. Her 13 year old daughter became ill on January 20 2005. She later died. H5N1 infection was confirmed. Corresponds to Olsen et al. cluster 9

Cambodia - 2005 January
A 14 year old boy from Kampot province became ill with respiratory symptoms and died on January 20 2005. He was not tested for H5N1 infection. His 25 year old sister became ill on January 21 2005. She traveled to Vietnam to receive care but died on January 30. H5N1 infection was confirmed. Corresponds to Olsen et al. cluster 10

Viet Nam - 2005 February
A 21 year old man from Thai Binh province ate meat from a sick chicken on February 8 2005. He developed a high fever and cough on February 14 2005. On February 20, he was admitted to an hospital with severe pneumonia. He received oseltamivir (Tamiflu -75 mg twice a day for 7 days) on February 23. He was discharged from the hospital on May 13. H5N1 infection was confirmed. His 14 year old sister cared for him from February 14 to February 21. She became ill with a mild cough and mild fever on February 23 2005. H5N1 infection was confirmed. She received an initial treatment with oseltamivir (Tamiflu -75 mg once a day) from February 24 to February 27. She was admitted to a hospital for observation on February 24. At this time, she had no fever but did have a mild cough. On February 27, she developed a high fever and severe cough. On February 28, she received oseltamivir (Tamiflu -75 mg twice a day for 7 days). She was discharged from the hospital on March 14 2006. The girl had no contact with poultry prior to becoming ill. A 26 year old male nurse, who cared for 21 year old male patient mentioned above, was admitted to a hospital in early March. H5N1 infection was apparently detected. The 80 year old grandfather of the 21 year old and 14 year old brother and sister was reported to be infected with H5N1. He did not exhibit any symptoms. Corresponds to Olsen et al. cluster 11

Viet Nam - 2005 March
Five members of a family in the city of Haiphong were all reported to be infected with H5N1 influenza and were hospitalized on March 22 2005. The 35 year old father, 33 year old mother, 13 year old daughter, 10 year old daughter and 4 month old daughter were all infected. Corresponds to Olsen et al. cluster 14

Indonesia - 2005 July
An 8 year old girl from Tangerang, a suburb of Jakarta, became ill on June 24 2005 and died on July 13. She was reported to be H5N1 positive, but was later judged by the WHO not to have an acute H5N1 infection. Her 1 year old sister became ill on June 29 2005 and died on July 9. She was not tested for H5N1 infection. The father of the two girls, a 38 year old man, became ill on July 2 2005 and died on July 12 2005. H5N1 infection was confirmed. Corresponds to Olsen et al. cluster 15

Indonesia - 2005 September
On September 10 2005 a 37 year old woman from Jakarta died of confirmed H5N1. Her 9 year old nephew became sick with respiratory symptoms. Initially he tested postive with PCR. It was later reported that he was not infected with H5N1.

On September 20 2005 a 21-year-old man from Lampung province developed symptoms. On September 24 2005 he was hospitalized; H5N1 infection was confirmed. On October 4, the 4 year old nephew of this man became ill. H5N1 infection was confirmed.

China - 2005 October
On October 8 2005, a 12 year old girl from Hunan province became ill with respiratory symptoms. She died on October 16. Her 9 year old brother became ill with respiratory symptoms on October 10 2005. He was confirmed to be infected with H5N1. He was released from the hospital on November 12 2005.

Thailand - 2005 October
A 48-year old man from Kanchanaburi province became ill on October 13 2005 and died on October 19. His 7 year old son became ill on October 16, but recovered. H5N1 infection was confirmed in both cases.

Indonesia - 2005 October
On October 19 2005, a 19 year old woman from Tangerang became ill. She died on October 28. Her 8 year old brother became ill on October 25. H5N1 infection was confirmed in both cases.

Indonesia - 2005 November
On November 3, two brothers, ages 7 and 20, from West Java province developed fever and respiratory symptoms. They died on November 11. On November 6, their 16 year old brother also developed fever and respiratory symptoms. He was hospitalized on November 16. H5N1 infection was confirmed in the 16 year old. The 7 year old and 20 year old were not tested for H5N1.

Turkey - 2006 January
The first reported case of H5N1 influenza in Turkey occurred in a 14 year old boy from Dogubayazit, in the province of Agri. He died on January 1 2006. His 15 year old sister died of H5N1 influenza on January 5 2006. The 12 year old sister of these children died on January 6 2006. The 6 year old brother of these children was hospitalized.

Two brothers, 5 and 2 years old, from Ankara province were reported infected with H5N1 on January 8 2006.

A 9 year old girl and her 3 year old brother, from the Dogubeyazit district in Agri Province, were reported infected on January 9 2006.

A 14 year old girl from the Dogubayazit district of Agri province became ill on January 4 2006. She died of H5N1 influenza on January 15. Her 5 year old brother also became ill on January 4 2006. He was confirmed to be infected with H5N1 influenza.

Indonesia - 2006 January
On January 6 2006, a 13 year old girl became ill. She died of H5N1 influenza on January 14. On January 8 2006, her 4 year old brother became ill. He died of H5N1 influenza on January 17. Their 14 year old sister was hospitalized with respiratory symptoms on January 14 2006. Their 43 year old father was hospitalized on January 17 with respiratory symptoms. On January 19 2006, a 9 year old girl from a neighboring village was hospitalized, but later recovered. H5N1 infection was confirmed.

Iraq - 2006 January
The first person reported to contract H5N1 influenza in Iraq was a 15 year old girl from the town of Raniya. She became ill on January 2 2006 and died on January 17. A US naval Medical Research Unit located in Cairo, Egypt confirmed infection with H5N1. Her 39 year old uncle, who cared for her while she was sick, became ill on January 24 2006. He died of a respiratory illness on January 27. H5N1 infection was confirmed in the uncle.

Indonesia - 2006 February
A 12 year old girl from Boyolali, Central Java became ill on February 19 2006. She died on March 1. H5N1 infection was confirmed. Her 10 year old brother also became ill on February 19 and died February 28. He was not tested for H5N1.

Azerbaijan - 2006 March
A 17 year old girl from Salyan Rayon died on February 23 2006. H5N1 infection was confirmed. Her first cousin, a 20 year old woman from Salyan Rayon died on March 3. H5N1 infection was confirmed. This woman’s 16 year old brother died on March 10. H5N1 infection was confirmed. A 17 year old girl, who was a close friend of this family, died on March 8. H5N1 infection was confirmed. A 10 year old boy from Salyan Rayon became ill. H5N1 infection was confirmed. A 15 year old girl from Salyan Rayon became ill. H5N1 infection was confirmed.

Egypt - 2006 March-April
A 6 year old girl from the Kafr El-Sheikh governorate became ill. H5N1 infection was confirmed. Her 1.5 year old sister became also became ill. H5N1 infection was confirmed.

"We substantiate the claim based on the data above to elevate the current WHO pandemic level from 3 to 4," says Cornelius Robertson team spokesman. "The importance of recognizing level 4 is a key to minimizing public heath impact and the welfare of the general public. By informing the public of pandemic flu alert from level three to four would increase survivability from this natural flu cycle. Pandemics run in historical waves every 30-45 years

Robertson continues, "Evidence points to global organizations and world governments reacting in the same manner as in the 1918 Spanish Flu pandemic which killed Tens of millions. Either for social economic reasons, geographical differences there is much foot dragging and under reporting in areas of like Africa the Middle East and Southeast Asia."

In this information age, using online resources of thousands of data bases, the team compiled its opinion. "We say facts are facts. We are declaring Pandemic level 4 for Avian Influenza."

[[KERN]Codex]

.
.
While we have and are pursuing the extremely promising avian influenza studies through the efforts of our contract partners, our primary internal resources have been, and continue to be, focused on completing and filing our NDA for CFS. In the 1st Quarter we completed the construction of a facility within our New Brunswick plant to produce raw materials for the manufacture of Ampligen®. This in house capability will aid in fulfilling the manufacturing requirements of the Ampligen® CFS NDA. The pre-clinical section of the Ampligen® CFS NDA is on schedule to be completed by the end of this month. We anticipate having a pre NDA meeting with the FDA in late June of this year to obtain FDA input and thoughts on our Ampligen® CFS NDA filing and thereby allow us to maximize the presentation of our filing, which is on target to be completed and filed by year end.

The audited results of our Phase III trials with Ampligen® for Chronic Fatigue Syndrome (CFS) will be presented at the 5th International Conference on HHV-6&7 in Barcelona, Spain, April 30 – May 6, 2006.

The status of our trials and our path to commercialization will be presented at Rodman and Renshaw conferences in Monaco (May 15 and 16) and in New York City (June 9).
.
.

[[KERN]Codex]

What Is Chronic Fatigue Syndrome (CFS)





Main Category: Public Health News
Article Date: 23 Apr 2006 - 0:00am (PDT)

CFS is a complex and debilitating disorder. The patient experiences profound fatigue (extreme tiredness). Sleep, bed rest and relaxing do not help the patient feel better. Physical or mental activity often make the patient feel worse.

CFS is also known as ME (myalgic encephalomyelitis)

The patient becomes aware of a significant drop in his/her ability to function.

It is not uncommon for CFS patients to suffer for years.

It is important that a doctor eliminate any other known illness when carrying out a diagnosis. Many other illnesses and conditions, which are often treatable, make a patient feel chronic fatigue, such as:

-- alcohol or substance abuse
-- autoimmune disease
-- bipolar affective disorders
-- cancer
-- chronic mononucleosis
-- eating disorders
-- hormonal disorders
-- hypothyroidism
-- major depressive disorders
-- multiple chemical sensitivities
-- myalgic encephalomyelitis
-- neurasthenia
-- obesity
-- reactions to prescription drugs
-- schizophrenia
-- sleep apnea and narcolepsy
-- subacute infections
-- fibromyalgia syndrome

How Is A Diagnosis Made?

According to the CDC, a patient must satisfy two criteria to receive a diagnosis of CFS:

1. Six months or more of chronic fatigue, which is not connected to any other known medical condition.

2. Have four or more of the following symptoms at the same time:

-- substantial impairment in short-term memory or concentration
-- sore throat
-- tender lymph nodes
-- muscle pain
-- multi-joint pain without swelling or redness
-- headaches of a new type
-- pattern or severity
-- unrefreshing sleep
-- post-exertional malaise which lasts over 24 hours (you feel unwell for longer than 24 hours after exerting yourself)

The patient must have had these symptoms (four of them at the same time) for six consecutive months (or recurring very often).

[[KERN]Codex]

Das gibt bald ein schönes Kaufsignal, pünktlich zu den anstehenden Events

[Aptamilla]

Du sagst es Kern!Bin ganz Deiner Meinung.Denke,schon bald sehen wir viele Dinge klarer...mit bedeutenen Kurssteigerungen.

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.304.475 von Aptamilla am 24.04.06 23:55:00

Echt erstaunlich wie wenige sich mit HEB beschäftigen!

[zillus]

gut so !!!---Schönen Tag allen Hemisfans !!!

[[KERN]Codex]

AMI Bid 3,09 USD

[[KERN]Codex]

Hemispherx Biopharma Announces Retention of New Senior Personnel and Contractors Ahead of Key NDA Filing for Chronic Fatigue Syndrome Treatment
Tuesday April 25, 8:30 am ET
New Management and R&D Team to Build on Critical Research on CFS Just Unveiled by Centers for Disease Control


PHILADELPHIA--(BUSINESS WIRE)--April 25, 2006--Hemispherx Biopharma, Inc. (AMEX: HEB - News) today announced that it has retained a team of scientists and executives with unique experience in immunology, pharma manufacturing, and regulatory compliance to help the Company prepare for the filing of a new drug application (NDA) for the experimental immunostimulant Ampligen®, developed for the potential treatment of Chronic Fatigue Syndrome (CFS). The management and R&D expansion comes just as the federal Centers for Disease Control and Prevention has unveiled critical research that strengthens the belief that cases of CFS share common factors of hormonal and immune system dysregulation.
ADVERTISEMENT


The CDC's findings are built around sponsored research with 20 scientists on new genetic and environmental insights into CFS. According to Julie L. Gerberding, director of the Centers for Disease Control and Prevention, which sponsored the huge project, "This is a very important step forward in the field of chronic fatigue syndrome research." CFS is believed to affect nearly 1 million Americans. Genetic-based predispositions were identified that help lift the veils of medical uncertainty regarding what has often been considered a mysterious ailment.

Hemispherx has been on the front lines of CFS research for the past decade and has been systematically acquiring the resources and skills needed to achieve the status of the first formally recognized interventive therapy. At present, no approved and recognized therapy exists for CFS.

In a letter to shareholders and a corresponding conference call, Dr. William A. Carter, Chairman and CEO of Hemispherx Biopharma, outlined the delivery of a series of specific milestones that hold particular significance for the Company as it builds on its achievements.

The filing of a new drug application (NDA) for the Company's experimental immunostimulant, Ampligen®, developed for the potential treatment of Chronic Fatigue Syndrome (CFS), by the end of the year.
Opportunities to file influenza-related NDAs for Ampligen®, as a co-administered immunotherapeutic with influenza vaccines.
Ongoing discussions with key government officials on opportunities of particular interest for the company including CFS.
To help guide the Company down the path to regulatory approval, Hemispherx has now retained Michael D. Young, M.D., Ph.D., MBA, as Senior Vice President. Dr. Young, founder and Chief Executive of Michael D. Young Associates, has more than 30 years' experience in the pharmaceutical industry, with Board-level responsibility for Clinical Research and Development (Phase I through V); Preclinical Development (toxicology, drug metabolism and product formulation); and Regulatory Affairs. Before founding his own consulting business, he was Chief Scientific Officer at Celltech/Medeva and a member of the Board of Directors. Earlier, he was the Corporate Director responsible for creating and then managing the worldwide regulatory and clinical development functions for Proctor & Gamble. Dr. Young was also VP, worldwide Regulatory Affairs, and VP, Clinical Research (North America), for SmithKline, and VP, Scientific Affairs, for Astra Pharmaceutical, Inc.

To assist Hemispherx in its regulatory initiatives, as well as the Company's pursuits in influenza /vaccine-additive opportunities, Hemispherx has also retained the services of Dr. Alastair George Ramsay as Senior Vice President. Since 1989, Dr. Ramsay has been EVP, Technical and Regulatory Affairs, at Albamed, Inc, which he also co-founded. Albamed provides consulting support and hands-on guidance in the Regulatory, Chemistry/Manufacturing, Process and Product Validation and GMP areas. Dr. Ramsay also brings considerable experience in developing and manufacturing vaccines: He was recently a designated "expert" member of an FDA- and Federal Court- approved team at a major manufacturer of flu vaccine.

Hemispherx has also brought aboard Wayne R. Godfrey, M.D. in the key role of Associate Medical Director. Dr. Godfrey will initially be focusing on pre-clinical and clinical studies for development of the immunostimulant Ampligen. Dr. Godfrey has spent his career on the cutting edge of immunology. He was most recently Director of Cellular Immunology at a biotechnology company researching new immunotherapy strategies. Earlier, he was Assistant Professor, University of Minnesota, Departments of Medicine and Pediatrics and at the Division of Hematology, Oncology and Transplantation, as Hematology/Bone Marrow Transplantation Fellow, Stanford University Hospital, Palo Alto. Dr. Godfrey's practical expertise in immunology brings high value.

To ensure that it also has the expertise needed in statistics and data formulation, Hemispherx has partnered with two renowned consulting firms. Octagon Research Solutions, a leader in the electronic transformation of clinical research and development for NDAs, has been brought in to streamline the regulatory filing process, and SM&A is offering its expertise to improve the process of responding to various federal procurement opportunities for the experimental immunotherapeutic Ampligen® and the approved natural interferon product, Alferon N .

"Building the right team for this challenging arena takes patience and dedication, and it's a task we take very seriously," Dr. Carter emphasized. "With the unique skill sets and competencies offered by each of these individuals and organizations, I'm confident that we have the infrastructure and knowledge base in place to not only deliver on the promise of our scientific breakthrough but further build on our market momentum."

About Hemispherx Biopharma

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Hemispherx Biopharma's flagship products include Alferon® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens(TM). Alferon® is approved for a category of STD infection, and Ampligen® and Oragens(TM) represent experimental nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has in excess of 140 patents comprising its core intellectual property estate, a fully commercialized product (Alferon® N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen®, Alferon® LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon® do not imply that the product will ever be specifically approved commercially for these other treatment indications.

[Aptamilla]

Das Vogelgrippe Thema ist noch lange nicht beendet.Heute ging folgenes über die Ticker:USA fördern nach Vogelgrippeimpfstoff mit 1 Mrd.Dollar.Denke,das bald das Virus auch Nordamerika erreicht.